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Abstract 
 
Umbilical cord blood (UCB) is a readily available option as a stem cell source 
for those requiring an allogeneic transplant as part of curative therapy for 
malignant or non-malignant haematological disorders. Immune reconstitution is 
essential in cord blood transplant (CBT) patients to reduce the development of 
post-transplant complications. The kinetics and diversity of reconstituting 
immune cells has not been comprehensively investigated in CBT patients within 
the UK. Thus, in this study the kinetics and diversity of reconstituting immune 
cell subsets within CBT patients in the UK has been analysed.  
 
CBT patients provided whole blood samples at 28, 60, 100, 180, 365 and 720 
days post-CBT. Flow cytometry was used to determine the kinetics and diversity 
of reconstituting immune cells. T-cell receptor excision circles (TRECs) and 
kappa deleting recombination excision circles (KRECs) were quantified using 
Real Time PCR (RT-PCR) to measure thymic and bone marrow output. NK cell 
function was determined through immunophenotyping of stimulatory and 
activating markers and cytotoxicity directed to K562 cells.  
 
CD45+ cells and CD14+ monocytes reconstitute by 60 days post-CBT. CD19+ 
B cells reconstitute by 100 days and a higher absolute count of CD19+ B cells 
at 28 days post-CBT correlates with improved overall survival. T cell 
reconstitution is delayed for up to 720 days for CD3+/CD4+ T cells and 365 
days for CD8+ T cells. Thymic output is delayed for up to 720 days with low 
absolute levels of naïve T cells and low TREC copy numbers. However, 
increased numbers of effector memory T cells demonstrate thymic independent 
expansion of T cells. NK cells are activated, producing IFN- and mount a 
cytotoxic response towards K562 cells. Therefore, this project provides an 
insight into the kinetics and diversity of reconstituting immune cell subsets in 
CBT patients, serving as a timeline that can be used clinically. 
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Chapter 1 : Introduction 
 
1.1 The immune system 
 
The human immune system is a complex system that consists of different 
molecules, cells and tissue types that interact with one another to protect the 
human body against damaging effects of pathogenic infection, toxins and 
cellular abnormalities. The immune system can be divided into two types: 
immunity and adaptive immunity (Abbas, 2017).  
 
1.1.1 Innate immunity 
 
Innate immunity is known as the natural immune defence system. This is a non-
specific system that is the initial defence mechanism against invaders. 
Furthermore, physical and chemical barriers (complement, cytokines, epithelium 
and antimicrobial molecules synthesised by the surface membrane) work 
synergistically within innate immunity.  
 
The human body has many first line barriers to prevent entry of pathogens. This 
includes epithelial surfaces such as the skin and the mucosa (mouth, gut and 
lungs). Within these barriers, proteins with antimicrobial properties and 
phagocytic cells are able to recognise microbes that penetrate epithelial 
barriers, which provide a secondary defence mechanism. In certain epithelial 
cell linings such as reproductive organs, respiratory and digestive tracts, there 
is secretion of mucus, which contains many factors such as enzymes, 
glycoproteins and peptidoglycans. These factors can protect epithelial cells 
from potential infections. (Russell and Mestecky, 2010, Turner, 2009, Knight 
and Holgate, 2003). Epithelial cells found within the respiratory tract and the 
digestive system express antimicrobial peptides such as cathelcidins and 
defensins. These protect the host by reducing and restricting the entry of 
pathogens (Skillman and Silen, 1972). 
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However, if pathogens can pass these physical barriers, they will interact with 
several phagocytic cells such as: dendritic cells (DCs), neutrophils, and 
macrophages. Phagocytes are the first cell type that can identify, engulf and 
destroy pathogens via a process called phagocytosis. This is the ingestion and 
digestion of microorganisms or foreign particles. Interactions between 
phagocytes and pathogens occur through receptors on the surface of 
phagocytic cells known as pattern recognition receptors (PRR), toll like 
receptors (TLR) and pathogen associated molecular patterns (PAMPS) found 
on the surface of pathogens (Dostert et al., 2008).  
 
Phagocytosis of pathogenic cells can be induced via soluble plasma proteins 
within the blood known as complement molecules. These molecules can react 
with one another to make a foreign cell more susceptible to phagocytosis. 
Complement molecules can bind together to form a transmembrane pore on the 
pathogen known as the membrane attack complex. These transmembrane 
channels cause the pathogenic cell to lyse. A phagocytic cell will then identify 
and phagocytose the pathogen coated with complement molecules (Tomlinson, 
1993).  
 
Macrophages are cells that reside within the parenchyma; they are also one of 
the first cell types to be recruited to the site of infection and are long-lived. 
Additionally, neutrophils are high in population number at the site of infection, 
however they are short lived (Cavaillon, 1994, Cavaillon, 2001). Macrophages 
and DCs can also be known as antigen presenting cells (APCs) as they can 
express digested pathogen-processed antigens to T cells. In turn, this leads to 
the induction of an adaptive immune responses (Abbas, 2017).  
 
Natural Killer (NK) cells play an important role in immunosurveillance. NK cells 
were originally described as granular lymphocytes that have natural cytotoxicity 
against tumour cells. Later, they were described as a separate lymphocyte 
lineage that have cytotoxic ability and can produce cytokines (Trinchieri, 1989). 
NK cells recognise transformed cells or infected cells and can kill these cells via 
antibody dependent cell cytotoxicity (ADCC). Furthermore, they can induce 
killing of target cells via the release of cytolytic granules such as perforin and 
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granzyme. NK cells release cytokines such as interferon-gamma (IFN-γ), which 
mediate critical roles in anti-tumour and anti-microbial responses. The 
responses initiated by IFN-γ includes: (1) initiating the transition of innate 
immune responses to adaptive immune responses via priming T cells; (2) 
stimulating the class switching of antibodies produced by B cells; (3) up-
regulating the expression of adhesion molecules on epithelial surfaces and (4) 
promoting the interaction between leucocytes and epithelial cells (Schroder et 
al., 2004). IFN-γ has also been demonstrated to aid in ADCC (Delves and Roitt, 
2000).  
 
Once NK cells are stimulated, they also produce tumour necrosis factor alpha 
(TNF-α). This further enhances NK cell activity and cytotoxicity by upregulating 
the expression of adhesion molecules such as ICAM-1; in turn, this induces 
target cell lysis (Wang et al., 2012a).  
 
1.1.2 The Adaptive Immune System 
 
The adaptive immune system differs from the innate immune system and the 
main features of adaptive immunity are specific immunological reactions and 
the formation of immunological memory. It is a very specific system that can 
recognise different pathogens via an array of specific antigen receptors. (Bonilla 
and Oettgen, 2010). There are two essential types of adaptive immunity, known 
as humoral and cell-mediated immunity.  
 
1.1.3 Humoral Immunity 
 
Humoral immunity is a facet of immunity that is mediated by antibodies released 
by B cells. During humoral immunity, there is formation of immunological 
memory, which is the proliferation of B cells that produce antigen specific 
antibodies with a high specificity to foreign antigens. Antibodies are 
glycoproteins that are made up of two identical polypeptide chains called heavy 
chains and two shorter polypeptide chains known as the light chains.  There are 
different classes of antibodies and they are categorised according to their heavy 
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chain type. This includes: immunoglobulin (Ig) A, IgD, IgE, IgG and IgM. Each 
type of antibody has a different function and is distributed differently throughout 
the body. Antibodies are required in humoral immunity to protect the host 
against extracellular microbes via recognition of microbe antigens, 
neutralisation of microbes and elimination (Abbas, 2017). Antibody production 
can take place in two ways; they are either secreted or bound to the membrane 
of plasma B cells as shown in Figure 1.1. However, both types of antibody are 
able to mount an effector function that involves the neutralisation of microbes, 
complement activation and induction of apoptotic pathways via ADCC (Murphy 
and Weaver, 2017). The humoral response is also characterised by long-lived 
antibody secreting cells with specific memory production that can respond to 
successive antigen exposure (Delves and Roitt, 2000). 
 
 
Figure 1.1 Humoral Immunity. Naïve B cells mature in to plasma B cells after recognising 
extracellular pathogens. This leads to the activation of plasma B cells and the secretion of 
antibodies that can bind to pathogens on the surface of extracellular pathogens. Subsequently, 
this leads to the elimination of the pathogen.  
 
Naïve B cells circulating within the peripheral blood (PB) system express 
membrane bound antibodies, IgG and IgM, and mediate immune surveillance. 
Specifically, peptide immune responses take place when antigenic peptides are 
recognised by B cells residing within follicular lymphoid organs, which then go 
on to interact with T cells. This demonstrates that B cells have an APC function 
via human leukocyte antigen (HLA) class II molecules, to present antigens to T 
cells. However, for antigens to be presented to T cells, B cells must first 
internalise an antigen through a sequence of steps known as B cell activation. 
This activation is triggered through the binding of an antigen to the B cell 
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receptor (BCR). In turn, this initiates a cascade of intracellular signals that leads 
to the internalisation of the antigen, which is then processed and presented to T 
cells (Lanzavecchia, 1985).  
 
B cells express two types of BCR known as IgM and IgD. The BCR consists of 
two regions: (i) membrane bound immunoglobulin (IgD, IgM, IgA, IgG or IgE) 
and (ii) an internalised signal transduction region Ig-α/Ig-β (CD79). CD79 has a 
cytoplasmic tail that is joined to an immunoreceptor tyrosine-based activation 
motif (ITAM) (Seda and Mraz, 2015). Upon activation of the ITAM motif, 
intracellular signalling cascade leads to the activation of various transcription 
factors, which translocate to the nucleus and induce class switching of antibody 
genes for antibody production. Class switching of genes involves an intricate 
process of gene reorganisation known as VDJ recombination, which takes 
place in somatic B cells. This occurs within the bone marrow (BM) and the 
variable; diversity and joining segments of the BCR are rearranged to give the 
BCR antigen specificity. The resulting effect is activation and proliferation of 
antigen-specific B cells that have the capacity to differentiate into antibody 
secreting plasma cells. Furthermore, different types of cytokines present during 
B cell differentiation will direct the class switching of heavy chains during 
antibody production (Mosmann and Sad, 1996).  
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1.1.4 Cell-Mediated Immunity 
 
T cells play a fundamental role in cell-mediated immunity. They provide 
protection against intracellular pathogens including viruses and bacteria, which 
reside and proliferate within cells. T cells can be sub-classified into two types of 
cells: T helper cells (TH or CD4+) or cytotoxic T cells (CTL or CD8+). For both 
types of T cells to mount a response, they require the recognition of cell-
associated antigens. This leads to the proliferation of antigen-specific T cell 
clones which then differentiate into effector or memory T cells (Abbas, 2017).  
 
T cell activation occurs through an interaction between highly specific T cell 
receptors (TCRs) and antigen presentation receptors known as HLA on APCs. 
TCR recombination takes place within the thymus during thymic selection. The 
TCR region is made up of an alpha and beta chain. For a functional TCR alpha-
beta unit to be produced, multiple gene segments along the genomic DNA are 
joined and transcribed. Firstly, beta chains are rearranged and this is followed 
by gene rearrangement of the alpha chain (Chou et al., 1987a, Chou et al., 
1987b). The TCR chain contains four regions encoded by the TCR-beta locus: 
variable, diversity, joining and constant region. Enzymes that mediate the 
recombination of the respective genes are known as RAG-1 and RAG-2 
(Yancopoulos et al., 1986). RAG-1 and RAG-2 genes regulate the 
recombination of genes within the TCR-beta locus and recognise the specific 
recombination signal sequences (RSS), which are located before and after the 
diversity and joining sequences. Once this takes place, different variations of 
the variable region will join the diversity-joining region (Dudley et al., 2005). This 
produces a fully functional transcript of the TCR beta region and this is followed 
by the development and expression of a pre-TCR alpha complex, which is 
expressed on the surface of the thymocyte. This maintains the survival of the T 
cell and promotes the proliferation and progression to the double positive stage 
of T cell development within the thymus (Yamasaki et al., 2006). Upon T cell 
selection within the thymus, T cells are released into the periphery as naïve T 
cells.  
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HLA molecules are highly polymorphic and are composed of two classes: class 
I and class II. The expression of class I HLA molecules are on all nucleated 
cells and class II is expressed on macrophages, DCs and B cells. Both classes 
of HLA have a peptide-binding cleft on their outer surface, enabling 
presentation of antigens to T cells, Figure 1.2. CD4+ T cells are able to 
recognise antigens presented by HLA class II molecules while CD8+ T cells 
recognise antigens presented by HLA class I (Parkin and Cohen, 2001).  
 
Macrophage with ingested pathogens 
T cell 
Macrophages release 
cytokines to induce T cell 
activation 
Antigen-MHC complex 
T cell receptor 
Macrophages lyse and process 
antigens which are then expressed 
on the surface via MHC molecules 
Cytokines 
 
Figure 1.2 Cell mediated immunity. Cell mediated immunity where protection is formed 
against pathogens that cause intracellular infection. Infected cells present processed antigens 
to T cells, which are then primed and activated to proliferate and mount an immune response 
against infected cells.  
Upon activation, CD4+ T cells differentiate and proliferate into different T cell 
subtypes such as Th1, Th2, Th17 and inducible regulatory T cells (iTregs). Th1 
cells are vital in responses to intracellular microbes and secrete IFN-γ while Th2 
cells are important for responses to extracellular microbes and secrete 
interleukin (IL)-4 (Mosmann and Sad, 1996). Th17 cells are protective against 
extracellular bacteria and secrete IL-17a, which has a fundamental role in 
autoimmune diseases and inflammation (Ouyang et al., 2008). Tregs are known 
to be immunosuppressive and regulate tolerance as well as immune 
homeostasis (Sakaguchi, 2005, Yamaguchi and Sakaguchi, 2006). Th cells are 
also able to induce destruction of microbes and can mediate the recruitment of 
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phagocytic cells to the site of infection to stimulate macrophages and B cells 
through cytokine secretion (Bettelli et al., 2007, Stout and Bottomly, 1989).  
 
In contrast to CD4+ Th cells, CD8+ T cells and CTL cells can directly recognise 
pathogen antigens on infected cells or antigens on tumour cells presented by 
HLA class I molecules. Once CD8+ T cells are activated, they will acquire 
cytotoxic abilities and can directly facilitate killing of infected cells and tumour 
cells, as shown in Figure 1.3 (Abbas, 2017). 
 
Cell infected with microbes 
Cytotoxic 
T cell 
Antigen – 
MHC 
complex 
T cell receptor 
Perforin/
Granzyme 
Cytotoxic 
T cell 
Pore 
Dying target cell 
Perforin/Granzyme release 
 
Figure 1.3 Cell mediated immunity. Protection is formed against pathogens that cause 
intracellular infection and there is direct lysis of the infected cell via cytotoxic T cells.  
 
Once the pathogen has been eliminated, antigen specific T cells then undergo 
apoptosis and this restores immune homeostasis. A small proportion of T cells 
will differentiate and proliferate into long-lived memory cells able to rapidly 
respond to exposure of the same antigen. There are two types of long-lived 
memory cells: central memory T cells (TCM) and effector memory T cells (TEM). 
TCM produce high levels of IL-2 and express CD45RO, L-selectin and CCR7. 
This phenotype enables them to remain within lymphoid organs and induce 
clonal expansion of T cells after secondary exposure of pathogenic antigen. In 
contrast, TEM express chemokine receptors such as CCR4, CCR5 and CXCR3. 
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These receptors enable TEM to migrate into inflamed tissues (Sallusto et al., 
2004).  
 
1.2 Human Leucocyte Antigens 
 
HLA are membrane bound glycoproteins that present processed antigenic 
peptides to T cells. Highly polymorphic genes located on chromosome 6p21.3 
encode for the HLA system. There are two types of polymorphic HLA genes: 
class I and class II. Class I HLA molecules are expressed on all nucleated cells. 
However, class II HLA molecules are expressed on immune cells such as B 
cells, DCs and macrophages.  
 
HLA class I molecules consist of two non-covalently linked polypeptide chains: 
44-47 kDa heavy chain (HLA-A, HLA-B and HLA-C) and a 12 kDa beta 2-
microglobulin, a non-HLA encoded subunit (Bjorkman et al., 1987). Degradation 
of intracellular proteins and foreign proteins takes place within the cytosol of 
cells. These are degraded by proteasomes into peptides. The peptides 
translocate to the endoplasmic reticulum (ER) via a transporter associated with 
antigen processing (TAP). Glycoproteins and chaperones then help form 
heterodimers within the ER before translocation of the HLA molecule to the cell 
surface (Vyas et al., 2008).  
 
Class II HLA molecules are coded for by three polymorphic genes known as 
HLA-DR, HLA-DQ and HLA-DP (Stern and Wiley, 1994). The expression of 
class II molecules occurs on APCs, DCs and B cells and class II molecules bind 
to different antigenic peptides expressed by the respective cells. Formation of 
the class II molecule takes place within the ER, subsequently being transported 
to the endosomal compartment. The HLA class II molecule is then digested, 
leaving a residual associated peptide known as a class II-associated invariant 
chain peptide (CLIP). The class II peptides then bind to the groove of the HLA 
class II molecule and releases CLIP, which is regulated by HLA-DM and HLA-
DO. The HLA class II molecule is then transported to the cell membrane where 
the antigen is expressed to CD4+ T cells (Kobayashi and van den Elsen, 2012).  
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1.3 Human Leucocyte Antigen Matching for Allogeneic Cord Blood 
Transplant  
 
Histocompatibility testing is used to find a suitable HLA-matched donor for the 
recipient with the intention of reducing post-transplant complications that could 
arise due to HLA-incompatibility (Hirayama and Azuma, 2011). In the UK, 70% 
of patients of white Northern European descent can be fully HLA-matched with 
a donor. However, in the UK only 20% of non-white Northern European descent 
can be fully matched with a donor (Marsh et al., 2013, Hough et al., 2016).   
 
In cord blood transplant (CBT), three HLA loci are matched between the donor 
and the recipient. This includes HLA-A, -B and –DRB1 (i.e. 6/6). HLA-A and 
HLA-B are matched at the antigenic level and HLA-DRB1 is matched at the 
allelic level. In CBT a patient should receive a 4/6 or better match for HLA-A, B, 
and DRB1 (Ballen and Lazarus, 2016). In comparison to BM or mobilized 
peripheral blood (mPB) transplant, HLA matching in CBT is less stringent as 
these treatments require high resolution tissue typing for HLA-A, -B, -C and -
DRB1 (i.e. 8/8) (Barker et al., 2010).  
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1.4 Haematopoietic stem cell transplantation 
 
1.4.1 Haematopoietic stem cells 
 
Haematopoietic stem cells (HSC) are multi-potent cells that have the capacity to 
produce and maintain all types of blood cells and immune cells within the 
human body. Furthermore, HSCs maintain the respective blood cells throughout 
an individual’s lifetime. They inhabit the BM and within this region they are able 
to continuously renew the populations of immune cells and blood cells.  
 
As HSCs are self-renewing, they can be divided into two types of cells. These 
are known as short term HSCs (ST-HSC) and long term HSCs (LT-HSC) 
(Morrison and Weissman, 1994, Weissman, 2000). ST-HSCs have limited 
capacity to self-renew and have temporary haematopoiesis. However, LT-HSCs 
can maintain long-term self-renewal and haematopoietic restoration (Ho, 2005).  
 
Both LT-HSCs and ST-HSCs can be defined by differential expression of cell 
surface markers. The process of haematopoiesis is sequential and LT-HSC will 
proliferate and differentiate into ST-HSC, which then differentiate into common 
lymphoid and myeloid progenitor cells. Common lymphoid progenitors can be 
identified via CD45 and CD7 cell surface markers. However, common myeloid 
progenitor cells are defined via the expression of CD45 and CD33 (Taussig et 
al., 2005). Subsequently, common lymphoid progenitors can differentiate into T 
cells (CD3+CD4+ or CD3+CD8+), B cells (CD19+), and NK cells (CD56+). 
Common myeloid cells will take a distinctive path of differentiation forming 
megakaryocyte/erythroid progenitors and granulocytes/macrophages known as 
MEP and GMP respectively. Furthermore, monocytes and neutrophils (myeloid 
cells) are generated from GMP. Red blood cells and megakaryocytes are 
produced from MEP (Weissman, 2015). HSC differentiation into different 
lineages is represented in Figure 1.4. 
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Figure 1.4 Haematopoietic stem cell differentiation, forming specialised blood cells. All blood lineages can be formed from long-term haematopoietic 
stem cells (LT-HSCs) that can generate short-term haematopoietic stem cells (ST-HSCs) that form common lymphoid and common myeloid progenitor 
cells. Subsequently these cells can produce all types of blood cells. 
. 
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1.4.2 History of haematopoietic stem cell transplantation 
 
The use of HSCs in haematopoietic stem cell transplantation (HSCT) originally 
comes from techniques used to repopulate cells within the BM. This was 
performed to reverse myelosuppression induced by radiation, which was seen 
in survivors of nuclear bombs in Nagasaki and Hiroshima, Japan. Nobel 
Laureate E. Donnall Thomas pioneered the technique of HSCT and performed 
the first syngeneic HSCT in 1956 (Thomas et al., 1975b, Thomas et al., 1957, 
Thomas et al., 1959, Thomas, 1975, Thomas et al., 1975a). Thomas and his 
respective colleagues pioneered HSCT by infusing BM from an identical twin to 
a recipient to treat a patient suffering from leukaemia in 1959 (Thomas et al., 
1959). HLA was discovered in 1960 and the use of allogeneic HSCs became 
more practical. It was later discovered that HLA molecules are inherited, as 
haplotypes from both parents and the probability of two siblings to have HLA 
identity is one in four. This therefore led to Thomas and colleagues in 1977 to 
treat patients who suffered from end-stage leukaemia with BM of HLA-identical 
siblings (Thomas et al., 1977).  
 
HSCT is mainly used to treat haematological diseases and cancers. More 
recently, HSCs have also been used to treat autoimmune diseases, 
immunodeficiencies and anaemias. Before HSCT can be performed, HSC must 
be acquired from a suitable source. A suitable source can be found who is a 
HLA matched donor, this is known as allogeneic. Allogeneic HSC can treat 
haematological diseases. However, there is a risk of developing complications 
post-transplant (Bensinger and Storb, 2001, Tabbara et al., 2002). 
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1.4.3  Haematopoietic stem cell sources 
 
There are different sources of HSC that can be used for HSCT. BM has been 
the original source of HSC and is collected from donors under general 
anaesthetic from their iliac crests (Bahceci et al., 2000). Alternatively, mobilised 
peripheral blood (mPB) can be used whereby HSCs are harvested via 
apheresis after the donor has been treated with granulocyte colony stimulating 
factor (GCSF) (Copelan, 2006, Bensinger and Storb, 2001, Bensinger et al., 
2001). More recently, cord blood (CB) has been used as an alternative source 
of HSC for transplantation. The use of CB originates from its initial use in 1988, 
where a patient with Fanconi’s anaemia was infused with CB from a HLA 
matched sibling (Gluckman et al., 1989).  
 
Haploidentical transplants are also considered to be a source of HSC and have 
been used in recent years. This is where the donor shares one HLA haplotype 
with the recipient and the patient is mismatched for HLA genes on the unshared 
haplotype. Donors for HLA-haploidentical transplant can either be biological 
parents, biological children, full or half siblings (Fabricius and Ramanathan, 
2016).  The pros of haploidentical grafts are that they can immediately be 
available and a graft can be mobilised within 10 - 12 days, which reduces the 
time to transplant compared to CBT, which can take several weeks. 
Haploidentical grafts have adequate doses of HSCs for transplantation and this 
includes adequate numbers of memory T cells, which are limited in CB grafts. 
Furthermore, there is immediate availability of the donor for repeated donations 
of HSCs in order to treat relapse within the patient, which is unavailable in CBT 
(Raiola et al., 2014). Respectively, the cost of graft acquisition in haploidentical 
transplant is lower compared to CBT. Haploidentical transplant also has major 
disadvantages and due to the high frequency of host and donor T cells being 
reactive to HLA alloantigens there is strong alloreactivity. Furthermore, this 
increases the risk of fatal graft rejection (Szydlo et al., 1997, Kindwall-Keller and 
Ballen, 2017). Additionally, in haploidentical transplant due to HLA disparity 
there is a high risk of GvHD and graft failure. However, when T cells are 
depleted from haploidentical grafts and post-transplant cyclophosphide is used 
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there is reduced incidence of GvHD but this could increase the risk of graft 
rejection and relapse (Ash et al., 1991, Barrett et al., 2011).  
 
In 2016, a total of 1279 transplants were performed in the UK. This includes 33 
BM transplants, 1210 mPB transplants and 36 CB transplants. (Source of 
information: http://bsbmt.org/activity/2016/). Furthermore, in 2016 a total of 
3699 BM transplants, 13,481 mPB transplants and 437 CB transplants were 
performed (Source of information: https://www.ebmt.org/registry/transplant-
activity-survey)
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1.5 Early and delayed complications of haematopoietic stem cell 
transplantation  
 
HSCT patients can be affected by complications post-transplant. The key issues 
faced post-transplant are: infections, graft versus host disease (GvHD), relapse, 
graft failure and delayed immune recovery. These are discussed below.  
 
1.5.1 Delayed immune reconstitution and transplant related infections 
 
Delayed immune reconstitution is one of the major issues faced after HSCT and 
is one of the major causes of infection in HSCT patients. Furthermore, the delay 
in immune reconstitution also leads to the increased risk of relapse of disease 
(Chakrabarti et al., 2002a, Chakrabarti et al., 2002b). The use of different 
conditioning agents, regimens and different sources of graft are contributors to 
the rate of immune reconstitution.  
 
A number of studies have investigated immune reconstitution in HSCT. It has 
been shown that irrespective of the graft source, NK cells are the first 
lymphocytic cell type to reconstitute. The median day of neutrophil recovery is 
14 days post-transplant (Komanduri et al., 2007, Beziat et al., 2009, Wu and 
Lanier, 2003, Szabolcs and Cairo, 2010). The reconstitution of NK cells, T cells 
and B cells reach normal healthy levels within the first three months post-
transplant after BM transplantation (BMT) (Morecki et al., 2001, Fujimaki et al., 
2001, Bartelink et al., 2013).  
 
In contrast, the reconstitution of NK cells and CD8+ T cells in mPB recipients 
takes place within the first 100 days post-transplant. However, B cell and CD4+ 
T cell numbers have been shown to recover later and do so between 18 months 
to two years to reach the healthy adult range in mPB recipients (Fry and 
Mackall, 2005, Jacobson et al., 2012, Storek et al., 2001a).  
 
Moreover, the reconstitution patterns of immune cells differ in CBT patients and 
are delayed in CBT patients compared to other graft sources. The first immune 
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cell type to reconstitute within CBT patients are NK cells, where patients reach 
normal healthy levels within three months post-transplant. Sequentially, B cells 
are the second type of immune cell to reconstitute within CBT patients, taking 
place between three and six months post-transplant (Komanduri et al., 2007, 
Beaudette-Zlatanova et al., 2013, Nakatani et al., 2014, Kanda et al., 2012).  
 
T cell reconstitution is also delayed in CBT patients and the reconstitution of 
central memory and effector memory T cells takes place before naïve T cells 
(Komanduri et al., 2007). Furthermore, CD3+, CD4+ and CD8+ T cell numbers 
remain lower compared to healthy adults for up to one to two years post-
transplant (Kanda et al., 2012, Jacobson et al., 2012, Komanduri et al., 2007).  
 
The reconstitution of immune status after HSCT is affected by the type of 
progenitor cells infused into the patient and the types of conditioning regimen 
used prior to transplant are: myeloablative conditioning (MAC), reduced 
intensity conditioning (RIC) or non-myeloablative conditioning. Furthermore, the 
degree of histocompatibility between the recipient and donor (sibling, unrelated 
or mismatch) and types of GvHD prophylaxis (calcenurin inhibitors, 
mono/polyclonal antibodies or T cell depletion) can delay the reconstitution of 
immune cells post-transplant. In turn, this can lead to the development of 
opportunistic infection (Tomblyn et al., 2009).   
 
Infection is a major issue that can arise after HSCT and three phases can be 
distinguished where specific pathogens infect HSCT patients at the respective 
phases. The three phases are known as phase I - pre-engraftment, phase II - 
post-engraftment and phase III - late phase, as shown in Figure 1.5. 
Conditioning can induce an initial period of pancytopenia immediately after 
HSCT (phase I). This is the phase where patients experience mucosal injury 
and neutropenia (Bearman et al., 1989). Patients within the first 30 days are at 
risk of bacterial infection from both gram-positive (e.g. Streptococcus, 
Staphylococcus and Staphylococcus aureus) and gram-negative (e.g. 
Enterobacter and Escherichia coli) bacteria. Additionally, during the first 100 
days post-transplant, patients are also at risk of fungal infections such as 
Aspergillus, Candida and viral infections such as Herpes Simplex Virus. 
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(Balletto and Mikulska, 2015, Wingard et al., 2010). The damage caused to 
mucosal membranes and neutropenia is the major cause for these infections to 
arise within the pre-engraftment phase. Phase II is known as the post-
engraftment phase. During this phase, HSCT patients will have 
immunodeficiency and reduced T cell and B cell functionality, which could be 
due to acute GvHD (aGvHD) development and aGvHD prophylaxis. In turn, this 
increases the chances of viral and fungal infections to develop. During phase II, 
the most common fungal infection is Candida albicans and the most common 
viral infections are cytomegalovirus (CMV), Epstein Barr Virus (EBV) and 
Adenovirus (Chakrabarti, 2007, Bitan, 2006, Tomblyn et al., 2009, Girmenia et 
al., 2011). Phase III takes place between 100 and 365 days post-transplant and 
many patients during this phase may be suffering from chronic GvHD (cGvHD) 
for which they are being treated. Respectively, during this time, patients are 
prone to fungal infections such as Candida and Aspergillus species (Marr, 
2008, Girmenia et al., 2011). An overview of the various common infections in 
HSCT patients is detailed in Figure 1.5.  
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Day 0                                30                                                                100                            365 Reference 
 
Phase 1 
Pre-engraftment 
Phase 2 
Post-Engraftment 
Phase 3 
Late phase  
Risks 
- Neutropenia 
- Mucosal Injury 
- Reduced functional 
Immunity 
- Decreased T cell and B cell numbers 
- Decreased T cell and B cell functionality  
- aGvHD  
- aGvHD treatment 
- Decreased T cell 
and B cell 
functionality  
- cGvHD 
- cGVHD treatment 
(Bearman et al., 
1989) 
Viral 
Herpes Simplex Virus 
(Tomblyn et al., 2009, 
Wingard et al., 2010) 
 
Adenovirus (Chakrabarti, 2007) 
 
CMV (Bitan, 2006, Farnault 
et al., 2015) 
  
EBV 
Fungal 
Candida species 
  
(Girmenia et al., 
2011) 
 
Aspergillus Species (Marr, 2008) 
Bacterial 
Gram Negative Bacteria  (Balletto and 
Mikulska, 2015, Ninin 
et al., 2001) 
Gram Positive Bacteria  
Figure 1.5 Types of common opportunistic infection in HSCT patients post-transplant. 
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1.6 Graft versus host disease 
 
GvHD is a major cause of morbidity in HSCT patients (Ferrara et al., 2009). 
Bellingham et al. first distinguished GvHD in murine models of HSCT over 50 
years ago (Billingham, 1966). The development of GvHD takes place when 
donor T cells respond to recipient tissue antigens presented by HLA molecules 
on the tissues of the recipient (Petersdorf et al., 1995). The risk of developing 
GvHD and its severity is associated with the level of HLA match/mismatch 
between the donor and the recipient (Kanda, 2013). Furthermore, mismatching 
of minor histocompatibility antigens can also lead to the development of GvHD 
(Goulmy et al., 1996). Antigen processing and post-transplant modification of 
peptides via HLA-molecules leads to donor T cells reacting to recipient 
antigens, which initiates GvHD (Goulmy et al., 1996).  
 
1.6.1 Graft versus host disease classification 
 
In 2005, the National institute of health (NIH) released new guidelines and a 
classification system to aid in the diagnosis of GvHD. Through these guidelines, 
two major classifications of GvHD are better known: aGvHD and cGvHD 
(Filipovich et al., 2005). 
 
1.6.2  Acute graft versus host disease 
 
Acute GvHD generally occurs in HSCT patients and is a reaction of the donor 
immune cells that react against the host cells. Commonly in aGvHD, the skin, 
liver and gastrointestinal tract (GIT) are affected and typically occur within the 
first 100 days post-transplant (Martin et al., 1990).  
 
Ferrara and colleagues have detailed the pathophysiology of aGvHD as a 
three-stage process: phase 1, 2 and 3 (Hill and Ferrara, 2000). During phase 1, 
tissue damage and inflammatory response occurs causing the release of pro-
inflammatory cytokines, such as IL-1, IL-6 and Tumour necrosis factor – alpha 
(TNF-α), from host tissues. This causes activation of neutrophils and 
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exacerbates pro-inflammatory cytokine release and chemokine production 
leading to increased inflammation (Hill et al., 1999, Ferrara et al., 2003, Ferrara 
et al., 2009). During this inflammatory response, MHC molecules become 
expressed on the host tissue and this leads to the activation of APCs. During 
phase 2, the induction and expansion phase, donor T cells become activated 
within the lymph nodes due to the presence of IL-12. T cells then secrete IL-2 
and IFN-γ, which further recruits, expands and activates host-specific NK cells, 
CTLs and Th (Jadus and Wepsic, 1992). Phase 3 is the final phase, where, 
effector functions take place through the migration of effector cells (NK cells and 
CTLs) and pro-inflammatory cytokines to the target organ. In turn, this induces 
localised target injury and destruction of the target tissue via interaction of 
CD95 to the CD95 ligand and the release of perforin and granzyme, which lyses 
the tissue (Nagata, 1994, Nagata and Golstein, 1995, Remberger et al., 2003).  
 
1.6.3 Chronic graft versus host disease 
 
Chronic GvHD is a multi-organ pathology that can develop in HSCT patients 
post-transplant. Chronic GvHD occurs in 60-80% of long-term survivors of 
HSCT (Nash et al., 2000, Ratanatharathorn et al., 1998). The common features 
of cGvHD are listed in the NIH guidelines (Jagasia et al., 2015). Many of the 
clinical features seen in cGvHD resemble clinical presentations within 
autoimmunity and immunodeficiencies such as scleroderma, lupus 
erythematous and Sjogren’s syndrome (Snover, 1984, Shulman et al., 1980). 
The cause of cGVHD is complex and includes various factors such as: 
preceding development of aGvHD, age of the donor/recipient and the degree of 
HLA-mismatch between patient and donor (Carlens et al., 1998, Lee et al., 
2002, Storb et al., 1983).  
 
T cells have been shown to play a fundamental role in the development of 
cGvHD. Donor T cells play a central role in the attack against host tissue and 
the release of Th2 cytokines predominate in cGvHD (Sakoda et al., 2007). 
Additionally, donor B cells have been shown to have a potential involvement in 
the initiation and development of cGVHD. The homeostasis of B cells and 
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tolerance mechanisms are disrupted post-HSCT and this causes reduction in 
the formation of B cell memory. This leads to expansion of B cells that are 
activated by host antigens within the reconstituting B cell population (Allen et 
al., 2012, Corre et al., 2010, Greinix et al., 2008).  
 
The severity of cGvHD is measured by clinical presentations that are graded 
using the NIH global grading system (Carlens et al., 1998). The clinical 
diagnosis of cGvHD is based on the differential presentations within HSCT 
patients that might occur. Differential sites of the body can be affected such as 
the oral cavity, skin, eyes, liver and GI tract. (Carlens et al., 1998, Aractingi and 
Chosidow, 1998, Serota et al., 1982, Shulman et al., 1988, Redding et al., 
1998).  
 
1.6.4 Prevention and treatment of graft versus host disease 
 
As GvHD is one of the major complications post-transplant, prophylaxis is used 
to ensure that GvHD is controlled. Preventative measures are taken via the 
administration of immunosuppressive drugs.  
 
In the prevention of GvHD, immunosuppressive agents are incorporated into 
reduced intensity and myeloablative conditioning protocols. The most 
commonly used agents for GvHD prophylaxis are listed in Table 1.1.  
 
T cells play a vital role in the development of GvHD and immunosuppressive 
agents added to conditioning protocols are used to suppress T cell activity 
(Juliusson et al., 2006). Calcineurin inhibitors such as Tacrolimus and 
Ciclosporin A are frequently used to prevent the incidence of GvHD. Calcineurin 
inhibitors prevent the activation of nuclear factor of T cells (NFAT).  
Subsequently, this suppresses T cell expansion, which would be caused by IL-2 
cytokine release (Solomon et al., 2003, Sabry et al., 2009). As part of 
preventative measures, antibodies are frequently used as part of conditioning 
regimes to prevent GvHD. The most commonly used are anti-thymocyte 
globulin (ATG) and CAMPATH-1H. ATG directly binds to T cells and induces T 
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cell depletion, whereas CAMPATH binds to CD52 present on mature 
lymphocytes inducing a wide spread depletion of lymphocytes within the HSCT 
recipient (Finke et al., 2009, Hale et al., 1998, Walker et al., 2016). 
 
Agent Mode of Action Reference 
Anti-thymocyte 
Globulin 
Antibodies that recognise and 
bind to T cells 
(Finke et al., 
2009, Walker 
et al., 2016) 
Ciclosporin A (CsA) Calcineurin inhibitor and 
blockade of T cell action 
(Solomon et 
al., 2003, Storb 
et al., 1986) 
Cyclophosphamide Cytotoxic agent that induces 
death of proliferating cells 
(Colvin and 
Hilton, 1981) 
Methotrexate Interferes with metabolic activity 
of cells 
(Storb et al., 
1986) 
Methylprednisolone Lysis of lymphocytes via specific 
glycoprotein receptor binding 
(Kanojia et al., 
1984) 
Mycophenolate Mofetil Inhibition of DNA synthesis, 
inducer of lymphocyte apoptosis 
(Mohty et al., 
2004) 
Monoclonal Antibodies 
(Alemtuzamab -
CAMPATH) 
Anti-CD52 binding on the surface 
of mature lymphocytes 
(Hale et al., 
1998) 
Sirolimus Blocks T cell and B cell activation (Benito et al., 
2001) 
Tacrolimus Calcineurin Inhibitor and 
blockade of T cell activation 
(Sabry et al., 
2009) 
Table 1.1 Immunosuppressive agents used in the prevention of GvHD 
Although HSCT recipients are administered pre-transplant GvHD prophylaxis, 
patients can still develop aGvHD and cGVHD. This has led to development of 
post-transplant treatment plans of GvHD using a number of immunosuppressive 
agents. The first line of treatment includes the use of steroids (Hockenbery et 
al., 2007, McDonald et al., 1998, Dignan et al., 2012a, Dignan et al., 2012b, 
Dignan et al., 2012c).  However, long-term use of steroids can suppress the 
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immune system and lead to morbidity and mortality in HSCT patients. The most 
commonly used first line treatment plans are steroid combination therapies; 
methylprednisolone with or without calcineurin inhibitors (Martin et al., 2012).  
 
There is no standard second line therapy for GvHD and treatment is guided on 
the basis of the grade and clinical presentation of GVHD.  Second line options 
include the use of Imatinib (Glivec) and Sirolimus. Furthermore, the use of 
extracorporeal photopheresis (ECP) and new biological therapies are being 
used including Rituximab and Infliximab (Cutler et al., 2006, Olivieri et al., 2009, 
Sullivan et al., 1981). There are further possibilities for treatment of GvHD via 
the use of Thalidomide, Tacrolimus, Rapamycin and using pulsed doses of 
steroids. Additionally, patients could be administered total lymphoid irradiation 
in an attempt to reduce allo-reactive T cells.  
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1.7 Relapse 
 
Relapse of the initial disease is one of the major causes of treatment failure and 
mortality in HSCT patients. Relapse can take place any time after transplant 
and can occur soon after HSCT. This could be due to the fact that resistant 
disease cannot be effectively eradicated by the conditioning regimen used prior 
to transplant. Relapse could also occur later due to a delay in immune 
reconstitution and weakness of the immune system (Komanduri et al., 2007, 
Murata et al., 2008).  
 
1.8 Graft failure 
 
Straight after HSCT, graft failure is a major complication that could take place. 
Recipient antibodies, T cells and NK cells are known to cause rejection of the 
graft through responses against donor haematopoietic cells. Additionally, other 
factors such as grafts with higher HLA disparities, unrelated grafts and T-replete 
grafts are also shown to be causes of rejection (Mattsson et al., 2008, Lamba et 
al., 2004). During graft failure, it has been demonstrated in murine models that 
T cells and NK cells become activated and proliferate within the recipient. This 
leads to responses against the donor’s haematopoietic cells. Additionally, the 
source of graft is an important factor in graft failure development as it has been 
shown that BMT recipients have a lower chance of graft failure compared to 
CBT patients (Murphy et al., 1987, Raff et al., 1986, Kiessling et al., 1977, 
Cudkowicz and Bennett, 1971).  
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1.9 Graft versus leukaemia effect 
 
Graft versus leukaemia (GvL) was first described in 1956 in a murine model. 
The initial concept was that donor marrow cells were responsible for the 
clearance of leukaemia (Barnes et al., 1956). A similar observation was seen in 
human BMT studies in 1965, where donor cells eliminated the leukaemia 
(Mathe et al., 1965). GvL is an important effect that has been shown to reduce 
relapse and could take place independently of GvHD (Gale and Horowitz, 
1990). T cells have been shown to play a pivotal role in GvL effects. In 
particular, their responses to chronic myeloid leukaemia (CML) have been 
demonstrated after donor lymphocyte infusion (DLI) and allogeneic HSCT 
(Dickinson et al., 2017) Furthermore, T cells have also been demonstrated to 
have anti-tumour effects in HSCT patients against acute leukaemia or 
Myelodysplastic syndrome (MDS) (Daguindau et al., 2010). Respectively, NK 
cells have also been shown to play a critical role in GvL effects. A study 
conducted by Velardi et al. demonstrates donor versus recipient NK reactivity 
after acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) 
where patients were transplanted with a HLA-haploidentical mismatched family 
donor (Velardi, 2008).  
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1.10 Conditioning regimens used for haematopoietic stem cell 
transplantation 
 
HSCT recipients are prepared with chemotherapy and/or radiotherapy. The 
principle of undertaking chemotherapy is to ablate the malignant cells within the 
patient therefore eradicating disease. Conditioning also serves various 
purposes such as prevention of graft rejection and development of GvHD. 
Conditioning therefore prepares the patient for engraftment of HSCs, which will 
later be infused into the patient. However, it is also known that conditioning can 
cause mortality due to toxicity related complications (Vriesendorp, 2003, Santos 
et al., 1983).  
 
1.10.1 Types of conditioning regimens 
 
There are three main groups of conditioning regimens that are used pre-
transplant: myeloablative conditioning (MAC) (with or without total body 
irradiation (TBI)), reduced intensity conditioning (RIC) and non-myeloablative 
conditioning (NMA) (Bacigalupo et al., 2009).  
 
1.10.2 Myeloablative conditioning 
 
One of the earliest studies by Thomas et al. has demonstrated the 
administration of a BM graft to patients receiving radiation and chemotherapy 
(Thomas et al., 1957). Myeloablation was first tested in murine models, where 
mice were exposed to 10 gray (Gy) of TBI. These were shown to have 
pancytopenia, which was recovered by BMT (Lorenz et al., 1952). 
Myeloablation causes complete haematological destruction and a patient must 
be followed up with a HSCT to recover their haematopoiesis. Myeloablation is 
used to eradicate the haematological or non-haematological disease and to 
suppress the recipient’s immune system, thus preparing the recipient for HSCT. 
The main chemotherapeutic agents used to prepare patients for HSCT using 
the MAC regimen are TBI, Cyclophosphamide (CY) and Busulfan (Bu) and the 
combination of CY-TBI or BU-CY common myeloablative conditioning regimens. 
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In MAC, other high dose chemotherapeutic agents such as Dimethylbusulfan, 
Etoposide, Thioteopa (Thio) and Melphalan (Mel) can also be used in 
combination with CY or TBI (Terenzi et al., 1996, Kanfer et al., 1987, Jamieson 
et al., 2003, Helenglass et al., 1988). 
 
1.10.3 Reduced intensity conditioning 
 
This conditioning protocol was set up to reduce toxicity in HSCT patients. 
Reduced intensity regimens have been formed as many studies supported the 
fact that lower doses of chemotherapy are associated with successful 
engraftment in related and unrelated donors (Giralt et al., 1997, Niederwieser et 
al., 2003). Furthermore, these regimens also demonstrated that older patients 
suffered reduced toxicity and a stable GvL effect was established (Niederwieser 
et al., 2003). RIC regimens cause cytopenia that can be prolonged in patients 
and this means that patients require HSCT. The TBI or alkylating agents are 
reduced in RIC regimens. RIC regimens can include Fludarabine (Flu) with 
other alkylating agents such as Mel, Bu, and Thio (Tauro et al., 2005, Corradini 
et al., 2005, Slavin et al., 1998). 
 
1.10.4 Non myeloablative conditioning 
 
It has been demonstrated that transplant related mortality increases if 
myeloablative conditioning is used and it also increases with the patient age 
(Jamieson et al., 2003). With this in mind, NMA conditioning regimens were 
devised and are predominantly used in older patients. NMA regimens cause 
little cytopenia and have a very low toxicity. However, they have an 
immunosuppressive capacity. When NMA regimens are combined with mPB 
transplant, the results have shown that patients have complete donor 
engraftment. Common combinations of NMA regimens are Fludarabine and 
Cyclophosphamide (Flu-Cy), Total lymphoid radiation (TLI), TBI at 1 Gray (Gy), 
TBI at 2 Gy and ATG (Ballen et al., 2004, Storb, 2001, Lowsky et al., 2005, 
Khouri et al., 1998). Patients administered with NMA regimens usually have 
delayed GvHD development and this normally takes place after 100 days post-
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transplant. However, GvHD is a significant cause of morbidity and mortality in 
NMA conditioned patients (Mielcarek et al., 2003).  
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1.11 Cord blood transplantation 
 
1.11.1 The history of cord blood transplantation 
 
The use of cord blood (CB) was first proposed as an alternative source of HSCs 
for transplantation in 1982. Subsequently, Gluckman et al. performed the first 
related CBT in 1989 to a patient with Fanconi’s anaemia (Gluckman et al., 
1989). The patient had complete engraftment with donor cells and has 
remained in haematological remission for more than 20 years without any 
GvHD development. Following these promising results in related CBT, an 
unrelated CBT was first performed in 1993 in a patient suffering from refractory 
leukaemia (Kurtzberg et al., 1996). Furthermore, a paediatric study performed 
by Wagner et al. demonstrated that cryopreserved CB units could be used as a 
safe source of transferable HSC in clinical transplantation. Additionally, Wagner 
et al. demonstrated that CB contains adequate CD34+ cells, which can aid in 
replacing the haematopoietic system (Wagner et al., 1996). Since then, much 
work has been undertaken to understand the immunology of umbilical cord 
blood (UCB) and refinement in the procedures of collection, processing and 
preservation and thawing techniques.  
 
1.11.2 Cord blood banking 
 
The first cord blood bank (CBB) was established in 1993 in New York, Milan 
and Dusseldorf and this was followed by the first CBB bank in the UK in 1996 
(Bradley and Cairo, 2005). There are various bodies that govern the quality and 
standards of CB units collected. Organisation such as NETCORD, Eurocord, 
FACT and the European Blood and Marrow Transplantation society ensure that 
standards are met for the volumes of CB collected, sterile processing of the CB 
unit, the measurement of CD34+ counts within the CB unit, cell recovery 
methods after processing and red blood cell depletion of the CB unit. It has 
been reported by the Bone Marrow Donors Worldwide (BMDW) that there are 
36 countries worldwide that contain a total of 53 cord blood registries. 
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Furthermore, there are 721,289 CBU registered (as of August 2017) 
(https://www.bmdw.org).  
 
1.11.3 Advantages and disadvantages of cord blood transplant 
 
Over the last 25 years, CBT has become a source of HSC increasingly used for 
HSCT. CB is easily obtained from the donor and no harm is caused to the 
donor when collecting a CB sample. The CB sample is cryopreserved after 
collection and when required is easily available. Compared to mPB and BMT 
recipients, CBT patients require less stringent HLA matching between the donor 
and the recipient, this is due to the naivety of the CB cells. This therefore makes 
CB a viable source of HSC for patients who are unable to find a related or 
unrelated BM or PB donor (Gluckman et al., 1989, Broxmeyer et al., 1989). 
Furthermore, the processing and delivery of CB into the recipient can be 
undertaken easily in comparison to PB and BM harvests and there is a reduced 
risk of the transfer of infections from the donor to the recipient. CBT patients 
have also shown to have a lower incidence of GvHD even though there can be 
CBT with tolerable higher degree of donor-recipient HLA-mismatches (Barker et 
al., 2010, Rocha et al., 2004).  
 
Despite the advantages, the use of CB faces drawbacks. It has been 
demonstrated that there is a low cell dose within the CB unit compared to mPB 
and BM grafts. Additionally, CBT patients cannot be given a DLI post-
transplant. Furthermore, the use of CB is associated with an increased risk of 
graft failure and delayed immune reconstitution (Rocha et al., 2004, Laughlin et 
al., 2001). CBT patients have also been shown to have a delay in the time to 
neutrophil and platelet engraftment when compared to BMT and mPB 
transplant patients. The median time to neutrophil engraftment is 30 days in 
CBT patients, 21 days in BMT patients and 14 days in mPB transplanted 
patients (Seggewiss and Einsele, 2010). The delay in immune reconstitution 
could therefore lead to a higher risk of infection post-transplant, which leads to 
transplant related mortality (TRM) (Laughlin et al., 2001, Laughlin et al., 2004). 
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As a result of delayed immune reconstitution in CBT, the most common 
infection is CMV and EBV (Locatelli et al., 1999, Wagner et al., 2004).  
 
1.11.4 Single versus double cord blood transplant 
 
Single CB units were first used to treat paediatric patients diagnosed with 
haematological and non-haematological diseases (Locatelli et al., 1999, 
Locatelli et al., 2003). CB contains a higher concentration of HSCs. However, 
each CBU contains fewer total nucleated cells (TNC) by one or two logs 
compared to BM or mPB grafts (Rocha and Broxmeyer, 2010). Studies have 
shown that the use of single CBU has been demonstrated to account for long-
term haematopoiesis in 80% of transplanted patients within 30 days of 
transplant and 100% of patients by 365 days post-transplant (Brunstein et al., 
2007). Furthermore, a study comparing single CB treated patients versus BM 
transplanted patient’s shows that the clinical outcomes (relapse, overall 
survival, leukaemia free survival, total relapse mortality and GvHD) of CBT 
patients are similar to that of BMT patients (Atsuta et al., 2009). The CD34+ cell 
dose and the TNC dose are important factors associated with the probability 
and rate of neutrophil engraftment. Due to the lower TNC count in a single cord 
blood unit (sCBU), the infusion of double cord blood units (dCBU) have been 
used to increase the number of TNC infused into patients, known as double 
umbilical cord blood transplant (dUCBT) (Cornetta et al., 2005, Gluckman et al., 
1997, Laughlin et al., 2004, Wagner et al., 2002, Rubinstein et al., 1998). There 
is an overall consensus that a recipient should be infused with a minimal TNC 
dose of 2.5x107/kg of the recipient’s body weight and should be matched with at 
least 4/6 HLA matches per unit (Barker et al., 2001, Barker et al., 2005, Hough 
et al., 2016, Snowden et al., 2016). Since there is a higher TNC content by 
using dUCBT, clinical studies have also shown that there is improved 
engraftment with a reduced risk of relapse and severe aGvHD (Barker et al., 
2003, Barker et al., 2005).  
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1.11.5 Cord blood unit dominance 
 
The use of dUCBT has decreased the rate of graft failure and TRM in adults 
and this has led to further understanding of the biology post-transplant as it has 
been noted that one CBU is dominant over the other and serves as source of 
long-term haematopoiesis (Barker et al., 2005, Brunstein et al., 2007, Ballen et 
al., 2007). The biology of unit dominance remains unclear and factors such as 
HLA-disparity, sex mismatch, TNC count, CD34+ count and viability have not 
been reliable predictors of which unit will be dominant over the other (Majhail et 
al., 2006). However, it has been demonstrated CD34+ cells with viability less 
than 75% infused into recipients is associated with poor engraftment 
(Scaradavou et al., 2010).  
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1.11.6 Methods to improve outcomes of cord blood transplant 
 
Many of the techniques used to improve the outcomes are used to induce 
engraftment and to improve immune reconstitution following CBT, as detailed in 
Table 1.2.  
 Technique Reference 
Modification of 
conditioning 
regimens 
- T-cell depletion 
protocols 
- Reduced intensity 
conditioning 
(Eyrich et al., 2001) 
(Barker et al., 2003) 
CB unit selection 
- KIR matching 
- Detection of donor 
specific antibodies 
(Willemze et al., 2009) 
 
(Takanashi et al., 2008) 
CB cell dose 
- Improved collection, 
processing and freezing and 
thawing 
- Infusion of two CBU 
- Infusion of CB with third 
party donor cells 
- Ex vivo expansion of CB 
cells 
 
(Naing et al., 2015) 
 
 
(Rocha et al., 2010) 
(Bautista et al., 2009) 
 
(Mohamed et al., 2006) 
Delivery and homing 
of HSCs 
- CD26 inhibition 
- Intrabone infusion of CB 
- Fucosylation of HSC within CB 
units 
(Cutler et al., 2013) 
(Frassoni et al., 2008) 
(Popat et al., 2015) 
Post-transplant 
cytokines 
- Administration of 
Granulocyte colony stimulating 
factor (GSCF) 
- Administration of stem 
cell factor (SCF) 
(Gotoh et al., 2014) 
 
(Mohamed et al., 2006) 
Use of accessory 
Cells 
- The use of 
Mesenchymal stem cells 
- The use of Tregs 
(Luan et al., 2015) 
(Brunstein et al., 2011) 
Transplant protocol 
modifications 
- Reduced intensity 
protocols 
(Rocha et al., 2009) 
Table 1.2 Improving outcomes of cord blood transplant 
Various approaches have been used to improve the time to engraftment and 
immune reconstitution in CBT patients. However, further studies are required to 
better understand the kinetics and diversity of reconstituting immune cell 
subsets. This will provide a better insight into the reconstitution of immune cells 
within CBT patients, which will aid in guiding clinical decisions and post-
transplant therapeutics. Additionally, this will provide alternative pathways that 
!! 54 
could be researched to improve the time to engraftment and immune 
reconstitution. In this current study, the focus has been on immune 
reconstitution in CBT patients. A detailed description is discussed in the 
following sections.  
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1.12 Immune reconstitution in cord blood transplant 
 
Monitoring immune reconstitution in CBT could allow the identification of the cell 
types involved in the recovery of the haematological system. By measuring the 
kinetics and diversity of recovering immune cell subsets, cell types can be 
identified which could influence the exacerbation of post-transplant 
complications such as relapse, GvHD and infections. Immune reconstitution is 
the time taken for immune cells to replenish and for the immune system to 
recover within a patient once they have undergone HSCT. Patients who 
undergo CBT are known to experience delayed engraftment and poor immune 
reconstitution. This has been compared to a number of BM and mPB studies as 
discussed previously. 
 
1.12.1 Immune cells within the cord blood graft 
 
1.12.1.1 Monocytes in cord blood grafts 
 
Little is known about the absolute numbers of monocytes within CB grafts.  
However, it has been demonstrated that monocyte absolute counts within CB 
grafts are similar to absolute counts recorded in BM grafts. Furthermore, the 
number of monocytes and the frequency of monocytic populations are similar to 
that seen in adult PB (Sohlberg et al., 2011, Sorg et al., 2001).  
 
1.12.1.2 NK cells in cord blood grafts 
 
Within CB grafts there is a high proportion of NK progenitor cells such as 
CD16positiveCD56negative. NK cells within the CB graft are mainly of two subtypes: 
CD56bright and CD56dim. These NK cell populations are in similar proportions to 
NK cells within adult PB (Gaddy et al., 1995, Verneris and Miller, 2009). NK 
cells within CB grafts have a low level expression of adhesion molecules. This 
is supported by the fact that NK cells within CB grafts highly express NKG2A, 
an inhibitory receptor and a low level expression of granzyme B. This could 
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mean that NK cells engrafted into patients may have decreased cytotoxic 
activity (Tanaka et al., 2003, Wang et al., 2007).  
 
1.12.1.3 B cells in cord blood grafts 
 
CB grafts contain B cells that are predominantly naïve characterised by the 
expression of CD5 and IgM. Furthermore, they have low-level expression of 
CD23 compared to adult PB, which is a low affinity receptor for IgE. This 
receptor plays an important role in parasitic infections and allergic reactions 
(Szabolcs et al., 2003). It has been demonstrated that CB B cells have a high 
number of poly-reactive IgM antibodies. However, they have a decreased 
capacity to class switch, which leads to a decrease in the IgA and IgG 
antibodies produced by CB B cells (Durandy et al., 1990). In addition, B cells 
within CB grafts have an increased susceptibility to lyse via apoptosis (Kessel et 
al., 2006).  
 
1.12.1.4 T cells in cord blood grafts 
 
The majority of CD4+ and CD8+ T cells within the CB graft are considered to be 
naïve as compared to BM and PB grafts, which contains a higher proportion of 
memory T cells within the graft. Furthermore, the majority of CB T cells have a 
naïve phenotype and have not been challenged by antigens. Overall, this 
means that CB T cells are considered to be less alloreactive compared than 
adult donor T cells. CB contains a lower absolute numbers of CD4+ and CD8+ 
T cells compared to BM and mPB (Szabolcs et al., 2003). The proliferation of T 
cells after CBT has been shown to occur rapidly, which is particularly caused by 
allogeneic stimulation. However, CB T cells have limited antigen specific 
cytotoxicity post-transplant (Risdon et al., 1994). Despite the limited antigen-
specific cytotoxicity, CB T cells attain an enhanced anti-tumour function against 
B cell lymphoma compared to PB T cells, which has been shown in murine 
models (Hiwarkar et al., 2015).  
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Moreover, there is a high proportion of Tregs (CD4+CD25+FoxP3+) within the 
CB grafts; these cells have a highly suppressive function (Godfrey et al., 2005). 
CB Tregs have a naïve phenotype and they predominantly express CD45RA 
and low expression of CD45RO in comparison to Tregs from healthy adult PB 
(Chang et al., 2005). Furthermore, CB Tregs have a higher rate of expansion 
after being stimulated with anti-CD3 and anti-CD28 antibodies. This highlights a 
potential of Treg expansion, where Tregs might be able to expand in vivo post-
transplant (Torelli et al., 2012).  
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1.12.2 Platelet and neutrophil engraftment in cord blood transplantation  
 
Following conditioning chemotherapy and/or TBI and the infusion of CB, there is 
an initial phase of aplasia. During this phase, CB HSCs engraft, proliferate and 
expand within the BM of the recipient. TNC counts of the graft are an important 
factor for efficient engraftment in CBT patients and it has been demonstrated 
that increased CD34+ cells and higher TNCs are associated with an increased 
probability and rate of neutrophil and platelet engraftment (Danby and Rocha, 
2014, Gluckman et al., 2004).   
 
CB contains lower TNC doses compared to BM and mPB grafts. The time to 
neutrophil engraftment is defined as the first three consecutive days with a 
neutrophil count greater than 0.5 x 109/L. Comparatively, it has been seen that 
the median time to neutrophil engraftment in CBT patients is 30 days, which is 
slower compared to BM and mPB recipients where a median time to 
engraftment is 21 days and 14 days, respectively (Seggewiss and Einsele, 
2010). The time to platelet recovery is recorded as the first three consecutive 
days with a platelet count greater than 20 x 109/L. It has been observed that the 
time to platelet recovery is also delayed in CBT recipients compared to BM and 
mPB recipients and the time to platelet engraftment can range between 50 days 
to 100 days post-transplant (Nakasone et al., 2016, Storek et al., 2001a, 
Seggewiss and Einsele, 2010).  
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1.12.3 NK cell reconstitution in cord blood transplantation 
 
NK cells are one of the first lymphocytic populations that reconstitute in CBT 
patients. In adult CB recipients, the time to NK cell reconstitution has been 
observed as 30 days post-transplant (Brahmi et al., 2001, Jacobson et al., 
2012, Ruggeri et al., 2011). It has been demonstrated that CBT recipients have 
both populations of NK cells CD56dim and CD56bright. However, there are 
discrepancies in the reconstitution of NK cell populations within CBT recipients. 
Early post-transplant, the reconstitution of NK cells in CBT patients occurs 
through the expansion of CD56bright NK cells and absolute numbers return to the 
healthy range within three months post-transplant (Somers et al., 2013, Ruggeri 
et al., 2011). Following the initial three months, there is an increase in the 
proportion of CD56dim NK cells and this coincides with an absolute count 
increase in the number of CD56dim NK cells (Cooley et al., 2005, Nguyen et al., 
2008). There is a temporary increase in the absolute counts of NK cells, which 
exceeds the normal range of NK cells compared to healthy controls. This could 
occur to compensate the T cell lymphopenia post-CBT (Komanduri et al., 2007). 
Additionally, the reconstitution of NK cells has been demonstrated to occur 
through NK cells from the predominant unit in dUCBT patients and 
reconstitution of NK cell subsets can occur between 180 days to 365 days post-
transplant (Ruggeri et al., 2011, Somers et al., 2013).  
 
1.12.3.1  NK cell function in cord blood transplantation 
 
CD56dim NK cells are known to have a higher cytotoxicity compared to 
CD56bright NK cells (Cooper et al., 2001, Nagler et al., 1989). In HSCT, NK cells 
could play a role in GvL. T cell reconstitution is delayed and this means that the 
clearance of infection and residual diseases could be delayed. However, NK 
cells could compensate for the delay in T cell reconstitution and are shown to 
be key mediators of GvL responses, which have been demonstrated in haplo-
identical transplantation (Ruggeri et al., 2002). In CBT studies, it has been 
demonstrated that the reconstituting NK cells are fully functional and mature 
within the first three months post-transplant. NK cells in CBT patients are able 
!! 60 
to lyse leukaemic blast cells through direct lysis and through ADCC pathways 
(Beziat et al., 2011, Beziat et al., 2009). However, few studies have investigated 
the function of NK cells post-transplant and further work is required to elucidate 
the functional activity of NK cells in CBT patients.  
 
1.12.4 B cell reconstitution in cord blood transplantation 
 
B cell reconstitution occurs between 100 and 180 days post-CBT. 
Comparatively, the reconstitution of B cells is faster compared to BM and mPB 
recipients (Beaudette-Zlatanova et al., 2013, Kanda et al., 2012, Komanduri et 
al., 2007). A study undertaken by Nakatani et al. demonstrates that 
reconstitution of CD19+ B cells takes place in the first three months post-
transplant in adult recipients (Nakatani et al., 2014). However, through BMT and 
mPB transplant studies, there is an increase in the absolute number of B cells 
and within the first three months post-transplant (Beaudette-Zlatanova et al., 
2013, Jacobson et al., 2012, Kanda et al., 2012, Mehta and Rezvani, 2016). 
Little is known about B cell subset reconstitution in CBT of adults. Additionally, 
HSCT patients have an increase in the absolute numbers of transitional B cells 
(CD19+CD24+CD38+). This leads to an increase in the absolute numbers of 
mature B cells (CD19+CD24+CD38-) in HSCT patients (Marie-Cardine et al., 
2008). Overall, the increase in the absolute number of B cells, in CBT patients, 
also exceeds the range of B cells seen within healthy adults, which could be 
due to the T cell lymphopenia experienced by patients post-transplant 
(Komanduri et al., 2007).  
 
During B cell development within the BM, B cells arise from undifferentiated 
haematopoietic precursors. B cell development is split into two phases: the 
initial antigen-independent phase, where precursor B cells mature into 
functional B lymphocytes and the antigen-dependent phase, where mature B 
cells are generated through selection processes (Ghia et al., 1998). During B 
cell maturation within the BM, kappa deleting recombination excision circles 
(KRECs) are formed. These are bi-products of allelic exclusion of the Ig kappa 
locus (IGK) (van Zelm et al., 2007, Siminovitch et al., 1985). KRECs are formed 
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when B cells rearrange the IGK and within B cells the Ig kappa locus becomes 
non-functional and is deleted from the immunoglobulin constant gene (IGC). 
The IGK is located 24 kilobases (kb) downstream from the IGC gene segment. 
During gene re-arrangement, the IGK is excised from the IGC and recombined 
within a RSS, which is located on either side of IGK variable gene segment. 
After the IGK recombines with the RSS, there is formation of a coding joint that 
prevents any further attachment of the IGK within the IGC locus. Thus, the IGK 
is excised from the DNA forming a KREC excision loop (van Zelm et al., 2007, 
van Zelm et al., 2011, Beishuizen et al., 1997). KRECs are found in high copy 
numbers in naïve/transitional B cells that are released into the periphery. The 
copy numbers of KRECs become diluted as B cells proliferate within the 
periphery.  
 
The detection of KRECs can be utilised to understand the output of B cells from 
the BM, which has been demonstrated in a number of CBT studies and HSCT 
studies (Nakatani et al., 2014, Chiarini et al., 2013, Serana et al., 2013). The 
quantification of KRECs has shown that reconstitution of B cells occurs as early 
as one month post-CBT. Furthermore, at three months post-CBT, patients have 
the highest level of KRECs. This indicates that BM output of B cells occurs 
within the first three months post-transplant (Nakatani et al., 2014).  
 
1.12.4.1  B cell subset reconstitution in cord blood transplantation 
 
The number of B cells that reconstitute within CBT patients occurs within three 
to six months post-transplant and the absolute counts reach the healthy adult 
ranges within a median time of six months (Renard et al., 2011, Kanda et al., 
2012, Servais et al., 2014). KREC assays have been utilised to demonstrate 
that B cell reconstitution is enhanced in CBT recipients compared to mPB and 
BMT (Nakatani et al., 2014). The reconstitution of B cells is quicker compared T 
cells and T cell subsets (Bemark et al., 2012). The functional reconstitution of B 
cells is dependent on the reconstitution of a number of B cell subsets within 
CBT patients. During the first three months post-transplant, there is an 
increased circulation of transitional B cells within the periphery (Marie-Cardine 
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et al., 2008). The early circulating B cells are BM emigrants that have a very low 
BCR specificity and a partial response to antigen stimulation (Storek et al., 
1993). Gradually, over the subsequent months, transitional B cells and 
immature B cells differentiate into mature B cells. Jacobson et al. demonstrated 
that dCBT recipients have quicker recovery of IgG compared to mPB recipients 
and the levels of IgG recover between five and six months post-transplant. This 
therefore demonstrates that B cell functionality and the capacity to produce 
antigen specific antibodies occurs within the first year post-CBT (Jacobson et 
al., 2012). However, it has been reported that long-term functional maturation of 
B cells could take longer than one year as most of the circulating B cells are of 
a naïve phenotype (Charrier et al., 2013, Servais et al., 2014). Limited data 
exists on the crucial developmental stages for B cell maturation in CBT patients.  
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1.12.5 T cell reconstitution in cord blood transplantation 
 
T cells reconstitution is delayed CBT patients, taking between six months and 
two years post-transplant. The reconstitution of T cells is dependent on different 
pathways known as the thymic independent and the thymic dependent 
pathways (Williams et al., 2007).  
 
1.12.5.1 Thymic independent reconstitution of T cells 
 
Early post-transplant adoptively transferred T cells proliferate within the 
recipient. Upon exposure to antigens, T cells proliferate within the recipient 
(Mackall et al., 1996). In dUCBT, it there are elevated levels of IL-7 in CBT 
patients for up to two years (Politikos et al., 2015). IL-7 plays an important role 
in regulating the thymic independent expansion of T cells and IL-7 levels are 
inversely correlated with absolute counts of CD4+ T cells (Politikos et al., 2015).  
T cells within the CB graft are predominantly naïve and have limited TCR 
diversity. This limits their ability to recognise a plethora of self and non-self 
antigens compared to healthy adult T cells. Therefore, CBT recipients are 
unable to provide sufficient protection against pathogens, early post-transplant, 
due to limited memory T cell formation (Chalandon et al., 2006). During 
homeostatic peripheral expansion (HPE), T cells within the graft change their 
characteristics from a naïve phenotype to an effector memory and central 
memory phenotype (Mackall et al., 1993). This is a phenotypic and functional 
change. In a study undertaken by Komanduri et al. there is skewing of the T cell 
phenotype, where there is a higher proportion of memory and central memory T 
cells in dUCBT recipients. Furthermore, Komanduri et al. investigated the 
kinetics and diversity of T cell reconstitution in CBT patients, looking at the 
specific reconstitution patterns of CD4+ and CD8+ naïve T cells 
(CD45RA+CCR7+), effector T cells (CD45RA-CCR7-) effector memory T cells 
(CD45RA+CCR7-), and central memory T cells (CD45RA-CCR7+). The findings 
from this study showed that there is delayed reconstitution of naïve T cells and 
an increase numbers of effector memory T cells post-transplant. Furthermore, T 
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cells have an impaired functionality in responses to CMV peptides (Komanduri 
et al., 2007). 
 
As CBT recipients have delayed T cell reconstitution, it has been shown that T 
cells that proliferate via the thymic independent pathway are prone to apoptosis. 
This could reduce the cell number of T cells within the periphery post-transplant. 
As a result, this could lead to a reduced TCR repertoire and limit the antigenic 
specificity in CBT patients, which could be one of the main causes as to why 
there is a high prevalence of infection early post-transplant (Hakim et al., 1997, 
Roux et al., 1996). 
 
Additionally, Tregs are considered an essential component of central and 
peripheral tolerance of the immune system (Sakaguchi et al., 2009). Tregs have 
suppressive and immunomodulatory effects and have a positive correlation with 
preventing the exacerbation of immune responses, thus preventing tissue injury 
(Di Ianni et al., 2011, Misra et al., 2004). In CBT recipients, the absolute 
numbers of Tregs are low for up to six months post-transplant (Jacobson et al., 
2012).  
 
1.12.5.2 Thymic dependent reconstitution of T cells 
 
Long-term immune reconstitution of T cells is also dependent on the 
development of T cells through the thymus. Through this pathway, there is 
generation of naïve T cells with a broad TCR diversity and ability to recognise a 
variety of antigens (Politikos and Boussiotis, 2014, Roux et al., 2000). In order 
for thymic production of T cells to take place, lymphoid progenitors from the 
graft must engraft within the recipient and migrate to the thymus. In the thymus, 
they will interact with cortical thymic epithelial cells and undergo maturation to 
undertake lineage commitment. Notch signalling induces lineage commitment 
within T cells and induces their differentiation and commitment to naïve T cells 
(De Smedt et al., 2002).  
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During thymic development of T cells, there is rearrangement of the TCR, as 
described in section 1.1.4. Gene rearrangement takes place at the TCR beta 
region, TCR delta region and TCR alpha region of TCR loci. The gene 
rearrangement leads to the specific shape of the TCR, which is specific to an 
antigen. These T cells are known as a double positive T cells as they express 
CD4 and CD8 glycoproteins on the surface of the cell. These double positive T 
cells are then positively selected within the thymus upon their ability to bind to 
self-peptide via MHC class I and MHC class II binding (Anderson et al., 2005). 
To survive and further differentiate into a naïve T cell, double positive T cells 
must only bind to MHC class I and class II molecules weakly. If the interaction 
strength is correct, double positive T cells that interact with MHC class I 
molecules will mature into CD8+ T cells and cells that interact with MHC class II 
molecules will mature into CD4+ T cells (Anderson et al., 2002).  
 
T cell maturation and development takes place within the thymus. During thymic 
development there is development of T cell receptor excision circles (TRECs). 
These are bi-products of TCR gene rearrangements similar to KRECs. During 
the maturation process of the TCR αβ receptor, the heavy and light chains 
undergo genomic rearrangement to form a functional receptor. TCR α (TCRA) 
genes contain the TCR variable (TCRV) and TCR joining (TCRJ) joining 
segments. The TCRA segment is excised through the gene rearrangement and 
forms a stable circular loop of DNA known as TRECs. TRECs are found in high 
copy numbers in naïve T cells that are released into the periphery upon T cell 
maturation within the thymus. Respectively, as T cell proliferation takes place 
within the periphery, TRECs become diluted as T cells mature and differentiate 
into further subtypes (Gaballa et al., 2016, Mensen et al., 2013, Ribeiro and 
Perelson, 2007, Sottini et al., 2014). In HSCT and CBT studies, TREC 
quantification has been performed to measure thymic output. Furthermore, 
TRECs have been quantified in healthy individuals and copy numbers of TREC 
decrease with age due to thymic involution (Douek et al., 1998, Gaballa et al., 
2016, Junge et al., 2007, Kimmig et al., 2002, Kohler and Thiel, 2009, Kohler et 
al., 2005, Ribeiro and Perelson, 2007, Sottini et al., 2014).  
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Naïve T cells and recent thymic emigrants (RTEs), which emigrate from the 
thymus, contain high copy numbers of TRECs. CD31 is a surface marker 
expressed by T cells upon egression from the thymus (Kohler and Thiel, 2009). 
Additionally, CD31 (PECAM-1) is a member of the Ig superfamily and is a 
transmembrane surface marker expressed on a number of cells such as T cells, 
mast cells, NK cells, platelets and granulocytes (Newman, 1997). Kohler et al. 
has showed that CD31+ T cells contain high copy numbers of TRECs. This 
suggests that CD31+ T cells are naïve and are recently released from the 
thymus. In a study conducted by Komanduri et al. there are low absolute counts 
of RTEs and low copy numbers of TRECs for up to 365 days post-transplant. 
This suggests that thymic recovery is delayed in CBT patients (Komanduri et 
al., 2007).  
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1.12.6 Overall survival after cord blood transplant 
 
Double CBT patients have a similar overall survival compared to patients 
transplanted with alternative donor sources such as BM, mPB and 
haploidentical transplant. This has been particularly seen in patients 
conditioned via myeloablative conditioning regimens (Brunstein et al., 2010, Liu 
et al., 2014, Takahashi et al., 2007). Respectively, RIC regimens also 
demonstrated that the overall survival of patients is similar to patients 
transplanted with BM and mPB and haploidentical graft sources (Brunstein et 
al., 2012, Chen et al., 2012, Majhail et al., 2008, Weisdorf et al., 2014, Malard 
et al., 2015). It has also been shown that patients infused with dCBU have 
similar disease free survival and overall survival compared to matched 
unrelated donor grafts (Rocha et al., 2004). This demonstrates that the overall 
survival of CBT patients is similar to the survival observed for a variety of graft 
sources used for transplantation. However, discrepancies may occur between 
studies, as there are patients within the respective studies with varying severity 
of disease. The survival time may differ between patients due to the inclusion of 
patients with myeloid and lymphoid malignancies.  
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1.12.7 Factors that affect immune reconstitution in cord blood transplant 
 
Factors that affect immune reconstitution include: the type and intensity of 
conditioning regimens, the use of immunosuppressive therapy, GvHD and age 
of the recipient. These have been detailed in Table1.3.  
 
Factor Effect on immune reconstitution Reference 
Conditioning 
- Presence of chemotherapeutic agents 
post-conditioning that could delay 
engraftment 
- Chemotherapeutic agents delay the 
maturation of T and B-cell subsets 
required for adaptive immune responses 
(Brunstein et al., 2007) 
Immunosuppressiv
e therapy 
- T-cell proliferation is inhibited by 
immunosuppressive drugs such as 
Ciclosporine A (CsA) and 
Mycophenolate mofetil (MMF) 
- ATG and Alemtuzamab (CAMPATH) 
deplete T cells 
(Solomon et al., 2003, 
Storb et al., 1986, Mohty et 
al., 2004) 
(Pascal et al., 2015, Roll et 
al., 2015, Lowdell et al., 
1998) 
GvHD 
- Induces thymic damage 
- Poor thymic function develops and 
results in exacerbated maturation of 
overactive T cells, which cause damage 
to the host  
- Causes delay in the B and T cell 
reconstitution and reductions of 
lymphocytic numbers takes place 
- aGvHD – strong inflammatory 
components causing tissue damage 
- cGvHD – autoimmune like features 
and fibrotic features 
(Wu et al., 2013, Snover, 
1984, MacMillan et al., 
2009, Clave et al., 2009, 
Billingham, 1966) 
Age of Recipient 
- Patients between the ages of one to 24 
have a greater rate of thymopoeisis 
compared to older patients.  
- Older patients have a reduced thymic 
homeostatic proliferation, which results 
in reduced thymic reconstitution.  
(Mackall et al., 1995, 
Komanduri et al., 2007) 
Table 1.3 Factors affecting immune reconstitution in CBT recipients 
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1.12.8 Immune reconstitution in cord blood transplant compared to other 
graft sources 
 
Compared to other graft sources, CBT can be performed in a short period of 
time (Barker et al., 2002). However, due to the naivety of the immune cell 
content and lower TNC content, compared to other graft sources, CBT 
recipients have slower myeloid and platelet recovery. This increases the graft 
incidence of graft failure and non-relapse mortality in CBT patients compared to 
other graft sources (Brunstein et al., 2010, Jacobson et al., 2012). 
 
Neutrophil engraftment takes place in the majority of CBT patients and can take 
place between 5-21 days (Laughlin et al., 2004, Rocha et al., 2004). 
Additionally, CB cells have a high proliferative capacity. However, the slower 
time to engraftment could be due to lower TNCs and fewer CD34+ cells within 
CB grafts compared to BM and mPB (Eapen et al., 2010, Atsuta et al., 2009). 
To overcome this two CB units have been used, which increases the TNC and 
CD34+ cells infused into patients (Barker et al., 2005). However, this does not 
enhance the time to engraftment in dUCBT patients compared to sUCBT 
recipients (Scaradavou et al., 2013, Verneris et al., 2009).  
 
CBT patients conditioned with reduced intensity protocols have a faster 
neutrophil engraftment time compared to CBT patients conditioned with 
myeloablative protocols and recipients of BM and mPB (Oran et al., 2011, Chen 
et al., 2012, Sandhu et al., 2016). However, there is a greater risk of developing 
graft failure in RIC transplants, as the residual disease may not be completely 
cleared post-conditioning (Brunstein et al., 2012, Weisdorf et al., 2014). 
 
1.12.8.1 NK cell reconstitution in cord blood transplant patients 
compared to other graft sources 
 
NK cells are one of the first lymphocytes to reconstitute irrespective of the graft 
source. The kinetics of NK cell reconstitution is similar in CBT patients 
compared to mPB and BM recipients, occurring within the first month post-
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transplant (Ottinger et al., 1996, Buhlmann et al., 2011, Shenoy et al., 1999, 
Jacobson et al., 2012, Brahmi et al., 2001). The reconstitution of NK cells 
occurs through the differentiation of progenitor NK cells. NK cells are of an 
immature CD56bright phenotype for several months and this shifts towards an 
increase in the CD56dim NK cell phenotype between three to six months post-
transplant (Cooley et al., 2005, Beziat et al., 2009, Nguyen et al., 2005, Nguyen 
et al., 2008).  
 
1.12.8.2 B cell reconstitution in cord blood transplant patients 
compared to other graft sources 
 
B cells are also one of the first lymphocyte subsets to reconstitute within CBT 
patients. As shown in CBT studies, B cell reconstitution occurs within 180 days 
post-CBT. Comparatively, this is faster compared to BM and mPB recipients, 
where B cell reconstitution takes place between 180 and 365 days post-
transplant (Avanzini et al., 2005, Lev et al., 2012, Marie-Cardine et al., 2008, 
Nakatani et al., 2014, Storek et al., 1993, Storek et al., 2001b). Furthermore, 
CBT patients reach the B cell absolute healthy adult range in a median time of 
180 days, post-transplant (Nakatani et al., 2014). Moreover, B cells in CBT 
recipients produce higher amounts of B cell activating factor (BAFF) compared 
to mPB recipients, which promotes B cell survival (Jacobson et al., 2012). This 
suggests B cells could have a better survival in CBT recipients compared to 
mPB recipients.  
 
1.12.8.3 T cell reconstitution in cord blood transplant patients 
compared to other graft sources 
 
Studies comparing CBT to BMT and mPB transplant show that the absolute 
levels of CD3+, CD4+ and CD8+ T cells are lower in CBT recipients. 
Furthermore, T cell reconstitution is delayed for up to two years post-transplant 
and in some studies for up to five years post-transplant (Jacobson et al., 2012, 
Kanda et al., 2012, Beaudette-Zlatanova et al., 2013, Bejanyan et al., 2016, 
Mehta and Rezvani, 2016). Moreover, CBUs contain a higher proportion of 
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naïve T cells compared to other graft sources. However, several studies have 
shown that there are fewer circulating naïve T cells in CBT patients compared 
to BM and mPB patients (Kanda et al., 2012, Jacobson et al., 2012). 
 
Both thymic dependent and thymic independent T cell reconstitution is delayed 
in CBT patients compared to BM and mPB recipients. Thymic output is delayed 
with lower TREC copy numbers and low absolute counts of RTEs in CBT 
recipients compared to BM and mPB recipients (Komanduri et al., 2007). In 
CBT patients, thymic independent reconstitution is skewed and patients have 
increased numbers of central memory and effector memory T cells post-
transplant. However, the number of central memory and effector memory T cells 
are lower in CBT patients compared to BM and mPB recipients (Komanduri et 
al., 2007). Additionally, the reconstitution of Tregs in CBT patients is also 
delayed compared to mPB patients. The numbers of Tregs are lower in CBT 
patients up to 180 days post-transplant compared to mPB recipients (Jacobson 
et al., 2012).  
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1.13 Aims of the Project 
 
Delayed immune reconstitution is a barrier towards successful CBT. Studies 
show that immune reconstitution is a major issue in HSCT and specifically in 
CBT (Komanduri et al., 2007, Jacobson et al., 2012). The delay in immune 
reconstitution leads to an increased risk of post-transplant complications such 
as relapse and increased risk of infection (Chakrabarti et al., 2002b, Chakrabarti 
et al., 2002a, Lamba et al., 2004).  
 
Mapping the kinetics of immune cell reconstitution in CBT patients requires the 
investigation of a broad set of immune cells that play a fundamental role in 
innate and adaptive immune responses. The aim of this study is to define the 
kinetics and diversity of major immune cell subsets such as NK cells, B cells, T 
cells and their respective subpopulations, which will enhance our understanding 
of the immune cells that could influence post-transplant outcomes.  
 
NK cells reconstitute within the first month post-CBT (Small et al., 1999, 
Jacobson et al., 2012, Brahmi et al., 2001). Furthermore, NK cells in CBT 
patients mediate GvL responses post-transplant (Beziat et al., 2011, Beziat et 
al., 2009). However, limited data exists on the activation of NK cells and their 
cytolytic capacity post-CBT. Therefore, the aim is to elucidate the functionality 
of NK cells in CBT patients and further analyse whether NK cells have a 
cytotoxic capacity against a malignant cell line.  
 
B cells reconstitute within 180 days post-CBT (Nakatani et al., 2014), as a 
crucial component of adaptive immunity, B cells are required for the 
development of long-term immunity via the production of antigen specific 
antibodies. In CBT studies, the kinetics of B cell reconstitution has been 
focused on limited subsets of B cells such as transitional and mature B cell 
subsets (Cuss et al., 2006, Malaspina et al., 2007, Marie-Cardine et al., 2008, 
Sims et al., 2005). With this in mind, it is crucial to understand whether B cell 
developmental stages take place in CBT patients.  This could provide an insight 
into the developmental stages involved in reconstituting B cell subsets and 
reconstitution of long-term immunity. Therefore, the aim of this current study is 
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to investigate the kinetics and diversity of B cell subsets in CBT patients with a 
further aim of elucidating whether there is reconstitution of developmental 
stages in B cell maturation.  
 
Additionally, T cells are also a key cellular component of adaptive immune 
responses. Rapid reconstitution of T cells and expansion of T cell subsets in 
CBT patients has been associated with development of GvHD (Sakoda et al., 
2007). T cells are further required post-transplant to reduce the incidence of 
relapse and for an optimised GvL response (Barrett, 2008). T cell reconstitution 
differs compared to NK cells and B cells and is delayed in CBT patients 
(Komanduri et al., 2007, Jacobson et al., 2012). Thymic dependent 
reconstitution has specifically been demonstrated as delayed in CBT patients 
(Gaballa et al., 2016, Kimmig et al., 2002, Sottini et al., 2014). However, thymic 
independent reconstitution in CBT patients includes the peripheral expansion of 
effector and central memory T cells, with reduced levels of naïve and RTEs 
(Komanduri et al., 2007). With this in mind, limited studies demonstrate a 
comprehensive analysis of thymic dependent and thymic independent 
reconstitution in CBT patients. Therefore, further work is required to better 
understand the reconstitution of T cell subsets in CBT patients.  
 
Comprehensive studies are required to better understand the immune kinetics 
and diversity of reconstituting cell subsets in CBT patients. So far, published 
data demonstrates the reconstitution patterns of specific cell subsets in CBT 
patients. However, the patterns of reconstitution have not been broadly 
investigated in CBT patients within the UK. Herein, it highlights the importance 
of studying immune reconstitution in CBT recipients, as it will provide a better 
understanding of immune cell recovery post-transplant. The current study is the 
first clinical study within the UK to investigate the kinetics and diversity of 
reconstituting immune cell subsets in CBT patients.  
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The specific aims for this thesis were as follows: 
 
Chapter 3 – To investigate the kinetics and diversity of recovering immune cell 
subsets in CBT patients.  
 
Chapter 4 – To investigate NK cell functionality in CBT patients.  
 
Chapter 5 – To investigate the kinetics and diversity of B cell reconstitution and 
whether reconstitution of B cells impacts the overall survival in CBT patients.  
 
Chapter 6 – To investigate the kinetics and diversity of T cell reconstitution in 
CBT patients. 
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Chapter 2 :  Materials and Methods  
 
2.1  Blood 
 
2.1.1 Umbilical cord blood 
 
All CB units were obtained from the Anthony Nolan Cord Blood Bank, 
Nottingham. CB was obtained under prior informed consent and approval by the 
ethical committee (NREC Reference no 10/H0405/27). All samples were 
processed within 24 hours upon delivery to the Anthony Nolan Research 
Institute.  
 
2.1.2 Peripheral blood 
 
Healthy adult peripheral blood (PB) blood was obtained from healthy volunteers 
with informed consent.  
 
2.1.3 Patient blood 
 
Patients undergoing CBT as a treatment for a variety of haematological 
malignancies and disorders were recruited at the respective hospitals: 
 
1. Beatson West of Scotland Cancer Centre, Glasgow 
2. Bristol Royal Infirmary 
3. Christies NHS foundation Trust, Leeds 
4. Freeman Hospital, Newcastle 
5. Heart of England NHS Foundation Trust, Birmingham 
6. Kings College Hospital, London 
7. Manchester Royal Infirmary 
8. Queen Elizabeth Hospital, Birmingham 
9. Royal Hallamshire Hospital 
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10. Royal Marsden Hospital, Sutton 
11. St. Bartholomew’s Hospital, London 
12. St James’s Hospital, Leeds 
13. UCLH, London 
 
CBT Patients were recruited between January 2009 and October 2015. Patients 
provided informed consent before a blood sample was obtained. Patient blood 
samples were taken at the same time as routine hospital checks and patients 
did not require an additional vene-puncture. Blood samples were collected from 
patients at 28, 60, 100, 180, 365 and 720 days post-transplant. At the 
respective time points 40 mL of PB were obtained in transport media and 10 mL 
of PB in EDTA vacutainer. All samples were processed within 24 hours upon 
delivery to the Anthony Nolan Research Institute.  
 
The Immune reconstitution study (IRES-CBT, REC number: 09/H0706/35) was 
set up in 2009 and has been funded by the UK Stem Cell Foundation and 
Anthony Nolan. Patient samples were initially collected by Dr Sameer Tulpule 
Patient sample collection and processing was followed up by Dr Damini Tewari. 
I then started patient sample collection and processing on May 1st 2012. At the 
respective time points the number of samples processed by myself are listed in 
Table 2.1.  
 
Day 28 60 100 180 365 720 
Samples 
Processed 
38 38 38 25 26 14 
Table 2.1 Number of samples processed by myself during the immune reconstitution 
study 
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2.2 Materials used for cellular studies 
 
All the materials used in the cellular studies are stated in table 2.2. 
Table 2.2 Media, reagents and serum used in this study. 
 
Media/Reagents/Serum Manufacturer Country 
β-mercaptoethanol (β-ME) Life technologies Paisley, UK 
Bovine Serum Albumin Sigma Poole, UK 
Dextran 40 Fresenius Kabi Barcelona, Spain 
DNAase – 1  Merck K GaA Darmstadt, Germany 
Dimethyl sulphoxide (DMSO) Sigma Poole, UK 
Ethylenediaminetetraacetic acid (EDTA) 
0.5M ultra pure pH8.0 
Life Technologies  Paisley, UK 
Fetal Calf Serum (FCS) Lonza Verviers, Belgium 
Fixation/ Permeabilization buffer eBiosciences Hatfield, UK 
FACS Lysis Solution BD Pharmingen Oxford, UK 
Lympholyte-H VWR Leicestershire, UK 
Magnesium Chloride (MgCl2) Sigma Poole, UK 
Phosphate Saline Buffer (PBS) 10X Lonza Verviers, Belgium 
Penicillin and Streptomycin (Pen/strep) Lonza Verviers, Belgium 
Pharm Lyse BD Pharmingen Oxford, UK 
Proteinase K Sigma Poole, UK 
Roswell Park Memorial Institute media with 
L-glutamine 1640 (RPMI-1640) 
Lonza Verviers, Belgium 
Sterile Water Baxter Zurich, Switzerland 
Trisodium Citrate Sigma Poole, UK 
Tryphan Blue (0.4%) Sigma Poole, UK 
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All the materials used during cellular studies are listed in Table 2.3. 
 
Material Manufacturer Country 
1 mL, 5 mL, 10 mL and 50 mL syringes BD Plastipack Madrid, Spain 
5 mL polypropylene round bottom tubes BD Pharmingen 
Erembodgen, 
Belgium 
Cryotube Vials Nunc Roskilde, Denmark 
CoolCell Cell Freeze Containers Sigma-Aldrich 
 
St. Louis, Missouri, 
United States 
 
EDTA - 10.0 mL BD Vacutainer® plastic 
EDTA tube. Lavender BD Hemogard™ 
closure 
BD Pharmingen Erembodgen Belgium 
Falcon Tube (15 mL, 50 mL) Starsted Numbrecht, Germany 
Minidstart Sterile Filter 
Sartorius Stedium 
Biotech 
Munich, Germany 
Partec CellTrics 30 micron filters Partec Germany 
Pasteur Pipette 
Thermo Fisher 
Scientific 
Loughborough, UK 
Serological pipette (5 mL, 10 mL, 25 mL) Starstedt Numbrecht, Germany 
Tissue Culture Flask (25, 75 and 150 cm2) Starstedt Numbrecht, Germany 
TruCount Tubes BD Oxford, UK 
U-bottom 96-well plate Starstedt Numbrecht, Germany 
V-bottom 96-well plate Starstedt Numbrecht, Germany 
Table 2.3 List of materials used during cellular studies. 
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2.2.1 Buffers 
 
All the buffers used for cell staining, isolation and washing are listed in Table 
2.4. 
Buffer Components 
Cell Thawing Buffer RPMI 1640 + 20% FCS 
Dextran Thawing 
Buffer 
5% FCS, 0.63% Trisodium Citrate, 5 mM MgCl2, 1000 IU/mL DNase-1 
in Dextran 40 
FACS buffer 1X PBS and 10%V/V FBS 
Lysing Buffer 10X BD FACS lysis solution diluted to 1X with distilled water 
MACS buffer 1X PBS, 1%w/v BSA and 2mM EDTA 
PBS 10X PBS diluted to 1X with distilled water 
Table 2.4 List of Buffers 
2.2.2 Media 
 
All the media used for cellular studies are listed in Table 2.5. 
Medium Components 
Culture medium RPMI 1640, 5µM 2 β-ME, 1% Pen-Strep and 10% v/v FCS 
Freeze Media FCS, 10% DMSO 
Transport Medium RPMI 1640, 33% v=w/v Tri-sodium citrate, 5µM 2 β-ME 
Table 2.5 List of Media 
2.2.3 Kits 
 
All the commercial kits used for cellular isolation and DNA/RNA extraction are 
listed in Table 2.6. 
Kit Manufacturer 
BD Cytofix/Cytoperm Kit BD, Frembodgen, Belgium 
FoxP3 Transcription Factor Fixation/Permeabilization Kit eBiosciences, Hatfield, UK 
NK Cell Isolation Kit Miltenyi Biotec, Germany 
PKH67 Green Flourescent Cell Linker Kit for General Cell 
membrane Labelling 
Sigma, Poole, UK 
PureYield Plasmid Miniprep Kit Promega, Wisconsin, USA 
RNeasy Mini kit Qiagen, Germany 
Table 2.6 List of Kits 
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2.2.4 Antibodies  
 
All the antibodies used in immune reconstitution immunophenotyping are listed 
in Table 2.7. Furthermore, all antibodies used for immunophenotyping in 
immune function analysis are listed in Table 2.8. 
Surface 
Marker 
Company 
Catalogue 
Number 
Fluoroch
rome 
Dilution Clone Isotype 
CCR7 BD 560765 PE 1/20 150503 Mouse IgG2a 
CD3 BD 345766 PerCP 1/10 SK7 
Mouse BALB/c 
IgG1, κ 
CD3 BD 555335 APC 1/10 UCHT1 Mouse IgG1, κ 
CD4 BD 555346 FITC 1/100 RPA-T4 Mouse IgG1, κ 
CD4 BD 345770 PerCP 1/100 SK3 Mouse IgG1, κ 
CD8 BD 555634 FITC 1/10 HIT8a Mouse IgG1, κ 
CD10 BD 555375 PE 1/10 HI10a Mouse IgG1, κ 
CD14 BD 555397 FITC 1/100 M5E2 Mouse IgG1, κ 
CD16 BD 555406 FITC 1/5 3G8 Mouse IgG1, κ 
CD19 BD 345778 PerCP 1/20 4G7 Mouse IgG2a, κ 
CD19 BD 555415 APC 1/20 HIB19 Mouse IgG1, κ 
CD21 BD 559867 APC 1/10 B-ly4 Mouse IgG1, κ 
CD24 BD 555427 FITC 1/10 ML5 Mouse IgG1, κ 
CD25 Biolegend 302625 
PerCP-
Cy5.5 
1/20 BC96 Mouse IgG1, κ 
CD27 BD 555440 FITC 1/10 M-T271 Mouse IgG2a, κ 
CD31 BD 555446 PE 1/50 WM59 Mouse IgG1, κ 
CD38 BD 555460 PE 1/10 HIT2 Mouse IgG1, κ 
CD45 BD 332784 
PerCP-
Cy5.5 
1/50 2D1 Mouse IgG1, κ 
CD45 BD 555485 PerCP 1/10 H130 Mouse IgG1, κ 
CD45RA BD 550855 APC 1/100 HI100 Mouse IgG1, κ 
CD56 BD 555516 PE 1/10 B159 IgG1, κ 
CD127 BD 557938 PE 1/50 
HIL-7R-
M21 
Mouse IgG1, κ 
Table 2.7 Cell surface staining antibodies for immune reconstitution. 
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         Table 2.8 Antibodies used for immunophenotyping for functional analysis 
Surface Marker Company Catalogue Number Fluorochrome Dilution Clone Isotype 
CD3 BD 557851 PE-Cy7 1/10 SK7 Mouse IgG1, κ 
CD3 BD 561027 Alexa Flour 700 1/50 UCHT1 Mouse BALB/c IgG1, κ 
CD4 BD 555349 APC 1/20 RPA-T4 Mouse IgG1, κ 
CD8 BD 565310 PerCP-Cy5.5 1/20 SK1 Mouse BALB/c IgG1, κ 
CD8 BD 555634 FITC 1/20 HIT8a Mouse IgG1, κ 
CD14 BD 555399 APC 1/25 M5E2 Mouse IgG2a, κ 
CD16 BD 555406 FITC 1/20 3G8 Mouse BALB/c x DBA/2 
CD16 Biolegend 302011 APC 1/50 3G8 Mouse IgG1, κ 
TCR -αβ BD 555547 FITC 1/10 T10B9.1A-31 Mouse BALB/c IgM, κ 
TCR- γδ BD 555717 PE 1/20 B1 Mouse IgG1, κ 
CD56 BD 560842 PerCP-Cy5.5 1/10 B159 Mouse IgG1, κ 
CD56 BD 557747 PE-Cy7 1/20 B159 Mouse IgG1, κ 
CD57 BD 562488 PE-CF594 1/10 NK-1 Mouse IgM, κ 
CD25 BD 341011 PE 1/25 M-A251 Mouse BALB/c IgG1, κ 
CD25 BD 555434 APC 1/20 M-A251 Mouse BALB/c IgG1, κ 
CD69 BD 557756 APC-Cy7 1/10 FN50 Mouse IgG1, κ 
HLA-DR BD 560651 PE-Cy7 1/10 G46-6 Mouse IgG2a, κ 
NKG2A R&D Systems FAB1059A APC 1/10 131411 Mouse IgG2A 
NKG2C Biolegend FAB138P PE 1/10 134591 Mouse IgG1 
IFN-γ BD 552887 PE 1/100 B27 Mouse IgG1, κ 
CD127 BD 557938 PE 1/100 HIL-7R-M21 Mouse IgG1, κ 
FoxP3 eBioscience 45-4776-42 PerCP-Cy5.5 1/80 PCH101 Rat IgG2a 
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2.2.5 Materials used for molecular work 
Table 2.9 List of Media, reagents and serum used for molecular work. 
Media/Reagents/Serum Manufacturer Country 
ABI BigDye Terminators V3.0 ready reaction mix Applied Biosystems California, USA 
Absolute Ethanol VWR Leicestershire, UK 
BigDye reaction buffer Applied Biosystems California, UK 
EcoRI restriction enzyme Sigma Poole, UK 
Ethidium Bromide (EtBr) Sigma Poole, UK 
EDTA 0.5M Ultra pure pH8.0 Life Technologies Paisley, UK 
Glycerol VWR Leicestershire, UK 
HEPES buffer (pH7.4) 10mM Sigma Poole, UK 
HiDI Formamide solution Applied Biosystems California, UK 
Hyperladder IV Bioline London, UK 
Kanamycin Sigma Poole, UK 
LE Agarose Invitrogen Paisley, UK 
MgCl2 50 mM Bioline London, UK 
Oneshot TOP10 Component cells Invitrogen Carlsbald, USA 
Proteinase K Sigma Poole, UK 
Sodium Chloride (NaCl) Sigma Poole, UK 
Sodium Dodecyl Sulphate (SDS) Sigma Poole, UK 
Sterile Water Baxter Zurich, Switzerland 
Tris Sigma Poole, UK 
Tris-Boric Acid EDTA (TBE) Sigma Poole, UK 
TaqMan Universal Master Mix, with UNG Life Technologies Paisley, UK 
Xho I restriction enzyme Sigma Poole, UK 
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All the materials used in molecular studies are listed in Table 2.10. 
 
Materials Manufacturer Country 
Hard-shell PCR plates 96-well, thin wall Bio-Rad Oxford, UK 
PCR Plate Sealer Bio-Rad Oxford, UK 
Whatman filter paper Whatman Inc New Jersey, USA 
Table 2.10 Materials used for molecular studies 
2.2.6 Instruments and software 
 
All the instruments and software used for molecular biology work are listed in 
Table 2.11. 
 
Instrument Software 
ABI GA-3730xl genetic analyser (Applied Biosystems, Foster 
City, California, USA). 
Data Collection software 
version 2.0,  
 
Bio-Rad CFX96 Real-Time System 
Bio-Rad CFX Manager software 
version 3.1 
NanoDrop – 1000 Spectrophotometer (US) NonoDrop-1000 version 3.3.1 
Table 2.11 Instruments and software used for molecular studies 
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2.3 Methods 
 
2.3.1 Cellular biology 
 
All cellular work was conducted in a class II laminar flow tissue culture cabinet 
(Astec Micro, UK) using aseptic techniques and sterile laboratory consumables.  
2.3.2 Mononuclear cell isolation  
 
Patient and healthy donor peripheral blood mononuclear cells (PBMC) or Cord 
blood mononuclear cells (CBMC) samples in transport media were separated 
via density gradient centrifugation using Lympholyte-H at 2200 rpm for 22 
minutes with the break off at 500 rpm. The mononuclear layer was collected 
and washed twice; the first wash was undertaken at 1800 rpm for 10 minutes 
and then 1600 rpm for 5 minutes. The PBMC pellet was re-suspended for cell 
enumeration however for the CBMC pellet required further lysis to remove red 
blood cells.  
2.3.3 Red blood cell lysis 
 
The amount of red blood cells harvested from the mononuclear layer was 
higher in CB than in PB. Therefore a lysis step was required for 8 minutes at 
room temperature with 1X lysing buffer for CBMC. Cells were then washed with 
RPMI 1640 and centrifuged at 1800rpm for 10 minutes. 
2.3.4 Cell enumeration and viability 
 
Cell number and viability measurements were performed using two different 
exclusion dye methods: Trypan Blue to determine viability and Turk’s count to 
determine the number of nucleated cells. For both methods, the solution of 
Trypan Blue or Turk’s was in a 1:1 ratio with cells within a 0.1mm 
haemocytometer counting chamber (Hawkley, UK). Viable cells were counted 
under a phase contrast DM LB Microscope (Leica, Germany). 
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2.3.5 Cell cryopreservation 
 
For cryostorage, isolated cells were re-suspended in Freeze Media. Isolated 
mononuclear cells were stored in cryotube vials at a concentration of 10 x 106 
cells and 5 x 106 cells in a 1 mL and 0.5 mL respective volume. The cells were 
stored at this concentration to ensure a balanced concentration allowing the 
cells to mix evenly within freezing medium. Cryovials containing the cell 
suspensions were placed into -70oC within CoolCell Cell freezing containers. 
This allowed a liquid cooling rate of 1oC per minute. After 24 hours the cells 
were transferred to liquid nitrogen for long-term storage.  
2.3.6 Cell thawing 
 
Healthy donor and patient PBMCs or CBMC samples were thawed in a 37oC 
water bath (Fischer Scientific, UK) and mixed very gently with a cooled thawing 
mix of Dextran thawing buffer. Patient PBMCs and healthy control PBMCs were 
thawed in a cell thawing buffer and rested for 30 minutes before being 
centrifuged at 1600 rpm for 5 minutes. The cells were then resuspended in 
RPMI 1640.  
2.3.7 Immunophenotyping for immune reconstitution  
 
Immunophenotyping panels (Table 2.12) were established to identify cellular 
reconstitution in CBT patients. 
Cell subtype FITC PE PerCP APC 
T-cells/B-cells/Natural Killer Cells CD16 CD56 CD3 CD45 
Monocytes/B-cells CD14  - CD45 CD19 
Regulatory T-cells CD4 CD127 CD25 CD3 
T-stages CD4 CCR7 CD3 CD45RA 
T stages CD8 CCR7 CD3 CD45RA 
B stages CD24 CD38 CD4 CD19 
B stages CD27 CD10 CD19 CD21 
Recent Thymic Emigrants CD4 CD31 CD3 CD45RA 
Recent Thymic Emigrants CD8 CD31 CD3 CD45RA 
Table 2.12 Fluorochrome staining panel for assessment of immune recovery and kinetics 
in CBT patients 
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The immunophenotyping panel was established in 2009 by Dr Sameer Tulpule 
and the panel set up was used throughout the immune reconstitution study to 
ensure consistent analysis between patient samples. The immunophenotyping 
panel was established so that the following cellular subsets could be analysed 
within CBT patients.  
 
1) T cells (CD3+) 
2) CD14+ monocytes 
3) CD19+ B-cells 
4) CD45+ cells 
5) Regulatory T cells (Tregs): CD3+ CD25+ CD25+ CD127low 
6) CD4 T-stages 
a) Naïve T cells - CD3+CD4+CD45RA+CCR7+ 
b) Effector T cells - CD3+CD4+CD45RA+CCR7- 
c) Effector memory T cells - CD3+CD4+CD45RA-CCR7- 
d) Central memory T cells - CD3+CD4+CD45RA-CCR7+ 
7) CD8 T-stages 
a) Naïve T cells - CD3+CD8+CD45RA+CCR7+ 
b) Effector T cells - CD3+CD8+CD45RA+CCR7- 
c) Effector memory T cells - CD3+CD8+CD45RA-CCR7-  
d) Central memory T cells - CD3+CD8+CD45RA-CCR7+ 
8) B-cells  
a) Transitional B cells – CD4-CD19+CD24+CD38+ 
b) Mature B cells – CD4-CD19+CD24+CD38- 
c) Activated B cells - CD19+CD10-CD21+CD27+ 
d) Memory B cells - CD19+CD10-CD21-CD27+ 
e) Naive B cells - CD19+CD10+CD21+CD27-  
9) CD4 recent thymic emigrants – CD3+CD4+CD31+CD45RA+ 
10) CD8 recent thymic emigrants – CD3+CD8+CD31+CD45RA+  
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2.3.8 Cell surface staining of whole blood for flow cytometry 
 
The 10 mL EDTA patient blood sample was used for cell surface staining to 
identify the cell subsets listed in the Table 2.12. 50 µL of blood was aliquoted 
into ten 5 mL polystyrene round bottom tubes. 25 µL of the respective antibody 
master mix was added to each round bottom tube before being incubated at 
4oC for 20 minutes. The red blood cells were lysed using FACS lysing solution 
for 10 minutes at room temperature. Thereafter, the cells were centrifuged for 5 
minutes at 1200 rpm. The supernatant was discarded and the cells were re-
suspended in 1 mL of FACS buffer. The cells were centrifuged for 5 minutes at 
1200 rpm. The supernatant was discarded and the cells were re-suspended in 
400 µL of FACs buffer. The cells were acquired on the flow cytometer within 1 
hour. 
2.3.9 Measurement of absolute cell count numbers in whole blood using 
TruCount staining 
 
Absolute cell numbers in each whole blood sample were measured within two 
hours of receiving the sample using TruCountTM Tubes. Each TruCountTM tube 
contains a pre-determined number of fluorescent beads and during the 
acquisition and analysis are gated to compare the cell frequency in each blood 
sample, which was stained with fluorochrome-labelled antibodies as listed in 
Table 2.7 to make up cocktails shown in table 2.12. 
 
50 µl of whole blood was pipetted into each tube. Two separate tubes were 
used: one containing 25 µl CD16-FITC/CD56-PE/CD3-PerCP/CD45-APC 
labelled antibodies, the other containing 25 µl CD14-FITC/CD45-PerCP/CD19-
APC labelled antibodies. Samples were then vortexed and incubated in the dark 
at room temperature for 15 minutes. Thereafter 450 µl of 1X FACSTM Lysis 
solution was added to each tube and incubated in the dark at room temperature 
for 15 minutes. The samples were acquired on the flow cytometer within one 
hour.  
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2.3.10 Flow cytometry sample acquisition 
 
Characterisation of the cell subsets was undertaken via flow cytometry using a 
FACSCalibur (BD, UK), FACSCanto II (BD, UK) and LSR Fortessa (BD, UK). 
Data analysis was undertaken via the use of FlowJo software (Treestar Inc., 
USA). Single stains and negative controls were used to specifically validate the 
cell populations within all samples acquired for flow cytometry analysis.  Patient 
samples were initially processed using the NHSBT - Colindale facilities; this 
covered the time in which laboratory protocols could be set up at the Anthony 
Nolan Research Institute. At the NHSBT – Colindale the FACSCanto II (BD, 
UK) were used to acquire samples. Furthermore, at the Anthony Nolan 
Research Institute, the FACS Calibur (BD, UK) and the LSR Fortessa (BD, UK) 
were used to acquire samples.  
 
2.3.11 Clinical data  
 
Clinical data for each patient was obtained through the Eurocord Database. 
This data was collected at the respective transplant centres by clinical staff 
during the patient follow-ups and submitted to the Eurocord Database. (In this 
study, the median follow up of survivors was 25 months). The data was 
extracted from the Eurocord database and sent to myself at the Anthony Nolan 
Research Institute. 
!
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2.4 Characterisation of cellular subsets gating strategies for immune reconstitution  
 
The following gating strategy shown in Figure 2.1 was used to analyse and quantify CD3, CD16, CD45 and CD56 
Respectively, the following cellular subsets were quantified within healthy control and patient PB samples: CD56+ (NK-cells), 
CD3+ (T cells), CD56bright CD16negative and CD56dim CD16positive (NK cells) and CD45+ cells.  
 
 
 
 
 
 
 
 
 
 
 
A B C D E F 
Figure 2.1 Gating strategy for absolute counts (Panel 1). Healthy control and patient PB samples were stained with monoclonal antibodies for 
surface expression of CD3, CD16, CD56 and CD45. (A) Gating of TruCount beads, (B) Gating of the CD45+ cells, (C) Gating of lymphocytes (D) 
Gating of CD3+ and CD3- (E) Gating of CD56+ cells, (F) Gating of CD56dim and CD56bright to identify NK cells.  
 
!
 
!90 
0 50K 100K 150K 200K 250K
FSC
0
50K
100K
150K
200K
250K
SS
C
1.16
16
0 10 2 10 3 10 4 10 5
CD45 PerCP
0
50K
100K
150K
200K
250K
SS
C
96.6
0 50K 100K 150K 200K 250K
FSC
0
50K
100K
150K
200K
250K
SS
C
18
0 10 2 10 3 10 4 10 5
CD14 FITC
0
50K
100K
150K
200K
250K
SS
C
53.3
0 10 2 10 3 10 4 10 5
CD19 APC
0
50K
100K
150K
200K
250K
SS
C
13.8
The following gating strategy shown in Figure 2.2 was used to identify and quantify the following cell subsets in healthy control 
and patient PB samples; CD14+ (Monocytes), CD19+ (B cells) and CD45+ cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C D E 
Figure 2.2 Gating strategy for absolute counts (Panel 2). Healthy control and patient PB samples were stained with monoclonal antibodies for surface 
expression of CD14, CD19 and CD45. (A) Gating of TruCount beads, (B) Gating of the CD45+ cells, (C) Gating of lymphocytic and monocytic cell 
populations, (D) Gating of CD14+ Monocytes from the CD45+ cells, (E) Gating of CD19+ B cells from the CD45+ cells.  
!
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The following gating strategy shown in Figure 2.3 was used to analyse and quantify Regulatory T cells 
(CD3+CD4+CD25+CD127lo) in healthy control and patient PB samples.  
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A B C D E 
Figure 2.3 Gating of Regulatory T cells. Healthy control and patient PB samples were stained with monoclonal antibodies for surface expression 
of CD3, CD4, CD25 and CD127. (A) Gating of lymphocytes and exclusion of debris, (B) Gating of lymphocytes, (C) Gating of CD3+ T cells, (D) 
Gating of CD4+ T cells, (E) Gating of CD4+CD25+CD127lo Regulatory T cells.  
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The following gating strategy shown in Figure 2.4 was used to identify and quantify CD4+ T stages within healthy control and 
patient PB samples. Respectively the following subsets were identified: naïve T cells (CD3+CD4+CD45RA+CCR7+), central 
memory T cells (CD3+CD4+CD45RA-CCR7+), effector T cells (CD3+CD4+CD45RA+CCR7-) and effector memory T cells 
(CD3+CD4+CD45RA-CCR7-). 
 
 
 
 
 
 
 
 
 
 
 
A B C D 
Figure 2.4 Gating strategy for CD4+ T stages. Healthy control and patient PB samples were stained with monoclonal antibodies for surface 
expression of CD3, CD4, CD45RA and CCR7. (A) Gating of lymphocytes and exclusion of debris, (B) Gating of CD3+ T cells, (C) Gating of CD4+ T 
cells, (D) Gating of CD45RA and CCR7 subsets to distinguish the following cell subsets: naïve T cells (CD3+CD4+CD45RA+CCR7+), central 
memory T cells (CD3+CD4+CD45RA-CCR7+), effector T cells (CD3+CD4+CD45RA+CCR7-) and effector memory T cells (CD3+CD4+CD45RA-
CCR7-).  
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The following gating strategy shown in Figure 2.5 was used to identify and quantify CD8+ T stages within healthy control and 
patient PB samples. Respectively the following subsets were identified: naïve T-cells (CD3+CD8+CD45RA+CCR7+), central 
memory T cells (CD3+CD8+CD45RA-CCR7+), effector T cells (CD3+CD8+CD45RA+CCR7-) and effector memory T cells 
(CD3+CD8+CD45RA-CCR7-). 
 
 
 
 
 
 
 
 
 
 
A B C D 
Figure 2.5 Gating strategy for CD8+ T stages. Healthy control and patient PB samples were stained with monoclonal antibodies for surface 
expression of CD3, CD8, CD45RA and CCR7. (A) Gating of lymphocytes and exclusion of debris, (B) Gating of CD3+ T cells, (C) Gating of CD8+ T 
cells, (D) Gating of CD45RA and CCR7 subsets to distinguish the following cell subsets: naïve T cells (CD3+CD8+CD45RA+CCR7+), central memory T 
cells (CD3+CD8+CD45RA-CCR7+), effector T cells (CD3+CD8+CD45RA+CCR7-) and effector memory T cells (CD3+CD8+CD45RA-CCR7-).  
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The following gating strategy shown in Figure 2.6 was used to identify and quantify mature and transitional B cells within 
healthy control and patient PB samples. Respectively the following subsets were identified: transitional (CD4-
CD19+CD24+CD38+) and mature B cells (CD4-CD19+CD24+CD38-).  
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A B C D 
Figure 2.6 Gating strategy for Transitional and Mature B cells. Healthy control and patient PB samples were stained with monoclonal antibodies for 
surface expression of CD4, CD19, CD24 and CD38. (A) Gating of lymphocytes and exclusion of debris, (B) Gating of lymphocytes, (C) Gating of CD19+ 
B cells, (D) Gating of CD24 and CD38 subsets to distinguish the following cell subsets: transitional (CD4-CD19+CD24+CD38high) and mature B cells 
(CD4-CD19+CD24+CD38low).  
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The following gating strategy shown in Figure 2.7 was used to identify and quantify the following B cell subsets within healthy 
control and patient PB samples: activated B-cells (CD19+CD10-CD21+CD27+), memory B-cells (CD19+CD10-CD21-CD27+) 
and naive B-cells (CD19+CD10-CD21+CD27-). 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C D E 
Figure 2.7 Gating strategy for Activated B cells, Memory B cells and Naive B cells. Healthy control and patient PB samples were stained with 
monoclonal antibodies for surface expression of CD10, CD19, CD21 and CD27 (A) Gating and exclusion of debris, (B) Gating of lymphocytes, (C) 
Gating of CD19+ B cells, (D) Gating of CD10+ and CD10- B cells (E) Gating of CD10- subsets: activated B cells (CD19+CD10-CD21+CD27+), 
memory B cells (CD19+CD10-CD21-CD27+) and naive B cells (CD19+CD10-CD21+CD27-).  
 
!
 
!96 
0 50K 100K 150K 200K 250K
FSC
0
50K
100K
150K
200K
250K
SS
C
4.27
45.7
0 10 2 10 3 10 4 10 5
CD3 PerCP
0
50K
100K
150K
200K
250K
SS
C
22.3
0 10 2 10 3 10 4 10 5
CD4 FITC
0
50K
100K
150K
200K
250K
SS
C
91
0 10 2 10 3 10 4 10 5
CD31 PE
0
10 2
10 3
10 4
10 5
C
D
45
RA
 A
PC
8.77 12.9
13.864.5
The following gating strategy shown in Figure 2.8 was used to identify and quantify CD4+ T cell recent thymic emigrants 
(CD3+CD4+CD31+CD45RA+) within healthy control and patient PB samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C D 
Figure 2.8 Gating Strategy for CD4+ T cell recent thymic emigrants. Healthy control and patient PB samples were stained with monoclonal 
antibodies for surface expression of CD3, CD4, CD31 and CD45RA (A) Gating of lymphocytes and exclusion of debris, (B) Gating of CD3+ T cells, (C) 
Gating of CD4+ T cells, (D) Gating of CD45RA and CD31 to distinguish CD4+ recent thymic emigrants (CD3+CD4+CD31+CD45RA+).  
!
 
!97 
 
 
The following gating strategy shown in Figure 2.9 was used to identify and quantify CD8+ T cell recent thymic emigrants 
(CD3+CD8+CD31+CD45RA+) within healthy control and patient PB samples.  
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A B C D 
Figure 2.9 Gating strategy for CD8+ T cell recent thymic emigrants. Healthy control and patient PB samples were stained with monoclonal 
antibodies for surface expression of CD3, CD8, CD31 and CD45RA. (A) Gating of lymphocytes and exclusion of debris, (B) Gating of CD3+ T cells, 
(C) Gating of CD8+ T cells, (D) Gating of CD45RA and CD31 to distinguish CD8+ recent thymic emigrants (CD3+CD8+CD31+CD45RA+).  
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2.5 Patient flow cytometry database  
 
Flow cytometric data was recorded onto a database constructed by myself to 
handle and manage the subset data. FileMaker Pro software was used to 
construct the database and different layouts were produced so that flow 
cytometric data could be stored for the following cellular subsets: 
 
• Figure 2.10 – Database main page  
• Figure 2.11 - Absolute counts 1 for CD3+ T cells, CD16, CD45+ cells, 
CD56+ NK cells and CD56dim CD16positive NK cells 
• Figure 2.12 - Absolute counts 2 for CD14+ monocytes, CD19+ B cells 
and CD45+ cells 
• Figure 2.13 - Absolute bead counts 
• Figure 2.14 - Regulatory T cells (Tregs) 
• Figure 2.15 - CD4+ T stages 
• Figure 2.16 - CD8+ T stages 
• Figure 2.17 – B stages 
• Figure 2.18 – B stages - CD10 negative  
• Figure 2.19 - Recent thymic emigrants – CD4+ 
• Figure 2.20 - Recent thymic emigrants – CD8+  
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Figure 2.10 - Database – Main page 
Figure 2.11 Database - Absolute counts 1 
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Figure 2.12 Absolute counts 2 
 
 
 
Figure 2.13 Database - Bead Count 
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Figure 2.14 Database - Tregs 
 
 
 
Figure 2.15 Database - CD4+ T cell stages 
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Figure 2.16 Database - CD8 T stages 
 
 
Figure 2.17 Database - B cell stages 
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Figure 2.18 Database - B cell stages (CD10-) 
 
 
Figure 2.19 Database - CD4+ T cells - Recent thymic emigrants 
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Figure 2.20 Database - CD8+ T cells - Recent thymic emigrants 
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2.6 TruCount calculator 
 
To accurately quantify the absolute count of cells within patient samples a 
TruCount calculator was devised using FileMaker Pro. To quantify the number 
of cells, the relevant volumes of antibodies and respective chemical volumes 
are input into the system. The calculator performed various calculations and the 
final value given is a cells/microliter reading of the desired cell subset. This can 
be seen in Figure 2.21.  
 
 
Figure 2.21 TruCount Calculator produced on Filemaker Pro 
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2.7 Methods for molecular studies  
2.7.1 Genomic DNA extraction 
 
DNA was extracted from healthy adult PBMCs and patients PBMCs, as per the 
QIAamp DNA blood Mini Kit protocol.  
 
2.7.2 Quantification of nucleic acid 
 
DNA concentrations were quantified using the Nanodrop ND-1000 
spectrophotometer (Labteach, Lews, UK). This was undertaken as per the 
manufacturer’s recommendation. The purity of the sample was assessed by a 
ratio of absorbance OD260nm:OD280nm. A ratio between 1.6 and 1.8 would be 
considered satisfactory. Samples were then stored at 4oC for short-term storage 
or -20oC for long-term storage. The DNA concentration used for this study was 
100 ng/mL. 
 
2.7.3 Plasmid extraction 
 
The TOPO 2.1 plasmid (Figure 2.22) was donated by Dr A Sottini (CREA, 
Diagnosis Department, Spedali Civili di Brescia), which contained the triple 
insert for TREC, KREC and TRAC. The plasmid was bound to Whatmann paper 
and this was extracted by placing the Whatmann paper into TE buffer within an 
Eppendorf tube. Thereafter the Eppendorf tube was placed on a roller for three 
to six hours. Once diluted, 2 µL of diluted plasmid was used for transformation 
into E.Coli.  
 
 
 
 
 
 
 
!! 107 
2.7.3.1 Plasmid map of pCR 2. 1 TOPO  
 
2.7.4 Transformation into competent cells 
 
Oneshot TOP10 competent cells (Invitrogen, Life Technologies, Carlsbald, 
California) were used to transform the triple-insert plasmid. To perform the 
transformation chemically the rapid chemical transformation procedure was 
undertaken as per manufacturer’s instructions.  
 
 
 
Figure 2.22 Plasmid map of pCR-2.1 TOPO. This has multiple cloning sites and was used 
for expression of TREC, KREC and TRAC. The insertion of TREC, KREC and TRAC are 
within the T-A acceptor site of pCR2.1-TOPO Vector. Plasmid utilised for T-cell receptor 
excision (TREC) circle quantification and Kappa deleting excision circle (KREC) 
quantification. The arrows indicate the direction of transcription. Source of Image: 
https://www.addgene.org/PR/091911/ 
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2.7.5 Culture for plasmid extraction 
 
Transformed colonies were selected and placed into falcon tubes containing 
Laura Broth (LB) with Kanamycin. The falcon tubes were then placed into a 
shaking incubator at 2000 rpm at 37oC, overnight.  
2.7.6 Glycerol stocks of plasmids 
 
800 µL of transformed colony culture was added to two to four drops of 
autoclaved glycerol within a cryovial. The cryovial was shaken for one minute 
and then stored at -20oC until further plasmid stocks were required.  
 
2.7.7 Plasmid preparation 
 
Plasmid extraction and preparation was performed using the PureYield Plasmid 
Miniprep Kit as per the manufacturer’s instructions.  
 
2.7.8 Plasmid restriction digestion 
 
Two restriction digests were performed to ensure that the plasmid was 
linearised prior to sequencing for the TREC, KREC and TRAC genes. Plasmid 
DNA was linearised using Xho I or EcoRI restriction enzymes.  
 
2.7.9 Gel electrophoresis 
 
100 mL of 1X TBE buffer and 1.5g of agarose were used to produce a gel, 
which were mixed and heated in a microwave. The solution was then cooled 
and 5 µL of 1000X Ethidium Bromide (0.5 mg/ml) was then added. The gel was 
cast and the linearised gene sequences were then run on the gel for 45 minutes 
at 150V. 
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2.7.10 Cycle sequencing reaction 
 
Cycle sequencing was undertaken with the TREC/KREC or TRAC genes within 
the plasmid. Table 2.13 defines the master mix reaction used for the cycle 
sequencing reaction.  
Component Volume 
Ready Reaction Mix 1 µL 
5X Buffer 0.5 µL 
Primer 1 µL 
Distilled Water 2.5 µL 
Plasmid DNA 5 µL 
Table 2.13 Mastermix for the cycle sequencing reaction 
 
2.7.11 Precipitation of cycle sequenced products and ABI loading 
 
Once the cycle sequencing was performed the products were precipitated 
before they could be sequenced via the ABI sequencer. 2.5 µL of EDTA (125 
mM) and 30 µL of 100% ethanol were added to each well before being vortex 
mixed. The sequencing plate was incubated at room temperature for 15 
minutes followed by a 3200 rpm centrifugation for 30 minutes. The plate was 
then unsealed and inverted onto tissue and centrifuged at 900 rpm for three 
seconds. 30 µL of 70% ethanol was then added to each well. The plate was 
gently flicked to mix the contents within each well and centrifuged at 900 rpm 
for 3 seconds. The plate was air dried for 5 minutes and all the wells were 
rehydrated with 10 µL of HiDi solution (Applied Biosystems). The plate was then 
vortexed before a septa seal was placed over the wells. The plate was placed 
into the sequencing cassette and loaded into the ABI sequencer.  
 
2.7.12 Microelectrophoresis of sequences 
 
All sequencing data was generated via capillary electrophoresis using an ABI 
GA-3730xl genetic analyser. The sequencing platform is based on 96 well glass 
coated capillaries, 50 cm, and is filled with a polymer (POP-7). The runs on the 
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sequencer are performed at 60oC with an injection time of 15 seconds. The 
injection has a voltage of 1.5kV and a running voltage of 8.5kV. All settings 
were kept as recommended by the manufacturer.  
 
2.7.13 Analysis of the sequencing data 
 
The data generated post-capillary electrophoresis was transferred to a 
computer and analysed using Sequencing Analysis 5.2 or Seq Scape2.5.0 
Software (PE Applied Biosystem, Foster City, CA, USA). The data was then 
inverted and inserted into Factura (PE Applied Biosystem, Foster City, CA, 
USA). The sequence was then imported into Sequence Navigator (PE Applied 
Biosystem, Foster City, CA, USA) to identify the quality of the sequence 
generated. The average base pair read for TREC, KREC and TRAC was 600 
bp. The sequences were overlapped and aligned. A consensus sequence was 
produced and computed, thereafter being exported into a text file and pasted 
into a word document to be aligned with the primer sequences. BLAST 
searches were then performed to confirm 100% sequence identity within the 
plasmid samples. 
2.7.14 Primer/probe gene sequences for TREC, KREC and TRAC 
quantification via RT-PCR 
 
All primers used in TRAC, TREC and KREC quantification are listed in Table 
2.14. 
Gene  Sequence 5’-3’ 
TREC 
forward CAC ATC CCT TTC AAC CAT GCT  
reverse  TGC AGG TGC CTA TGC ATC A  
probe  FAM-ACA CCT CTG GTT TTT GTA AAG GTG CCC ACT-TAMRA   
KREC 
forward  TCC CTT AGT GGC ATT ATT TGT ATC ACT  
reverse AGG AGC CAG CTC TTA CCC TAG AGT 
probe HEX-TCT GCA CGG GCA GCA GGT TGG-TAMRA 
TRAC 
forward TGG CCT AAC CCT GAT CCT CTT 
reverse GGA TTT AGA GTC TCT CAG CTG GTA CAC 
probe FAM-TCC CAC AGA TAT CCA GAA CCC TGA CCC-TAMRA 
Table 2.14 Primer and Probe sequences for TREC, KREC and TRAC genes 
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2.7.15 Cell isolation procedures for T-cell Receptor Excision Circles 
(TREC) / Kappa chain Receptor Excision Circles (KREC)  
 
For the cells that were subjected to TREC and KREC quantification methods, 
three isolation methods were used to distinguish whether valid results can be 
achieved through differential cell isolation procedures, listed below.  
- Monoclonal antibody isolation via cell sorting 
- Magnetic bead isolation  
- Ficoll separation  
 
2.7.16 Monoclonal antibody isolation  
 
Cells were isolated using ficoll methods as described earlier. 10 x 106 isolated 
cells were stained with monoclonal antibodies against anti-FITC for CD4 / CD8 
(Miltenyi, Germany Cat No: 130-048-071), anti-APC for CD19 (Miltenyi, 
Germany Cat No: 130-090-855). Cells were stained at 4oC for 20 minutes and 
then washed at 1300 rpm for 5 minutes twice. Cells were re-suspended in 500 
µL of FACS buffer at each wash step. The cells were strained using a BD 
Falcon 70 µm cell strainer for 50 mL falcon tubes, prior to being sorted on the 
FACS Aria (BD, UK) within the Immunology department of the Royal Free 
Hospital. The respective cell subsets were then frozen for DNA extraction.  
 
2.7.17 Magnetic bead isolation  
 
Cells were isolated using ficoll methods described earlier. To further isolate 
certain subsets a vial of 10 x 106 isolated frozen CB cells were thawed and 
stained with monoclonal antibodies against CD4 (FITC), CD8 (FITC) and CD19 
(APC). Cells were then placed at 4oC for 20 minutes. The cells were then 
washed with 1 mL of MACS buffer and centrifuged at 1300 rpm for 5 minutes. 
This step was repeated twice. The cells were then re-suspended in 100 µL of 
MACS buffer. Cells were then subjected to staining with anti-FITC microbeads 
(130-048-70) (Miltenyi, Germany) or anti-APC conjugated microbeads. 10 µL of 
the conjugated beads were added to the cells, which were then incubated for 10 
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minutes in the dark at 4oC-8oC. The cells were then washed in 2 mL of MACS 
buffer and centrifuged at 1800 rpm for 10 minutes. The supernatant was then 
discarded and the cells are re-suspended in 500 µL of MACS buffer.  
Magnetic separation was then undertaken using a MACs column and MACS 
separator (Miltenyi, Germany). The CD4, CD8 and CD19 cell subsets were 
extracted using LS columns (130-042-401) (Miltenyi, Germany), which were 
used for positive selection of the desired cells. The cells were isolated as per 
the manufactures instructions and tested for purity and frozen for DNA 
extraction. 
2.7.18 Mononuclear isolation 
This was performed as described in section 2.3.2. 
2.7.19 Standard curve preparation for TREC/KREC and TRAC real time -
PCR 
A plasmid standard curve is used in RT-PCR to efficiently quantify and qualify 
the gene of interest. The triple inserted plasmid serves as a control to quantify 
TREC, KREC and TRAC copy numbers. Firstly, the mass of the plasmid copy 
numbers was calculated. This took into account that the plasmid size was 
4,846bp in length. The average mass per base pair was 1.096 x 1021 g/bp.  
Therefore, the mass of plasmid copy number is the following: 
(4,846 bp) x (1.096 x 10-21 g/bp) = 5.311 x 10-18g 
Using this mass the following table, Table 2.15, shows the mass per copy 
numbers required at each concentration.  
Copy Number 
X 5.311 x 10-18 g 
Mass of Plasmid DNA (g) 
1 x 106 5.311 x 10-12 
1 x 105 5.311 x 10-13 
1 x 104 5.311 x 10-14 
1 x 103 5.311 x 10-15 
1 x 102 5.311 x 10-16 
Table 2.15 Mass of plasmid required for each standard curve dilution point 
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Using the mass of plasmid concentrations (Table 2.15), the concentrations of 
plasmid DNA were calculated (Table 2.6) by dividing the masses by the volume 
to be pipetted into each reaction as shown below in Table 2.17. 
Mass of Plasmid DNA (g) 
÷5 
Final concentration of 
plasmid DNA (g/µL) 
5.311 x 10-12 1.062 x 10-12 
5.311 x 10-13 1.062 x 10-13 
5.311 x 10-14 1.062 x 10-14 
5.311 x 10-15 1.062 x 10-15 
5.311 x 10-16 1.062 x 10-16 
Table 2.16 Concentration of plasmid DNA  
An aliquot of plasmid was thawed and linearised using restriction enzyme Xho I. 
The concentration was determined via spectrophotometric estimation at 
260nm/280nm. A working stock of 1x10-10 g/µL was prepared. The following 
dilutions were made so that as shown in Table 2.17.  
Initial 
concentration 
(g/µL) 
Plasmid 
DNA (µL) 
Diluent 
Volume 
(µL) 
Final 
Volume 
(µL) 
Final 
Concentration 
(g/µL) 
Final Copy 
Number of 
Plasmid DNA / 5 
µL 
1x10-7 5 45 50 1x10-8 - 
1x10-8 5 495 500 1x10-10 - 
1x10-10 5 465 470 1.062x10-12 1x106 
1.062x10-12 5 450 500 1.062x10-12 1x105 
1.062x10-13 5 450 500 1.062x10-12 1x104 
1.062x10-14 5 450 500 1.062x10-12 1x103 
1.062x10-15 5 450 500 1.062x10-12 1x102 
Table 2.17 Working concentrations of plasmids 
The highest dilutions of 10 copies/ 5 µL were prepared before the assay as they 
contain a small quantity of plasmid DNA and are not stable enough to be stored 
for future use.  
 
The plate layout used to quantify TREC, KREC and TRAC genes in patient and 
healthy control samples is shown in Figure 2.23 
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Figure 2.23 RT-PCR plate layout for TREC/KREC and TRAC. The respective plate layout 
was used to quantify the copy numbers of TRAC, TREC and KRECs in healthy controls and 
patients.  
 
The following master mix solutions were performed and added to the respective 
wells as shown in Table 2.18 below.  
 
TREC/KREC TRAC 
H20 2.0 µL H20 4.75 µL 
KRECs forward 1.125 µL KRECs forward 2.0 µL 
KRECs reverse 1.125 µL KRECs reverse 2.0 µL 
KRECs probe 0.5 µL KRECs probe 2.0 µL 
TRECs forward 1.125 µL 
2x TaqMan Universal 
Master Mix 
2.0 µL 
TRECs reverse 1.125 µL   
TRECs Probe 0.5 µL   
2x TaqMan Universal 
Master Mix 
12.5 µL   
Table 2.18 Mastermix solutions for TREC/KREC and TRAC 
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20 µL of the respective master mixes and 5 µL of genomic DNA were added to 
the respective wells. 
 
The real-time PCR plate was then run using the Bio-Rad CFX96 Real-Time 
System. The protocol set for the TREC run was the following:  
 
- 50oC for 2 minutes 
- Initial heating at 95oC for 10 minutes 
- Forty-five denaturation cycles at 95oC for 15 seconds 
- Combined primer/probe annealing and elongation at 60oC for 1 minute 
 
2.7.20 Real time PCR standard curve calculations 
 
The data from the Bio-Rad CFX96 Real-Time System was then exported and 
before quantification of TREC, KREC and TRAC could be undertaken a 
standard curve for TREC, KREC and TRAC was generated. These were 
undertaken to verify the ideal exponential amplification rate, which would 
correspond to the RT-PCR efficiency. 
 
The following graphs represent standard curves generated to identify efficiency 
for a real-time PCR reaction.  
 
TRAC 
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TREC 
 
KREC 
 
 
2.7.21 PCR efficiency calculation 
 
PCR efficiency was calculated for each reaction using the plasmid lines of best 
fit for TRAC, TREC and KREC. This was to ensure that during the logarithmic 
phase of the PCR reaction the PCR product of interest is doubling with each 
cycle. To calculate the PCR efficiency, for each plasmid standard curve a line of 
best-fit equation was generated using Microsoft Excel. The equation was 
usually in the format of y = - mx+c. The –m value was input into the following 
equation to calculate the efficiency of the PCR:  
 
Efficiency of PCR = (10(-1/-m)-1) x 100 
 
Further calculations of copy numbers of genes were only calculated if the PCR 
efficiency was above 90%.  
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2.7.22 Calculations and quantification of TRAC, TREC and KREC 
 
To quantify the copy number of the TRAC, TREC and KREC genes the CT 
values were input into the plasmid standard curve equation. The calculation 
was performed as follows: 
 
1. Using the duplicate values for each patient sample an average value is 
calculated  
2. Using values from the slope gradient equations y = -mx+ c the following 
equation is constructed 
3. ((Average patient CT value – c)/ -m)) x 107 
4. The value calculated is the mean quantity TREC/KRECs within the 
patient samples 
5. The following formula should be used to calculate the copy number of 
TREC/KREC  
((Mean quantity of TREC or KREC / Mean quantity of TRAC/ 2)) x107  
 
The mean quantity of TRAC was divided by two as each cell had two gene 
copies, one for each chromosome.
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2.8 Methods for functional studies  
2.8.1 Cell surface staining protocol for immunophenotyping for functional 
cell analysis 
 
Isolated healthy control and patient PBMCs were thawed as described in 2.3.6. 
The cells were subjected to cell surface staining as described in 2.3.8. The cells 
were acquired on a flow cytometer as previously described in section 2.3.10.  
2.8.2 Intracellular staining for IFN- Ɣ  
 
Healthy control and patient PBMCs were thawed, as described in 2.3.6. The 
cells were surfaced stained in 50 µL of an antibody cocktail consisting of CD56, 
CD16, CD3, CD14, HLA-DR and CD69. The cells were centrifuged at 1500 rpm 
at room temperature and the supernatant was discarded. The cells were re-
suspended in 100 µL of BD Cytofix/CytoPerm solution and incubated for 20 min 
in the dark at 4-8oC. The cells were centrifuged at 1500 rpm for three minutes 
and washed in 200 µL of Perm/Wash Buffer. The supernatant was discarded 
and the cells were resuspended in 100 µL of IFN-γ antibody cocktail, which was 
freshly prepared at a 1/100 dilution within Perm/Wash buffer. The cells were 
incubated at 4oC for 30 minutes and washed twice in Perm/Wash buffer prior to 
centrifugation at 1500 rpm for three minutes. The supernatant was discarded 
and the cells were re-suspended in 400 µL of FACS buffer. The cells were 
transferred to Falcon round-bottom tubes for acquisition on a flow cytometer. 
2.8.3 Intra-nuclear staining for Foxp3 
 
Healthy and patient PBMCs were thawed as described in 2.3.6. The cells were 
surface stained in 50 µL of CD4, CD3, CD25 and CD127 for 15 minutes at room 
temperature. The cells were collected via centrifugation at 1500 rpm for four 
minutes at 4oC and the supernatant was discarded. The cells were re-
suspended in 100 µL of FoxP3 fixation/permeabilization buffer and incubated 
for 30 mins at 2-8oC in the refrigerator, in the dark. The cells were collected via 
centrifugation at 1500 rpm, for 4 mins, at 4oC and the supernatant was 
discarded. The cells were washed in 80 µL FoxP3 permeabilization buffer and 
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centrifuged at 1500 rpm for 4 minutes at 4oC, which was repeated twice. The 
cells were resuspended in 50 µL of FoxP3 antibody and incubated for 30 mins 
at 2-8oC in the refrigerator, in the dark. The cells were collected via 
centrifugation at 1500 rpm for four mins, at 4oC and the supernatant was 
discarded. The wash step was then repeated twice and the cells were then re-
suspended in 100 µL FACS buffer before being transferred to 5 mL round-
bottomed tubes and stored at 4oC prior to acquisition on a flow cytometer.  
2.8.4 Immunophenotyping to identify functional cellular subsets 
 
Thawed healthy control and patient PBMCs were used for Immunophenotyping 
to understand the function of immune cell subsets in CB transplanted patients. 
Immunophenotyping via flow cytometry was performed to distinguish the 
immune cells and respective functional markers:  
 
- Alpha-Beta and Gamma-delta T-cells 
- T cell activation markers 
- NK cell activation markers 
- NK cell activation and inhibitory markers 
- NK cell IFN-gamma expression 
- Regulatory T cells 
 
Respectively the phenotypes for these populations were the following: 
1. Alpha Beta and Gamma Delta T-cells  
a. CD3+ CD4+ TCR αβ  
b. CD3+ CD4+ TCR γδ 
c. CD3+ CD8+ TCR αβ  
d. CD3+ CD8+ TCR γδ 
e. CD3+ CD4- CD8- TCR αβ and TCR γδ 
 
2. T cell activation markers – CD4+ and CD8+ T cells  
a. CD4+ T cells 
i. CD3+ CD4+ HLA-DR+ 
ii. CD3+ CD4+ CD69+ 
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iii. CD3+ CD4+ CD25+ 
b. CD8+ T cells  
i. CD3+ CD8+ HLA-DR+ 
ii. CD3+ CD8+ CD69+ 
iii. CD3+ CD8+ CD25+ 
 
3. NK-cell/ T cell and NK-T cell activation markers 
a. CD3-CD56brightCD16negative  
i. HLA-DR+ 
ii. CD69+ 
b. CD3-CD56dimCD16positive 
i. HLA-DR+ 
ii. CD69+ 
c. CD3-CD56dimCD16negative 
i. HLA-DR+ 
ii. CD69+ 
4. NK cell IFN-gamma expression 
a. CD3-CD56brightCD16negative IFN-γ+ 
b. CD3-CD56dimCD16positive IFN-γ+ 
c. CD3-CD56dimCD16positive IFN-γ+ 
5. Activating and inhibitory markers of NK cells 
a. CD3-CD56brightCD16negative 
i. NKG2A 
ii. NKG2C 
iii. CD57 
b. CD3-CD56dimCD16positive  
i. NKG2A 
ii. NKG2C 
iii. CD57 
c. CD3-CD56dimCD16negative 
i. NKG2A 
ii. NKG2C 
iii. CD57 
6. Regulatory T cells – CD3+CD4+CD25+CD127low Foxp3+ 
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2.8.4.1 Gating strategies for functional immunophenotyping analysis 
 
The following gating strategy (Figure 2.24) was used to analyse and identify Alpha Beta and Gamma Delta T cells in thawed 
healthy control and patient PBMC samples. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
A B C D E F 
Figure 2.24 Gating strategy for Alpha Beta and Gamma Delta T cells. Thawed healthy control and patient PBMCs were stained with monoclonal 
antibodies for surface expression of CD3, CD4, CD8, TCR αβ and TCR γδ. (A) Gating of mononuclear cells, minus the debris, (B) Gating of 
lymphocytes, (C) Gating of CD3+ T cells from the lymphocyte gate, (D) Gating of CD4+, CD8+ T cells and CD4-CD8- T cells (E) Gating of TCR αβ and 
TCR γδ within the CD4+ T cell population, (F) Gating of TCR αβ and TCR γδ within the CD8+ T cell population (G) Gating of TCR αβ and TCR γδ within 
the CD4-CD8- T cells population.  
G 
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The following gating strategy shown in Figure 2.25 was used to analyse and identify activation markers, CD25, CD69 and 
HLA-DR on CD4 and CD8 T cells in healthy control and patient PBMC samples.  
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Figure 2.25 Gating strategy for T cell activation markers. Thawed healthy control and patient PBMCs were stained with monoclonal antibodies 
for surface expression of CD3, CD4, CD8, CD25, CD69 and HLA-DR. (A) Gating of mononuclear cells, minus the debris, (B) Gating of 
lymphocytes, (C) Gating of CD3+ T cells from the lymphocyte gate, (D) Gating of CD4+ and CD8+ T cells, (E) Gating of CD25 within CD4+ and 
CD8+ T cells, (F) Gating of CD69 within CD4+ and CD8+ T cells, (G) Gating of HLA-DR within CD4+ and CD8+ T cells. 
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The following gating strategy shown in Figure 2.26 was used to analyse and identify activation markers CD69 and HLA-DR on 
NK cell subsets in healthy control and patient PBMCs. Both CD69 and HLA-DR are analysed on CD56bright CD16dim, CD56dim 
CD16positive and CD56dim CD16negative NK cell subsets.  
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Figure 2.26 Gating strategy for NK cell activation markers. Thawed healthy control and patient PBMCs were stained with monoclonal antibodies 
for surface expression of CD3, CD16, CD56, CD69 and HLA-DR. (A) Gating of mononuclear cells, minus the debris, (B) Gating of lymphocytes, (C) 
Gating of CD3- from the lymphocyte gate, (D) Gating of CD56bright CD16dim, CD56dim CD16positive and CD56dim CD16negative NK cells, (E) Gating of CD69 
within CD56bright CD16dim NK cells, (F) Gating of HLA-DR within CD56bright CD16dim NK cells, (G) Gating of CD69 within CD56dim CD16positive NK cells, (H) 
Gating of HLA-DR CD56dim CD16positive NK cells, (I) Gating of CD69 within CD56dim CD16negative NK cells, (J) Gating of HLA-DR CD56dim CD16negative NK 
cells. 
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The following gating strategy shown in Figure 2.27 was used to analyse and identify the intracellular expression of IFN-Ɣ within 
CD56bright CD16dim, CD56dim CD16positive and CD56dim CD16negative NK cell subsets of healthy controls and patient PBMCs. 
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Figure 2.27 Gating strategy for intracellular IFN-Ɣ within NK cells. Thawed healthy control and patient PBMCs were stained with monoclonal 
antibodies for surface expression of CD3, CD16, CD56 and IFN-Ɣ (A) Gating of mononuclear cells, minus the debris, (B) Gating of lymphocytes, (C) 
Gating of CD3- from the lymphocyte gate, (D) Gating of CD56bright CD16dim, CD56dim CD16positive and CD56dim CD16negative NK cells, (E) Gating of IFN-Ɣ 
within CD56bright CD16dim NK cells, (F) Gating of IFN-Ɣ within the CD56dim CD16positive NK cells (G) Gating of IFN-Ɣ within CD56dim CD16negative NK cells. 
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The following gating strategy shown in Figure 2.28 was used to analyse and identify the expression of inhibitory and activation 
markers, NKG2C, NKG2A and a functional maturation marker, CD57, within CD56bright CD16dim, CD56dim CD16positive and CD56dim 
CD16negative NK cell subsets within healthy control and patient PBMCs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 A B C  D E F G 
Figure 2.28 Gating strategy to identify the expression of inhibitory and activation markers within NK cells. Thawed healthy control and patient 
PBMCs were stained with monoclonal antibodies for surface expression CD16, CD56, CD57, NKG2A and NKG2C. (A) Gating of mononuclear cells, minus 
the debris, (B) Gating of lymphocytes, (C) Gating CD56+ cells from the lymphocyte gate, (D) Gating of CD56bright CD16dim, CD56dim CD16positive and CD56dim 
CD16negative NK cells, (E) Gating of NKG2A and NKG2C within the CD56bright CD16dim, CD56dim CD16positive and CD56dim CD16negative NK cell subsets, (F) 
Gating of NKG2A+CD57+ expression within the CD56bright CD16dim, CD56dim CD16positive and CD56dim CD16negative NK cell populations, (G) Gating of 
NKG2C+CD57+ expression within the CD56bright CD16dim, CD56dim CD16positive and CD56dim CD16negative NK cell populations. 
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The following gating strategy was undertaken as shown in Figure 2.29 to identify and distinguish Regulatory T (CD3+ 
CD4+CD25+CD127lo FoxP3+) cells via intranuclear staining within healthy control and patient PBMCs.  
 
 
 
 
 
 
 
 
 
.
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Figure 2.29 Gating strategy for Regulatory T cells. Thawed healthy control and patient PBMCs were stained with monoclonal antibodies for surface 
expression of CD3, CD4, CD25, CD127 and FoxP3. (A) Gating of mononuclear cells, minus the debris, (B) Gating of lymphocytes, (C) Gating of CD3+ T 
cells from the lymphocyte gate, (D) Gating of CD4+ T cells, (E) Gating of CD25+ CD127lo, (F) Gating of FoxP3 within the CD4+CD25+CD127low T cell 
population. 
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2.8.5 NK cell isolation from thawed cell samples 
 
NK cell isolation was performed on thawed healthy control PBMCs and patient 
PBMCs. The negative selection procedure was performed using the NK Cell 
Isolation kit II (Miltenyi, Germany). Once the NK cells were isolated they were 
centrifuged at 1500 rpm for 10 minutes and suspended in RPMI containing 10% 
v/v FBS. The purity of the isolated NK cells was then determined via flow 
cytometry as CD3-CD56+ cells.  
2.8.6 Assessment of NK cell purity 
 
The following gating strategy (Figure 2.30) was performed to identify the purity 
of NK cells after NK cell isolation. The mean purity (%) ± SD of all isolations 
carried out was 93.6 ± 3.42. NK cell functional studies could only be performed 
if there were more than 90% of NK cells within the DAPI gate.  
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Figure 2.30 Gating strategy to determine the purity of isolated NK cells. The purity of 
isolated NK cells was confirmed by flow cytometry. (A) Gating of lymphocytes according to the 
forward (FSC) and side scatter (SSC). (B) Live cells were gated for using the DAPI stain. (C) 
Gating of NK cells (CD3-CD56+) from the live gate.  
A C B 
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2.8.7 NK cell culture 
 
NK cells from CBMCs, healthy adult and patient PBMCs were cultured 
overnight with IL-2. Protocols devised by Alnabhan et al. and Luevano et al. 
were followed. Table 2.19 describes the concentrations used for the respective 
NK cells (Alnabhan et al., 2015, Luevano et al., 2012).  
 
Cytokine PB NK cells CB NK cells 
IL-2 
200 IU/mL (Chiossone et 
al., 2007) 
1000 IU/mL (Condiotti 
et al., 2001) 
Table 2.19 IL-2 Concentrations for adult healthy control, CB and patient NK cells. 
IL-2 was added to promote NK cell expansion and proliferation. Cell culture 
media was prepared by adding 1% Penicillin-Streptomycin, 10% v/v FBS to 
RPMI 1640. Lyophilised human recombinant IL-2 was reconstituted in PBS 
supplemented with 0.1% w/v BSA. IL-2 was prepared and diluted in culture 
media before use. A volume of 1 mL of media containing IL-2 was added to 
1x106 NK cells. The cells were then cultured in 96 well-round bottom plates at 
37oC, 5% CO2 overnight before use.  
2.8.8 NK cell cytotoxicity 
 
NK cell cytotoxicity was investigated after NK cells from healthy controls patient 
PBMCs were incubated overnight. K562 target cell lines were used for this 
assay. These cells are HLA-deficient leukaemic cells and were sub-cultured 
prior to use within 20% v/v FBS culture media and used for the assay when 
they had reached a log phase of 0.5 x 106 / mL. K562 cells were then washed 
and labelled with a PKH67 Green Fluorescent Linker Kit (Sigma). K562 cells 
were labelled as per the manufacturer’s instructions. Fluorescently labelled 
K562 cells were washed and co-cultured with NK cells at a 1:1 ratio and 
incubated at 37oC, 5% CO2 for 4 hours. Cytotoxicity was measured via flow 
cytometry.  
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2.8.9 Assessment of NK cell cytotoxicity via flow cytometry 
 
The following gating strategy shown in Figure 2.31 was used to identify the 
cytotoxic capacity of NK cells, isolated from patient samples. Measuring the 
percentage reduction in the K562 cell population assessed the NK cell 
cytotoxicity. The percentage reduction of K562 cells was calculated where there 
was a reduction in the populations seen within figure 2.31, B (ii) and (iii). 
Respectively, this was compared to a complete K562 population that was not 
incubated with patient NK cells. 
 
 
 
 
 
 
 
 
 
 
 
 
2.8.10  Statistical analysis  
 
Statistical comparisons were performed with GraphPad Prism software using 
non-parametric, Mann-Whitney test. Results are presented as tukey plots and p 
values of  <0.05 (*), <0.01(**), <0.001 (***) and <0.0001 (****) were considered 
statistically significant. Furthermore, overall survival was evaluated with Kaplan-
Meier estimates. 
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Figure 2.31 Gating Strategy to determine the reduction in K562 cells after incubation with 
NK cells. NK cell cytotoxicity was assed via the percentage decrease in the K562 population. 
(A) Gating of co-cultured NK cells and K562 cells. (B) Gating of (i) CD56+ NK cells, (ii) K562 
Cells and conjugated CD56+ and (iii) K562 cells.  
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Chapter 3 :  Investigating the kinetics and 
diversity of immune cell reconstitution in cord 
blood transplant patients  
 
3.1 Background and Aim 
 
HSCT is associated with delayed immune reconstitution and the kinetics of 
reconstitution differs between graft types. Delayed immune reconstitution can 
persist for up to two years post-transplant, with an increased risk of infection, 
relapse and secondary malignancy (Ogonek et al., 2016, Gallagher and Forrest, 
2007, Rizzo et al., 2009). The speed of immune reconstitution post-HSCT is 
crucial as it could reduce the risk of infection and prevent disease relapse. 
Furthermore, studies have been performed in BM and mPB transplanted 
patients to understand whether the kinetics of immune reconstitution impacts 
post-transplant outcomes (Seggewiss and Einsele, 2010, Bosch et al., 2012, 
Peggs and Mackinnon, 2004, Fry and Mackall, 2005, Geddes and Storek, 
2007).  
 
Immune reconstitution is delayed in CBT recipients compared to BM and mPB 
transplanted patients. The reconstitution of immune cells could be delayed by 
variables such as: HLA-disparity between the host and the donor; types of 
conditioning (chemotherapy/radiation regimen) used; depletion of T cells within 
the graft; GvHD and low TNC count within the graft (Lucchini et al., 2015). 
Measuring the kinetics of reconstitution could provide a time frame of cellular 
reconstitution post-transplant.  
 
In HSCT, time to neutrophil and platelet engraftment has been used as a 
predictive factor for outcomes post-transplant. Neutrophil and platelet 
engraftment has been measured in CBT patients and is delayed when 
compared to BM and mPB recipients (Barker et al., 2015, Barker et al., 2005, 
Scaradavou et al., 2013). It has been further reported that the delayed 
engraftment leads to higher morbidity and mortality (Komanduri et al., 2007).  
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In CBT, identifying the kinetics of reconstitution of major immune subsets will 
provide a better understanding of their recovery post-transplant. This includes 
cells such as: CD45+ cells, CD14+ monocytes, CD3+ T cells, CD4+ T cells, 
CD8+ T cells and CD19+ B cells. The importance of these cells is described 
below.  
 
All haematopoietic cells except erythrocytes and platelets express CD45, which 
is transmembrane glycoprotein known as the common leucocyte antigen (CLA). 
CD45 is abundantly expressed on the surface of leucocytes such as B cells, NK 
cells, monocytes and T cells (Hermiston et al., 2003). With this in mind, the 
absolute counts of CD45+ cells have been measured in this current study to 
gain an insight into the kinetics of leucocyte reconstitution in CBT patients. 
Furthermore, the expression patterns of CD45 have also been used as a 
laboratory measure to identify and quantify the absolute levels of leucocytes 
within the patient samples. Additionally, the use of CD45 has allowed sub-
analysis of lymphocytes, monocytes and granulocytes within patient samples as 
detailed in Chapters 4, 5 and 6.  
 
In healthy individuals, monocytes are believed to have an important role at 
restoring injured tissues and controlling inflammatory responses. Monocytes 
express CD14 on their surface, which is a phospholipid anchored membrane 
protein. (Biswas and Mantovani, 2010, Thoma et al., 2012). BMT and mPB 
transplant studies have shown that CD14+ monocytes are one of the first 
immune cell types to recover post-transplant. Furthermore, reconstitution of 
monocytes occurs within one month post-transplant (Tayebi et al., 2001, Maris 
et al., 2003, Storek et al., 2001a). However, patterns of monocyte reconstitution 
within CBT patients are poorly defined and therefore have been investigated in 
this study.  
 
In adaptive immunity, CD19+ B cells are one of the vital immune cells involved 
in humoral immune responses. In a study analysing 133 paediatric and adult 
CBT patients, B cell reconstitution was shown to be quicker as compared to 
mPB and BM recipients (Nakatani et al., 2014), reaching normal healthy ranges 
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by a median time of six months. Therefore, measuring the kinetics of CD19+ B 
cell reconstitution will provide information into the restoration of humoral 
immunity. The overall association of CD19+ B cell reconstitution and outcomes 
post-CBT has not been clearly defined. However, it has been shown that CBT 
patients with higher absolute numbers of B cells post-transplant have a reduced 
incidence of cGvHD (Beaudette-Zlatanova et al., 2013).  
 
In CBT studies, T cell reconstitution is delayed compared to BM and mPB 
recipients (Moretta et al., 2001b, Renard et al., 2011, Jacobson et al., 2012, 
Bartelink et al., 2013, Charrier et al., 2013, Clave et al., 2013, Oshrine et al., 
2013). Komanduri et al. demonstrates that T cell reconstitution is delayed in 
CBT patients and believes that early B cell and NK cell reconstitution 
compensates this. Jacobson et al. also shows that T cell reconstitution is 
delayed for up to one year post-CBT and B cell reconstitution takes place within 
six months post-CBT (Jacobson et al., 2012, Komanduri et al., 2007). The 
patterns of T cell reconstitution varies between CBT studies and this is due to 
the fact that there are differences in conditioning regimens, varying recipient 
ages and certain patients are administered T-cell depletion. Additionally, as CB 
grafts have lower T cell numbers compared to mPB and BM grafts, it is believed 
that this delays T cell reconstitution in CBT patients. (Szabolcs and Niedzwiecki, 
2008).    
 
T cells are also vital cells involved in adaptive immune responses and are 
essential inducers of cell-mediated effects to clear infection. However, in HSCT 
T cells are also involved in GvHD development (Jadus and Wepsic, 1992). 
Rapid reconstitution of T cells could lead to peripheral expansion of T cells and 
subsequently lead to the development of aGvHD. Understanding the 
reconstitution patterns of T cells in CBT studies provides a deeper insight into 
how these cells may be able to control infection or whether they could be 
actively involved in GvHD reactions. Additionally, T cells are known to play a 
role in GvL, as previously described (Barrett, 2008). Therefore, monitoring the 
patterns of T cell reconstitution could give an insight as to whether there is an 
optimised GvL effect taking place in CBT patients post-transplant.   
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Reconstitution of T cells in CBT patients is partially dependent on the survival of 
adoptively transferred T cells that come from the CB graft. Patients are also 
reliant on the de novo production of T cells from the thymus for complete T cell 
reconstitution (Douek et al., 1998, Douek et al., 2000, Lewin et al., 2002, Poulin 
et al., 1999). T cells exclusively express a multimeric protein on their surface 
known as CD3. This is one of the surface receptors involved in activation of 
cytotoxic T cells and T helper cells. Polypeptide chains within the CD3 protein 
associate with the T cell receptor (TCR), which leads to the activation of the T 
cell (Guy and Vignali, 2009). Monitoring the expression of CD3+ T cells within 
this current study will provide an understanding of the overall kinetics of T cell 
reconstitution within CBT patients.   
 
T cells mature within the thymus into two types, CD4+ and CD8+ T cells. CD4+ 
T cells are also known as T helper cells, which express the CD4 glycoprotein on 
the surface of the cell. T helper cells play a vital role in adaptive immune 
responses and mediate cytotoxicity of infected cells via cytokine release (Gill et 
al., 2003). Important roles of CD4+ T cells in immunity are well illustrated in 
HIV/AIDS infected patients. These patients are immunodeficient due to the loss 
of CD4+ T cells. This can lead to the development of fatal opportunistic 
infections that cannot be cleared. Similarly, CBT patients are 
immunocompromised and have reduced numbers of CD4+ T cells within the 
periphery, which contributes to the development of opportunistic infections 
(Zajac et al., 1998). In HSCT, delayed reconstitution of CD4+ T cells increases 
the risk of transplanted related mortality and decreases overall survival of 
allogeneic HSCT recipients from conventional donors and sUCBT in paediatric 
patients. Therefore, this highlights a key role for CD4+ T cells that may be 
required in CBT recipients (Admiraal et al., 2015, Bartelink et al., 2013, Berger 
et al., 2008). 
 
Moreover, CD8+ T cells are cytotoxic T cells and are important for immune 
defences against intracellular pathogens such as viruses, bacteria and for 
tumour surveillance. CD8 receptors are a dimeric co-receptor expressed on 
CD8+ T cells (cytotoxic T cells). The co-receptor is composed of a CD8α and 
CD8β chain. CD8+ T cells recognise peptides presented by class I HLA 
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molecules, expressed on all nucleated cells. The CD8 α chain interacts with the 
α3 portion of the class I MHC molecule and this interaction keeps the TCR and 
the target cell closely bound together. The CD8 receptor also plays a 
fundamental role in T cell signalling, where the cytoplasmic tails of the receptor 
interact with lymphocyte-specific protein tyrosine kinase (Lck). In turn, this 
initiates phosphorylation of the CD3 receptor and chains of the TCR complex. 
Subsequently, this leads to activation of transcription factors such as NFAT, NF-
κB and AP-1. This leads to cytotoxicity of the target cell (Andersen et al., 2006, 
Artyomov et al., 2010, Smith-Garvin et al., 2009).  
 
Therefore, CD3, CD4 and CD8 have therefore been included as important T cell 
markers within this study. Measurement of the respective surface markers will 
provide information as to whether patients are able to restore the overall T cell 
population, T helper cell population and the cytotoxic T cell population post-
transplant.  
 
The Immune Reconstitution Study (IRES-CBT) REC number: 09/H0706/35 was 
designed and set up in 2009 to measure reconstitution of the main immune 
subsets in CBT patient samples. Patient samples were initially collected and 
processed by Dr Sameer Tulpule between 2009 and 2010. Dr Damini Tewari 
then followed this up between 2010 and 2011. I then processed patient samples 
from the 1st of May 2012. The patient sample collection and processing was 
kept uniform throughout the study.  
 
Taken together and considering the importance of the aforementioned cells, this 
current study investigated the diversity and kinetics of immune cells such as 
leucocytes, monocytes, B cells and T cells in CBT patients. The aims of this 
chapter are to investigate the following:  
1. Map the kinetics of recovery of CD45+ cells in CBT patients.  
2. Map the kinetics of recovery of CD14+ monocytes in CBT patients.  
3. Map the kinetics of CD19+ B cells in CBT patients. 
4. Map the kinetics of CD4+ and CD8+ T cells in CBT patients.  
5. Map the time to neutrophil and platelet engraftment in CBT patients.  
6. Determine the overall survival of CBT patients.  
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3.2 Diversity and kinetics of immune recovery in cord blood transplant 
patients 
 
A total of 67 adult patients were included in this study recruited from 13 
hospitals across the UK, as described in Chapter 2, section 2.1.3. The 
characteristics of the patients included in this study are listed in Table 3.1.  
  Count 
Total 
number of 
patients 
(%) 
Median Range 
Gender Female 24 36   Male 43 64   
Age (years)     48 21 - 70 
Diagnosis 
Acute Leukaemia 38 57   
Myelodysplastic 
syndrome/myelodysplasia (MDS) 11 16   
Myeloproliferative disorder (MPD) 3 4   
Lymphoproliferative disorder 13 19   
Bone marrow failure syndrome 2 3   
Status at 
Transplant 
Complete remission (CR) 44 66   
Partial remission (PR) 6 9   
Relapse/ Progression 6 9   
Stable/ Untreated 5 7   
Missing 6 9   
CMV (IgG) 
Negative 19 28   
Positive 43 64   
Missing 5 7   
ABO 
A 22 33   
B 7 10   
AB 1 1   
O 28 42   
Missing 9 13   
Conditioning MAC 17 25   RIC 50 75   
HLA Match 
3/6 3 4   
4/6 29 43   
5/6 19 28   
6/6 5 7   
Missing 11 16   
Graft type Single CBU 3 4   Double CBU 64 96   
Survival (months)     19 1 - 24 Table 3.1 Characteristics of patients enrolled onto the immune reconstitution study.  
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3.2.1 CD45+ cell count recovery following allogeneic cord blood 
transplantation 
 
CD45+ cells were quantified within CBT patients to better understand the 
overall leucocyte cell reconstitution post-transplant. CD45 is expressed on 
leucocyte cells and quantification of CD45+ leucocyte cells is poorly defined in 
CBT studies. CD45+ cells were quantified as cells per microliter and represent 
absolute counts of CD45+ leucocyte cells in CBT patients, as seen in Figure 
3.1. 
 
In CBT patient samples, the median absolute count (3710 cells/µl) of CD45+ 
cells at day 28, were lower compared to healthy control PB (5987 cells/µl). 
Respectively, at 28 days post-transplant, the interquartile range for patients 
(1302 - 8090 cells/µl) was lower compared to healthy control PB (4825 - 7568 
cells/µl). In comparison to the successive time points and healthy control PB, 
CD45+ cell counts were lowest in CBT patients at 28 days post-transplant. At 
subsequent time points the median absolute count of CD45+ cells increased in 
CBT patients and the interquartile ranges also showed to be broader compared 
to healthy control PB. There was a continued increase in the median absolute 
counts of CD45+ cells between 28 days and 180 days post-CBT. From 60 days 
to 720 days post-CBT, the CD45+ median absolute counts were within the 
same range as the median absolute counts measured in healthy control PB, 
indicating that patients had a rapid reconstitution of CD45+ cells by 60 days 
post-CBT. Absolute counts of CD45+ cells increased at 60 days post-CBT 
where median levels (8186 cells/µl) were higher compared to healthy control PB 
(5987 cells/µl). However, due to the interquartile ranges being within the healthy 
control PB range, no statistical significance was observed. This indicates that 
patients have complete reconstitution of CD45+ cells by 60 days post-CBT.  
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Figure 3.1 Absolute counts of CD45+ leucocytes in CBT patients. Box and whisker plots 
showing the absolute counts, cells per microliter of CD45+ leucocytes within CBT patients in the 
UK. Flow cytometry was performed to quantify CD45+ cells. At each time point the following 
number of samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26, 
D720 = 14 and healthy control PB = 10. Analysis was performed between the time points and 
the healthy controls as a non-parametric, Mann-Whitney test. Results are presented as tukey 
analysis. No significance was observed.  
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3.2.2 CD14+ monocyte count recovery following allogeneic cord blood 
transplantation 
 
Monocytes are involved in innate immune responses and are one of the first 
subset of cells recruited to sites of tissue injury and inflammatory sites. The 
reconstitution of monocytes is not well studied in CBT patients and 
quantification of monocytes in this current study will provide an insight in to their 
reconstitution after CBT. Monocytes (CD14+) were identified and quantified by 
flow cytometry and patterns of monocyte reconstitution within CBT patients  
(Figure 3.2) are compared to levels observed in healthy control PB. 
Reconstitution of CD14+ monocytes took place by 28 days post-CBT. In CBT 
patients, there was a greater range of CD14+ monocyte levels post-transplant 
in comparison to healthy control PB.  
 
Median absolute levels of monocytes were higher throughout all the time points 
studied compared to healthy control PB. CD14+ monocyte absolute counts 
increased between 28 and 180 days post-CBT. At 180 days post-CBT, the 
absolute counts of CD14+ monocytes were significantly higher compared to 
healthy control PB (p = 0.03). CD14+ monocyte absolute counts in patients 
remained higher between 180 and 720 days post-transplant compared to 
healthy control PB. The median absolute counts were 873 cells/µl and 741 
cells/µl at day 365 and day 720, respectively, which were significantly higher 
compared to healthy control PB (p=0.005 and p=0.03, respectively). The data 
therefore suggests that there is reconstitution of CD14+ monocytes within the 
PB of patients by 28 days post-CBT.  
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Figure 3.2 Absolute counts of CD14+ monocytes in CBT patients. Box and whisker plots 
showing the absolute counts, cells per microliter, of CD14+ monocytes cells within CBT patients 
in the UK. Flow cytometry was performed to quantify CD14+ monocytes. At each time point the 
following number of samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 
= 26, D720 = 14 and healthy control PB = 10. Analysis was performed between the time points 
and the healthy controls as a non-parametric, Mann-Whitney test. Results are presented as 
tukey analysis, p<0.05 (*), p<0.01 (**), p<0.001 (***) and p<0.0001 (****). 
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3.2.3 CD3+ T cell recovery following allogeneic cord blood transplantation 
 
CD3 expression levels were analysed within this study as it is a multimeric 
protein complex found on all T cells and is an important co-receptor that binds 
non-covalently with the T cell receptor (Smith-Garvin et al., 2009). The CD3 
molecule is primarily expressed on T cells therefore making it a key cell surface 
marker to monitor T cell reconstitution. In various CBT studies, it has been 
shown that T cells have a delayed pattern of reconstitution compared to BM and 
mPB transplant (Jacobson et al., 2012, Komanduri et al., 2007, Cohen et al., 
2006). By monitoring the reconstitution patterns of CD3+ T cells within this 
current study, the broad recovery of T cells within CBT patients has been 
distinguished. Levels of CD3+ T cells can be seen in Figure 3.3.  
 
At 28 days post-transplant, median absolute counts of CD3+ T cells within 
patients (138 cells/µl) were significantly lower compared to healthy control PB 
(1475 cells/µl) (p=0.0001). The absolute counts of CD3+ T cells increased at 60 
days in CBT patients. However, the interquartile range and median absolute 
levels remained below the healthy control PB interquartile range. At day 100, 
median absolute counts (528 cells/µl) of CD3+ T cells were significantly lower 
compared to healthy control PB (1475 cells/µl) (p=0.005). At 365 and 720 days 
post-CBT, the absolute counts of CD3+ T cells were lower compared to healthy 
control PB. However, the upper quartile of the interquartile ranges at the 
respective time points reached the interquartile range seen within healthy 
control PB. The data therefore highlights that the absolute numbers of CD3+ T 
cells increases over the two year follow up period, post-CBT. However, the 
median absolute counts at all times points were lower in CBT patients 
compared to healthy control PB. Overall, this indicates that there is a delay in 
CD3+ T cell reconstitution in CBT patients post-transplant. 
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Figure 3.3 Absolute counts of CD3+ T cells in CBT patients. Box and whisker plots showing 
the absolute counts, cells per microliter, of CD3+ T cells, in CBT patients in the UK. Flow 
cytometry was performed to quantify CD3+ T cells. At each time point the following number of 
samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26, D720 = 14 and 
healthy control PB = 10. Analysis was performed between the time points and the healthy 
controls as a non-parametric, Mann-Whitney test. Results are presented as tukey analysis, 
p<0.05 (*), p<0.01 (**) and p<0.0001 (****).  
!! 142 
3.2.4 CD4+ T cell count recovery following allogeneic cord blood 
transplantation 
 
The kinetics of recovery of CD4+ T cells was investigated within CBT patients, 
as CD4+ T cells are key mediators that clear pathogenic infection (Sant and 
McMichael, 2012). T cells also play a fundamental role in GvHD development 
and delayed reconstitution of T cells could be associated with the incidence of 
relapse. With these important challenges faced, it is important to define the time 
in which CD4+ T cell reconstitution takes place post-CBT. This will aid in 
defining whether T cells influence post transplant outcomes. Levels of CD4+ 
absolute counts can be seen in Figure 3.4. 
 
At 28 days post-CBT, median absolute count of CD4+ T cells (92 cells/µl) were 
significantly lower compared to healthy control PB (864 cells/µl) and CBT 
patients had a significantly narrower interquartile range (35-159 cells/µl) of 
CD4+ T cells compared to healthy control PB (729 - 1174 cells/µl) (p=0.0001). 
At 60 days post-CBT, median absolute counts of CD4+ T cells (188 cells/µl) 
were significantly lower compared to healthy control PB with a significantly 
narrower interquartile range in patients (129-229 cells/µl) (p=0.0001) compared 
to healthy control PB. At successive time points between 100 and 720 days 
post-CBT, the median CD4+ T cell absolute counts increased.  However, they 
remained significantly lower compared to healthy control PB. The broadest 
interquartile ranges were recorded in CBT patients at 365 days (343-898 
cells/µl) and 720 days (310-981 cells/µl) post-transplant. Overall, the CD4+ T 
cell data suggests that there is a gradual increase in absolute numbers of CD4+ 
T cells between 28 and 720 days post-CBT. However, the median absolute cell 
levels remained below the median levels in healthy controls PB for up to 720 
days post-transplant. This data therefore suggests that CD4+ T cell 
reconstitution is delayed in CBT patients and could take longer than 720 days to 
redevelop post-transplant.  
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Figure 3.4 Absolute counts of CD4+ T cells in CBT patients. Box and whisker plots showing 
the absolute counts, cells per microliter, of CD4+ T cells within CBT patients in the UK. Flow 
cytometry was performed to quantify CD4+ T cells. At each time point the following number of 
samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26, D720 = 14 and 
healthy control PB = 10. Analysis was performed between the time points and the healthy 
controls as a non-parametric, Mann-Whitney test. Results are presented as tukey analysis, 
p<0.05 (*) and p<0.0001 (****). 
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3.2.5 CD8+ T cell count recovery following allogeneic cord blood 
transplantation 
 
CD8+ T cells play a pivotal role in clearing fungal and viral infections (Andersen 
et al., 2006). In HSCT, CD8+ T cells have been shown to play a key role in the 
clearance of infection within the first 100 days of transplant (Montoro et al., 
2016, Cahu et al., 2009). Along with infection and their cytotoxic capacity, 
understanding CD8+ T cell reconstitution could also help determine whether 
they play a role in GvHD development or reduce the incidence of relapse in 
CBT patients. Overall, the absolute count of CD8+ T cells was measured in this 
study to define the time in which CD8+ T cells reconstitute in CBT patients.  
 
At 28 days post-CBT, absolute counts of CD8+ T cells, shown in Figure 3.5, 
were significantly lower compared to healthy control PB (p=0.0001). 
Respectively, at 28 days post-CBT, the interquartile range (12-50 cells/µl) was 
lowest compared to healthy control PB (442-898 cells/µl). Absolute counts of 
CD8+ T cells increased at 60 days post-transplant and continued to increase up 
to 365 days.  At 365 days, the absolute count of CD8+ T cells was similar to 
healthy control PB. Furthermore, at 365 days post-CBT, the interquartile range 
was broader (254-1500 cells/µl) compared to healthy control PB (442-898 
cells/µl). Overall, this data suggests that there is a gradual increase in the 
absolute number of CD8+ T cells between 28 days and 365 days post-
transplant. Also, there is reconstitution of CD8+ T cell counts within the 
peripheral blood of patients by 365 days post-CBT.  
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Figure 3.5 Absolute counts of CD8+ T cells in CBT patients. Box and whisker plots showing 
the absolute counts, cells per microliter, of CD8+ T cells within CBT patients in the UK. Flow 
cytometry was performed to quantify CD8+ T cells. At each time point the following number of 
samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26, D720 = 14 and 
healthy control PB = 10. Analysis was performed between the time points and the healthy 
controls as a non-parametric, Mann-Whitney test. Results are presented as tukey analysis, 
p<0.05 (*), p<0.01 (**), p<0.001 (***) and p<0.0001 (****).  
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3.2.6 CD19+ B cell count recovery following allogeneic cord blood 
transplantation 
 
In allogeneic HSCT studies, it has been demonstrated that B cells have a 
different pattern of reconstitution compared to T cells (Bemark et al., 2012, 
Ogonek et al., 2016). Furthermore, in CBT there is a normalization of CD19+ B 
cells counts by six months, which is faster compared to BM and mPB 
transplant. It has also been shown in other studies that early B cell 
reconstitution is also associated with reduced incidence of cGVHD (Beaudette-
Zlatanova et al., 2013). Overall, CD19+ B cells are known to play a fundamental 
role in adaptive immune responses and as CBT patients are prone to several 
opportunistic infections, B cells are highly required to protect and clear them. 
These fundamental roles post-transplant have led to us to determine the 
kinetics of reconstitution of CD19+ B cells in CBT patients.  
 
As shown in Figure 3.6, at 28 days post-transplant median absolute counts of 
CD19+ B cells (6 cells/µl) was significantly lower compared to healthy control 
PB (302 cells/µl) (p=0.0001). At 60 days post-CBT, there was an increase in the 
absolute counts of CD19+ B cells in CBT patients and the interquartile range 
was also seen to broaden. Subsequently, at day 100, there was a further 
increase in the CD19+ B cell counts within patients and the interquartile range 
(63 – 1211 cells/µl) was broader compared to healthy control PB (194 – 356 
cells/µl). Median absolute levels of CD19+ B cells increased in CBT patients 
(997 cells/µl) at day 180 and were significantly higher compared to healthy 
control PB (302 cells/µl) (p=0.01). The interquartile range (307 – 2403 cells/µl) 
was broadest in CBT patients at day 180 compared to all the respective time 
points and was broader compared to healthy control PB (194 – 356 cells/µl). 
Absolute counts of CD19+ B cells and the interquartile range remained higher 
compared to healthy control PB at 365 and 720 days post-CBT (p=0.0002 and 
p=0.0007, respectively). This data suggest that the reconstitution of CD19+ B 
cells takes place by 100 days post-CBT. The absolute number of CD19+ B cells 
increased between 100 days and 365 days post-transplant and exceeded 
absolute counts observed within healthy control PB.  
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Figure 3.6 Absolute counts of CD19+ B cells in CBT patients. Box and whisker plots 
showing the absolute counts, cells per microliter, of CD19+ B cells within CBT patients in the 
UK. Flow cytometry was performed to quantify CD19+ B cells. At each time point the following 
number of samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26, 
D720 = 14 and healthy control PB = 10. Analysis was performed between the time points and 
the healthy controls as a non-parametric, Mann-Whitney test. Results are presented as tukey 
analysis, p<0.05 (*), p<0.01 (**), p<0.001 (***) and p<0.0001 (****).  
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3.2.7 Engraftment following cord blood transplantation 
 
3.2.7.1 Neutrophil engraftment following cord blood transplantation 
 
Time to neutrophil engraftment was measured, at the respective transplant 
centres, in patients as three consecutive days at which they had a neutrophil 
count greater than 0.5 x 109/L. The data was retrieved as described in Chapter 
2, section 2.3.11. 62 patients (93% of the total patient group) had neutrophil 
count greater than 0.5 x 109/L. This was achieved for all 62 patients by 56 days 
post-transplant. The median time to neutrophil engraftment was 20 days post-
transplant. The range of neutrophil engraftment was 5-56 days post-transplant. 
For five patients, time to neutrophil engraftment data was unavailable and these 
five patients have been excluded from this analysis.  
 
3.2.7.2 Platelet engraftment following cord blood transplantation 
 
Time to platelet engraftment was measured in CBT patients; at their respective 
transplant centres, as three consecutive days at which they had a platelet 
engraftment count greater than 20.0 x 109/L. The data was retrieved as 
described in Chapter 2, section 2.3.11. Platelet engraftment occurred within 57 
patients (85% of the total patient group). Time to platelet engraftment for all the 
patients was 120 days post-transplant. The median platelet engraftment was 40 
days post-transplant. The range of platelet engraftment in CBT patients was 1-
118 days post-transplant. For ten patients, there was no data available for their 
platelet engraftment and these patients were excluded from this analysis. This 
data suggests that CBT patients have a median time to platelet engraftment 
within 40 days post-CBT and the time to platelet engraftment within all the CBT 
patients can take up to 118 days post-transplant. 
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3.2.8 Overall survival of patients after cord blood transplant 
 
Overall survival data was retrieved as described in Chapter 2, section 2.3.11. 
Figure 3.9 shows the probability of survival after CBT in patients recruited on to 
the immune reconstitution study.  
 
 
Figure 3.7 Overall survival in CBT patients. Kaplan-Meier curve for overall survival in CBT-
patients up to 720 days post-transplant.  
 
In this study, the probability of overall survival was 61% (95% Confidence 
interval (CI), 37-53%) at two years post-transplant. A total of 26 patients died 
(39% during the study (95% CI, 31-42%). 16 patients died of relapse or disease 
progression, eight patients died due to transplant related causes, two died due 
to unknown causes.  
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3.2.9 Summary of immune kinetics and diversity in cord blood transplant 
patients 
 
The following timeline was constructed to give an overview of the kinetics and 
diversity of immune reconstitution in CBT patients within this current study. 
Figure 3.8 summarises immune kinetics and diversity data obtained in this 
study and shows the various time points at which immune cells reconstitute 
within CBT patients. It had been decided that a population had reconstituted, as 
the median range was no longer statistically significantly different from healthy 
controls. The summary of the results (Figure 3.8) shows the kinetics and 
diversity of immune cell reconstitution that takes places over two years post-
transplant. Early reconstitution of CD14+ monocytes and CD45+ leucocytes 
took place by 60 days post-CBT. Furthermore, by day 60 there was complete 
neutrophil engraftment. Subsequently, CD19+ B cell reconstitution took place 
between 100 and 180 days post-CBT. At 120 days post-transplant, all CBT 
patients had complete platelet engraftment. T cell reconstitution occurred later 
with CD8+ T cell reconstitution occurring by day 365. However, CD3+ and 
CD4+ T cell absolute counts remained low for two years.  
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Figure 3.8 Summary of immune reconstitution kinetics and diversity in CBT patients. The figure above shows the various time points at which the 
various cellular subsets reconstitute within CBT patients. The figure summarises the data from all the absolute counts.  
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3.3  Discussion 
 
The current study is the first study within the UK to investigate the diversity and 
kinetics of immune cells in CBT patients. To date, CBT is performed within the 
UK as a single or double transplant for adult patients. Conditioning protocols 
that have been used in this current cohort of patients are either RIC or MAC. 
RIC protocols used in the UK are devised from the Minneapolis RIC protocol 
(Flu, Cy, TBI CsA and MMF and ATG). However, MAC protocols within the UK 
can be chosen from two protocols – Minneapolis MAC protocol (Flu and Cy, 
TBI, CsA and MMF) or the Valencia MAC protocol (Flu, Thio, BU, ATG and 
CsA+MMF) (Shaw et al., 2009, Hough et al., 2016). For this current study, 
patients have not been divided into their respective conditioning groups due to 
the limited number of myeloablative conditioning patients enrolled on to the 
study. Therefore, all the data presented includes patients from both conditioning 
regimens.  
 
The outcomes of CBT depend on the ability of the donor cells to migrate and 
engraft into the host without any hindrance (Zhang et al., 2003, Podesta, 2001). 
However, it is known that CBT patients have a delayed immune reconstitution 
post-transplant in comparison to BM and mPB transplanted patients 
(Beaudette-Zlatanova et al., 2013, Servais et al., 2014, Kanda et al., 2012). 
With this in mind, the current study was set up in 2009 to identify the 
reconstitution patterns of immune cell subsets in CBT patients.  
 
Following conditioning and the infusion of the CBU, patients undergo an initial 
period of aplasia. Within this period of time, the donor CB-HSC will engraft in 
the patient and the engrafted cells will differentiate and proliferate within the 
BM. However, the time to neutrophil and platelet engraftment in CBT patients is 
delayed in comparison to BM and mPB transplant recipients (Seggewiss and 
Einsele, 2010, Petropoulou and Rocha, 2011). Seggewiss et al. showed that 
the median time to engraftment in BM, mPB and CB recipients is 21, 14 and 30 
days, respectively(Seggewiss and Einsele, 2010). This highlights that 
engraftment is delayed in CBT recipients compared to BM and mPB recipients. 
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In this thesis, the time to neutrophil and platelet engraftment occurs earlier with 
a median time of 20 days and 40 days post transplant, respectively.  
 
Additionally, It has been reported that the overall survival of CBT patients is 
similar to that of matched related donor (MRD) and matched unrelated donor 
(MUD) recipients with a range of 33 - 66% at 720 days post-transplant. 
(Brunstein et al., 2012, Chen et al., 2012, Ponce et al., 2011, Brunstein et al., 
2010). Data from this current study also shows that CBT patients have an 
overall survival of 61% at 720 days post-transplant, which validates what has 
been documented in other studies. 
 
In this current study, there is rapid reconstitution of CD45+ leucocytes and 
CD14+ monocytes by 60 days post-transplant. This corroborates data by Li et 
al. who also shows that CD14+ monocytes reconstitute rapidly and the absolute 
numbers of CD14+ monocytes remain high early post-transplant (Li et al., 
2017). However, in the study conducted by Li et al. the reconstitution patterns of 
immune cells were recorded as early as seven days post-transplant, whereas in 
this current study the earliest reconstitution time point is 28 days post-
transplant. This could mean that patients within our study could have normal 
CD45+ cell counts and CD14+ monocytic cell counts before 60 days post-CBT. 
It is therefore essential to add earlier time points between seven days and 28 
days post-CBT in future immune reconstitution studies to better identify the 
kinetics and recovery of immune cell subsets in CBT patients. In this current 
project, blood samples were not collected before 28 days post-transplant, as 
routine blood tests required the collection of research blood samples after 28 
days. Furthermore, patients are lymphopenic early post-transplant and 
accuracy in the counts would decrease, as there would be fewer subsets of 
cells. Additionally, patients could be unwell early post-transplant and could 
refuse sample donation.  
 
In line with other studies, this project also shows that B cell reconstitution takes 
place early post-transplant, occuring between 100 and 180 days (Nakatani et 
al., 2014, Komanduri et al., 2007, Beaudette-Zlatanova et al., 2013). 
Furthermore, longitudinal studies of immune reconstitution in CBT recipients 
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show that absolute numbers of circulating B cells are higher in CBT patients 
compared to mPB and BM recipients (Beaudette-Zlatanova et al., 2013, 
Jacobson et al., 2012, Kanda et al., 2012). 
 
Data from this current study compared to mPB grafts and BM grafts shows that 
the recovery of B cells is rapid post-transplant in CBT patients, shown in Table 
3.2. There could be several reasons as to why B cells normalise faster within 
CBT patients compared to mPB or BMT recipients. Firstly, this could be due to 
a compensatory mechanism because of patients having significant T cell 
lymphopenia post-transplant. This has been demonstrated in HIV infected 
individuals where patients have deficiency of CD4+ T cells. However, this is 
compensated by expansion of CD19+ B cells (Malaspina et al., 2007, 
Malaspina et al., 2006). The second reason may be due to the fact that B cells 
arise from fetal stem cells within the liver and mature within the BM and not 
from adult stem cells. Once CB is infused into the patient, it is has been 
proposed that these B cells could expand from the fetal liver and induce rapid 
expansion of B cells within the recipient post-transplant. This gives rise to an 
expanded B cell population within the CBT patient (Parra et al., 2013). 
Furthermore, it has also been proposed that the increased numbers of B cells in 
CBT recipients is not due the compensatory expansion but due to 
lymphopoiesis or increased B cell survival induced by B cell activating factor 
(BAFF), produced by activated monocytes (Batten et al., 2000, Rolink et al., 
2002). This current study has shown that CBT recipients have higher absolute 
numbers of monocytes within peripheral blood and this could explain the higher 
numbers of B cells within CBT patients. However, further analysis and 
quantification of BAFF levels in patients would need to be performed to validate 
this. Although absolute numbers of B cells normalise rapidly after CBT, their 
functionality has been shown to require significantly longer for recovery. In this 
current study, functionality of B cells was not addressed, as the B cells were not 
able to withstand the thawing process for further functionality testing.  
 
There are various studies in HSCT that compare T cell reconstitution in CBT 
patients compared to BMT and mPB transplant recipients, shown in Table 3.2. 
However, there is variability in the patients that are investigated including: HLA-
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matched and mismatched patients; different conditioning regimens used 
(myeloablative or reduced intensity); infusion of single or double CB units; 
various GvHD prophylaxes and patient samples are acquired at differential time 
points. 
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Conditioning 
Regimen 
Post-
transplant 
assessment 
time points 
(days) 
 
Number 
of 
dUCBT 
patients 
Number of 
comparator 
patients 
Absolute counts of cells 
post-CBT compared to 
mPB and BMT Reference 
Absolute counts of 
cells post-CBT in this 
current study 
compared to reference 
studies 
RIC MAC mPB BMT 
CD3+/4+/8
+ T cells 
CD19+ B 
cells 
CD3+/4+/8+ 
T cells 
CD19+ B 
cells 
- MAC 
45, 90,180 
and 365 
29 66 - Lower Higher 
(Kanda et al., 
2012) 
Lower Higher 
- MAC 
30,60,90,18
0 and 365 
56 59 2 Lower Higher 
(Mehta and 
Rezvani, 2016) 
Lower Higher 
RIC MAC 
90,180 and 
365 
25 27 9 Lower Higher 
(Servais et al., 
2014) 
Lower Higher 
RIC - 
30,60,90,18
0 and 365 
241 151 - Lower Higher 
(Bejanyan et 
al., 2016) 
Lower Higher 
RIC - 
30,60, 90, 
180, 365 
and 720 
42 102 - Lower Higher 
(Jacobson et 
al., 2012) 
Lower Higher 
Table 3.2 Studies comparing T and B cell absolute counts after CBT compared to different graft sources 
!! 157 
In the studies compared in Table 3.2 and from this study, the recurring 
observation is that there are lower absolute counts of circulating CD3+ and 
CD4+ T cells in CBT patients compared to healthy controls, mPB and BM 
transplanted patients. In this current study, it has been shown that there is 
delayed reconstitution of CD3+ and CD4+ T cells for up to 720 days post-
transplant, which validates data from studies listed in Table 3.2. However, in a 
study by Servais et al. it has been shown that there are similar levels of CD4+ T 
cells compared to mPB recipients, which differs from other studies reporting 
lower absolute levels of CD4+ T cells post-CBT (Servais et al., 2014).  
 
Aside from CD4+ T cell reconstitution, the absolute counts of CD8+ T cells are 
also widely reported to reconstitute at 365 days post-transplant, listed in table 
3.2. CD8+ T cell reconstitution within this current study shows that these cells 
reconstitute by 365 days post-CBT. This is in line with other studies shown in 
Table 3.2. 
 
In CBT patients, T cells can recover via two pathways known as the thymic 
dependent or independent pathway. The thymic-independent pathway is where 
mature T cells from the graft expand and proliferate within the recipient. This 
can be delayed in CBT patients due to the low T cell doses and low numbers of 
mature T cells within the graft. The thymic dependent pathway occurs where 
there is production of naïve T cells via progenitor cells that mature within the 
thymus of the host (Williams et al., 2007). However, there are qualitative and 
quantitative differences in the CBU graft compared to BM and mPB, which 
could impact thymic dependent and thymic independent T cell reconstitution in 
CBT patients. The quantitative difference between CBU and BM and mPB 
grafts is that there are fewer absolute numbers of HSC and lymphoid progenitor 
cells in CBU grafts compared to BM and mPB grafts (Szabolcs and 
Niedzwiecki, 2008).  Respectively, the absolute T cell number is also lower in 
the CB graft, which could cause patients to experience delayed T cell 
reconstitution post-transplant. This highlights that T cell doses within the graft 
are an important factor that should be considered during CBU selection as a 
higher T cell dose could improve T cell reconstitution post-transplant.  
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T cell reconstitution can also be affected by the intensity of conditioning used 
pre-transplant. Cytotoxic chemotherapy and radiation negatively impact thymic 
function and thymic output (Mackall et al., 1995). Furthermore, the 
administration of GvHD prophylaxis can impact T cell reconstitution (Ogonek et 
al., 2016). The use of chemotherapeutic agents and GvHD treatment should be 
further investigated in future CBT studies to assess the level of impact on T cell 
reconstitution in CBT patients.  
 
ATG has also been shown to impact the reconstitution of CD4+ T cells and 
patients who are not administered ATG, have a faster reconstitution of these 
cells post-transplant (Sauter et al., 2011). Patients recruited on to the current 
study were not administered ATG and still had a delay in CD3+ and CD4+ T cell 
reconstitution. Furthermore, patients recruited onto the current study had a 
median age of 48 years old. Thymic involution is age related and is the 
progressive shrinking of the thymus, which is closely associated with a decline 
in T cell output from the thymus (Lynch et al., 2009).  The patients recruited 
onto the current study could have reduced thymic output due to thymic 
involution; this reduces absolute number of T cells released by the thymus and 
delays T cell reconstitution post -CBT.  
 
CBU are known to contain a higher proportion of naïve T cells that lack antigen-
specific memory T cells compared to mPB and BM grafts. These T cells are 
antigen inexperienced and once they engraft into the patient, they require clonal 
expansion before inducing a cell-mediated effect. However, as there are a lower 
number of T cells in the CB graft, the expansion and proliferation of T cells may 
take longer within the recipient. This is essential within the CBT recipients 
before T cells can exert a cell-mediated effect to clear pathogenic infections. 
Therefore, the limited number of antigen specific cells could delay the time in 
which infections are cleared, making the CBT patient prone to further 
opportunistic infections (Szabolcs and Niedzwiecki, 2007). To overcome this 
issue, CBU grafts with a higher T cell number could be used. This could reduce 
delay in T cell reconstitution. However, a broad TCR repertoire is still required 
to recognise and clear opportunistic infections whilst balancing an optimised 
GvL effect.  
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New approaches are therefore required to improve T cell reconstitution in CBT 
patients. Factors to improve CD3+, CD4+ and CD8+ T cell reconstitution could 
include the use of CBU units that are of a higher HLA match. This could be 
performed by using CBU with a 6/6 HLA match from an unrelated donor and by 
the use of CMV matched donor before transplantation. These factors have been 
shown to particularly improve CD4+ T cell reconstitution in paediatric patients 
(Niehues et al., 2001). Therefore, the use of these approaches could improve 
the kinetics of T cell reconstitution in adult CBT recipients.  
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In conclusion, this study shows the reconstitution patterns of the major immune 
cell subsets in CBT patients. By monitoring the expression patterns of CD45+ 
as a leucocyte cell marker, we have been able to identify that CD45+ leucocyte 
cell reconstitution takes place by 60 days post-CBT. Furthermore, CD14+ 
monocytes reconstitute by 28 days post-CBT. These are two key factors that 
have not been demonstrated widely in other HSCT and CBT studies.  
 
The current study also validates that the recovery of CD19+ B cells is rapid in 
CBT patients within the UK, which takes place by 100 days post-CBT (Nakatani 
et al., 2014). Furthermore, T cells require longer than 1 year to reconstitute in 
CBT patients. This suggests that there is delayed reconstitution of CD3+, CD4+ 
and CD8+ T cells post-transplant. Again, this corroborates with data from other 
CBT studies, detailed in Table 3.2. Herein, it has also been shown that 
neutrophil engraftment, platelet engraftment and overall survival data is similar 
to other CBT studies. (Brunstein et al., 2012, Brunstein et al., 2010, Ponce et 
al., 2011).  
 
However, the initial design of this current study was undertaken to monitor the 
major immune cell types in CBT patients. This was limited by the flow cytometry 
acquisition, which only allowed identification of four flourochromes in any single 
cell analysis. To reduce this limitation, an extensive immunophenotyping panel 
was devised to investigate the functionality of NK cells in CBT patients, 
discussed in the next chapter. This allowed for a broader number of 
flourochromes to be analysed. Furthermore, kinetic studies of reconstitution 
were set up using genetic techniques to better understand the absolute 
numbers of B cell and T cell subsets within CBT patients, as discussed in 
Chapter 5 and 6.  
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Chapter 4 : NK cells and functionality in cord 
blood transplant patients 
 
4.1 Background and Aims 
 
NK cells are the first lymphocytes to reconstitute within HSCT recipients 
irrespective of the graft source. This occurs within the first month of transplant, 
which has been widely reported in BM, mPB and CBT studies (Brahmi et al., 
2001, Buhlmann et al., 2011, Shenoy et al., 1999, Ottinger et al., 1996, 
Jacobson et al., 2012, Ruggeri et al., 2011, Saliba et al., 2015, Small et al., 
1999, Somers et al., 2013, Thomson et al., 2000). NK cell reconstitution is 
thought to take place as a result of the differentiation of progenitor cells rather 
than the expansion of mature NK cells within the graft. This theory has been 
supported by two major observations. Firstly, NK cell reconstitution is not 
dependent on the type of graft infused into the patient and the NK cell content 
present within the graft (Abrahamsen et al., 2005, Bjorklund et al., 2010, 
Martinez et al., 1999). The second major observation is that early NK cells have 
an immature CD56bright phenotype early post-transplant, which shifts to a 
CD56dim phenotype after several months post-transplant (Cooley et al., 2005, 
Nguyen et al., 2008). In healthy adults, up to 90% of NK cells are CD56dim and 
10% of NK cells are CD56bright. However, the latter subset constitutes most of 
the NK cells found within the lymph nodes. Within CB, NK cells constitute 15-
30% of the mononuclear population. Within the CB NK cell population, 90% are 
CD56dim and 5-10% are CD56bright (Dalle et al., 2005, Luevano et al., 2012, 
Kotylo et al., 1990).  
 
NK cells are defined as CD3-CD56+ and can be divided into further subsets 
depending on their expression of CD56 and CD16. Poli et al. has demonstrated 
that NK cells can be divided into five subpopulations in healthy individuals: (1) 
CD56bright CD16negative; (2) CD56bright CD16positive; (3) CD56dim CD16negative; (4) 
CD56dim CD16positive and (5) CD56negative CD16positive. The CD56bright CD16negative 
NK cells comprise 50-70% of the CD56bright NK cell population and the CD56bright 
CD16dim are 30-50% of the CD56bright NK cell population (Poli et al., 2009).  
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CD56bright CD16low/negative NK cells are not considered a minor NK cell 
subpopulation as they can produce a number of different cytokines such as 
IFN-γ and IL-10 to mediate adaptive immune responses and play an 
immunoregulatory role (Poli et al., 2009). CD56dim CD16positive NK cells are 
considered cytotoxic NK cells as they mediate direct lysis of target cells via the 
release of granules containing perforin and granzyme B, ADCC and activation 
of cell death pathways such as TRAIL or FAS/FAS-L (Cooper et al., 2001). The 
role and function of CD56dim CD16negative NK cells is poorly defined and requires 
further investigation, particularly within CBT patients. 
 
In this current study, there was a focus on the CD56bright CD16negative, CD56dim 
CD16negative and CD56dim CD16positive NK cells to further distinguish their 
functionality in CBT patients. Much is still unknown about the functions of NK 
cells post-transplant, particularly how NK cells function in CBT patients. As NK 
cells are the first lymphocyte to recover, it is likely that they are key mediators 
and effectors of GvL. Pioneering work by Ruggeri et al. showed that NK cells 
are alloreactive against leukaemic cells after haploidentical transplantation 
(Ruggeri et al., 2002). Further to this, NK cells with KIR-ligand incompatibility 
are also able to lyse recipient APCs and this reduces the incidence of GvHD, 
whilst providing a GvL effect (Ruggeri et al., 2005). With these key effector roles 
in mind, further studies are required to understand the functions of NK cells 
post-CBT.  
 
A study conducted by Beziat et al. shows that NK cells in CBT patients are 
functional post-transplant and possess phenotypic features associated with 
maturity. Furthermore, NK cells in CBT patients can directly lyse leukaemic 
blast cells, demonstrating a cytotoxic capacity (Beziat et al., 2009). Therefore, it 
has been proposed that NK cells within CBT patients could be involved in 
optimised GvL responses and could prevent relapse. Additionally, the cytotoxic 
capacity of NK cells from CBT patients has been exhibited via direct lysis of 
leukaemic blast cells such as K562 and RAJI, mediated through ADCC (Beziat 
et al., 2011). Overall, this displays that NK cells in CBT patients are functionally 
mature with a cytotoxic capacity to lyse leukaemic cells. Therefore, in this study 
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the phenotypes of NK cells in CBT patients and the overall capacity of NK cells 
to lyse leukaemic cells have been investigated.  
 
Additionally, the functions of NK cells are regulated through a number of signals 
that are delivered through activating and inhibitory receptors. NK cells have a 
unique property where they are able to eliminate target cells without prior 
stimulation. However, NK cells can be stimulated by cytokines, which leads to 
NK cell activation and increased cytolytic activity and proliferation.  
 
CD69 is an early activation marker expressed by activated lymphocytes, 
including NK cells (Hara et al., 1986). CD69 is involved in functions such as 
cytokine secretion, proliferation of NK cells and regulation of adhesion molecule 
expression on NK cells. Additionally, CD69 expressed by NK cells induces 
cytotoxicity (Borrego et al., 1999, Moretta et al., 1991). HLA-DR is a class II 
HLA surface receptor, where an initial theory was suggested that it was 
exclusively expressed by APCs to induce or supress T cell responses (Spits 
and Lanier, 2007). However, it has been displayed that NK cells express HLA-
DR upon activation and that the expression of HLA-DR on NK cells leads to 
cytokine release to induce CD4+ T cell proliferation (Hanna et al., 2004, Zingoni 
et al., 2004). Taken together, both CD69 and HLA-DR expression have been 
investigated in this thesis to understand the activation of NK cells in CBT 
patients.  
 
NK cell activation can occur through cytokine stimulation and through the 
recognition of antigens presented on target cells via class I and class II HLA 
receptors. NKG2C is a C-type lectin activating receptor expressed on NK cells 
that can recognise HLA-E, a class I molecule expressed on target cells. NKG2C 
induces signalling through DAP12 signalling molecules and the expression of 
NKG2C can imply that viral infection is being controlled (Braud et al., 1998, 
Fang et al., 2011). The increased expression of NKG2C can be associated with 
viral infections such Hepatitis B and Hepatitis C. Furthermore, the expression of 
NKG2C is increased in CBT patients infected with CMV, which is a common 
viral infection post-transplant (Beziat et al., 2012).  
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NK cells also express a variety of inhibitory receptors that can identify target 
cells. Normal cells express many of the ligands that are recognised by inhibitory 
receptors and this is a mechanism that prevents autoimmune killing (Moretta et 
al., 2001a). NKG2A is an inhibitory receptor expressed by NK cells and like 
NKG2C can also recognise HLA-E on all nucleated cells. However, their 
effector function differs compared to NKG2C, where NKG2A receptors transmit 
an inhibitory signal through the ITIM motif on the cytoplasmic domain. This 
transduces an inhibitory signal and suppresses the cytolytic activity of NK cells 
and preventing the lysis of the target cell (Lanier, 2008).  
 
CD57 is an additional marker associated with NK cell activation. CD57 was first 
thought to be exclusively expressed on NK cells and was used to define NK cell 
sub-populations. However, it was later revealed that CD57 is also expressed on 
CD8+ T cells (Abo et al., 1982). CD57 expression was also associated with NK 
cells that have poor proliferative capacity or even a degree of 
immunosenescence (Brenchley et al., 2003). More recently, it has been shown 
that NK cells stimulated by IL-2 have increased CD57 expression, which leads 
to a mature CD56dim NK cell subpopulation, therefore demonstrating that CD57 
is a marker of NK cell maturation (Lopez-Verges et al., 2010). The increased 
expression of CD57 on NK cells is correlated with infections such as HIV, 
Hepatitis B and Hepatitis C (Beziat et al., 2012, Hong et al., 2010). Furthermore, 
as CMV is one of the most common viral infections post-HSCT, it has been 
shown that these patients have increased expression of CD57 on NK cells 
compared to non-CMV infected patients (Lopez-Verges et al., 2010).  
 
Taken together, the expression of NKG2A, NKG2C and CD57 are important 
markers in NK cells in HSCT patients. Early post-transplant, NK cells in HSCT 
patients express higher levels of inhibitory receptors, NKG2A, compared to 
healthy controls. During the first three to six months post-transplant, there is 
loss of the NKG2A expression and increased expression of NKG2C and CD57 
(Bjorklund et al., 2010, Dulphy et al., 2008, Nguyen et al., 2005). This suggests 
that there is a shift towards an activating and functionally mature NK cell 
phenotype. However, there are discrepancies between studies regarding the 
reconstitution of NK cell functionality, which can occur anytime between three 
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and six months post-transplant (Bjorklund et al., 2010, Foley et al., 2011, Vago 
et al., 2008). With this in mind, the expression patterns of NKG2A, NKG2C and 
CD57 were measured to determine the kinetics of NK cell maturation in CBT 
patients.  
 
NK cells are actively involved in inflammatory reactions and participate in 
immune responses via the production of inflammatory cytokines. IFN-γ is 
produced by NK cells, which is induced by cytokines such as IL-12 and IL-18 
released by macrophages and DCs. Furthermore, TNFα also induces the 
production of IFN-γ from NK cells (Marshall et al., 2006). The secretion of IFN-γ 
by NK cells can lead to microbial and tumour clearance and this includes: (1) 
promotion of the interaction between NK cells and B cells, stimulating isotype 
switching in B cells to produce antigen specific antibodies; (2) upregulation and 
expression of adhesion molecules and chemokines and (3) transition between 
innate immune responses and adaptive immune responses via priming of T 
helper cells (Hayakawa et al., 2002). Investigating the intracellular expression of 
IFN-γ within NK cells in CBT patients could allow us to understand whether NK 
cells in CBT patients produce IFN-γ and whether these NK cells are associated 
in inflammatory responses.  
 
The cytotoxic capacity of NK cells is important post-transplant, as NK cells 
could clear residual disease whilst facilitating early engraftment of immune cells 
following CBT (Clausen et al., 2007, Ruggeri et al., 2002). As previously 
described, functionally mature CB NK cells can directly lyse leukaemic cell 
blasts such as K562 and RAJI cells (Tomchuck et al., 2015, Beziat et al., 2009). 
By understanding the cytotoxic capacity of NK cells in CBT patients, this could 
allow us to identify whether NK cells are associated with the prevention of early 
relapse and infection, post-CBT. CBU have a higher percentage of NK cells 
compared to mPB grafts.  However, NK cells within the CB graft have a lower 
cytotoxic capacity compared to adult PB NK cells (Alnabhan et al., 2015, 
Luevano et al., 2012). In addition, the cytotoxicity capacity of CB NK cells have 
been seen to significantly increase upon IL-2 and IL-5 stimulation (Dalle et al., 
2005). Overall, this highlights that CB NK cells possess a cytolytic capacity that 
could be actively involved in GvL responses.  
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Considering the importance of NK cells in HSCT, the activation of NK cells was 
investigated in CBT patients. Furthermore, the cytotoxic capacity of NK cells 
against K562 leukaemic cell blast was analysed. 
 
The specific aims of this chapter are to investigate the following:  
 
1. Identify the percentage expression of NK cell subsets in CBT patients.  
2. Identify the expression of activation markers on NK cell subsets within 
CBT patients.  
3. Identify the expression of inflammatory specific NK cells in CBT patients.  
4. Identify the percentage expression of IFN-γ on NK cell subsets within 
CBT patients.  
5. Identify the cytotoxic capacity of NK cells in CBT patients.  
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4.2 Percentage of NK cell subsets in cord blood transplant patients  
 
In this current study, the percentage of NK cell subpopulations in healthy adults 
and CBT patients were identified. The analysis was performed on isolated and 
thawed PBMC samples. The PBMCs were processed as described in Chapter 
2, section 2.3.2 and 2.3.6, respectively. Three NK cell populations were defined 
as the following phenotypes: CD56bright CD16dim NK cells, CD56dim CD16positive 
NK cells and CD56dim CD16negative NK cells. The percentages of the three NK 
cell populations were calculated as part of the CD56+ NK cell population.  
 
The data in Figure 4.1 shows that at 28 days post-transplant the median 
percentage of CD56bright CD16dim NK cells (Median: 6%, Interquartile range 
(IQR) 1-11%) within CD56+ population of patients is equivalent to the 
percentage seen in PBMCs of healthy adults (7%, IQR: 3-9%). Subsequently, 
between 60 and 100 days post-CBT the median percentage of CD56bright 
CD16dim NK cells remained at the same percentage median level compared to 
healthy controls. Overall, this shows that CD56bright CD16dim NK cells 
reconstitute within 100 days post-CBT.  
 
The median percentage of CD56dim CD16positive NK cells at 28 days post-CBT 
(17%, IQR: 14-37%) was significantly lower compared to healthy controls (85%, 
IQR: 77-89%) (p=0.0002). At 60 days post-transplant, the median percentage of 
CD56dim CD16positive NK cells increased (31%, IQR: 12-44%). However, the 
median percentage was significantly lower compared to healthy controls 
(p=0.002). The median percentage of CD56dim CD16positive NK cells by 100 days 
decreased (16%, IQR: 5-38%) compared to day 60. Furthermore, at 100 days 
post-CBT the median percentage level of CD56dim CD16positive NK cells remained 
significantly lower compared to healthy controls (p=0.001).  
 
At 28 days post-CBT, the median percentage of CD56dimCD16negative NK cells 
within the CD56+ NK cell population was significantly higher (66%, IQR 48-
78%) compared to healthy controls (10%) (p=0.0002). Subsequently, at 60 days 
post-transplant the median percentage of CD56dim CD16negative NK cells 
remained at a similar level to 28 days and was significantly higher compared to 
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healthy controls (p=0.002). By 100 days post-CBT, the median percentage of 
CD56dim CD16negative NK cells within the CD56+ NK cell population increased 
(77%, IQR: 65-88%) Again, this was significantly higher compared to healthy 
controls (p=0.001). Overall, this data shows that CBT patients had an equal 
percentage of CD56bright CD16dim NK cells compared to healthy controls. 
However, CBT patients had a lower percentage of CD56dim CD16positive NK cells 
compared to healthy controls. Furthermore, the predominant population of NK 
cells identified in CBT patients was the CD56dim CD16negative NK cell subset.  
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Figure 4.1 Percentage of NK cell subsets in CBT patients. The box and whisker plots 
represent the percentage of NK cell subsets, quantified within CBT patients. Three subsets 
were identified within CBT patients: CD56bright CD16dim, CD56dim CD16positive and CD56dim 
CD16negative NK cells. At the respective time points the number of patient samples collected were 
the following: D28: 14, D60: 10 and D100: 10. Furthermore, n=5 healthy control samples were 
collected. Analysis was performed between patient time points and healthy controls (p= 0.01, p= 
0.001). Results are presented as tukey analysis, where a non-paired Mann-Whitney test was 
performed between sample time points and healthy controls.  
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4.3 Activation markers of NK cells in cord blood transplant patients  
 
To determine the expression patterns of activation markers in NK cells, thawed 
isolated PBMCs from healthy adults and CBT patients were used. As previously 
described, CD69 and HLA-DR are activation markers that are expressed on NK 
cells that have a cytotoxic function. Both markers have been investigated in this 
study to better understand whether the NK subpopulations are activated in CBT 
recipients. The expression of activation markers were measured in CD56bright 
CD16dim, CD56dim CD16positive and CD56dim CD16negative NK cells, as shown in 
Figure 4.2, 4.3 and 4.4, respectively. 
 
The median percentage of CD56bright CD16dim NK cells expressing CD69 was 
significantly higher at day +28 (71%), +60 (65%) and +100 (65%) post-CBT 
compared to healthy controls (p=0.002, p=0.006 and p=0.012, respectively). 
Furthermore, the median percentage of CD56bright CD16dim NK cells expressing 
HLA-DR was similar at day +28 (74%), +60 (90%) and +100 (82%) post-CBT 
compared to healthy controls (79%). Overall, the data shows that the 
expression of CD69 in the CD56bright CD16dim NK cell population was higher 
compared to healthy controls. However, the expression HLA-DR was similar in 
the CD56bright CD16dim NK cell population of CBT patients compared to healthy 
controls.  
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Figure 4.2 Percentage expression of CD69 and HLA-DR in the CD56bright CD16negative NK 
cell population. The bar chart represents the percentage expression of CD69 and HLA-DR 
within the CD56bright CD16negative NK cell population of CBT patients. At the respective time points 
the number of patient samples collected were the following: D28: 14, D60: 10 and D100: 10. 
Furthermore, n=5 healthy control samples were tested. Result are presented as a tukey 
analysis and a non-parametric, Mann Whitney analysis was performed between the time points 
and the healthy controls, (p=0.05, p= 0.01, p= 0.001).  
 
 
 
 
 
 
 
 
 
 
!! 171 
The CD56dim CD16positive NK cell population within CBT patients also showed to 
have a similar pattern of CD69 and HLA-DR expression compared to CD56bright 
CD16dim NK cells, as seen in Figure 4.3.  
 
The median percentage of CD56dim CD16positive NK cells expressing CD69 was 
significantly higher at day +28 (84%), +60 (85%) and +100 (83%) post-CBT 
compared to healthy controls (p=0.0002, p=0.002 and p=0.001, respectively). 
Furthermore, the median percentage of CD56dim CD16positive NK cells expressing 
HLA-DR was similar at day +28 (72%) compared to healthy controls (72%). 
However, the median percentage of CD56dim CD16positive NK cells expressing 
HLA-DR was significantly higher at day +60 (82%) and +100 (85%) post-CBT 
compared to healthy controls (72%) (p=0.002 and p=0.007, respectively). 
Overall, this demonstrates that the percentage expression of CD69 is higher in 
CD56dimCD16positive NK cells of CBT patients compared to healthy controls. 
However, HLA-DR is similarly expressed in CD56dimCD16positive NK cells of CBT 
patients compared to healthy controls.  
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Figure 4.3 Percentage expression of CD69 and HLA-DR in the CD56dim CD16 positive NK cell 
population. The bar chart represents the percentage expression of CD69 and HLA-DR within 
CD56dim CD16positive NK cells in CBT patients. At the respective time points the number of patient 
samples collected were the following: D28: 14, D60: 10 and D100: 10. Furthermore, n=5 healthy 
control samples were tested. Result are presented as a tukey analysis and a non-parametric, 
Mann Whitney analysis was performed between the time points and the healthy controls, (p= 
0.01, p= 0.001).  
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The pattern of CD69 and HLA-DR expression was also similar in CD56dim 
CD16negative NK cells compared to CD56bright CD16dim and CD56dim CD16positive 
NK cells, as seen in Figure 4.4.  
 
The median percentage of CD56dim CD16negative NK cells expressing CD69 was 
significantly higher at day +28 (84%), +60 (83%) and +100 (86%) compared to 
healthy controls (43%) (p=0.0002, p=0.002 and p=0.001, respectively). The 
median percentage of CD56dim CD16negative NK cells expressing HLA-DR was 
higher at day +28 (73%). Additionally, the median percentage of CD56dim 
CD16negative NK cells expressing HLA-DR was significantly higher day +60 
(84%) and +100 (92%) compared to healthy controls (64%) (p=0.002 and 
p=0.001, respectively). Overall, this data suggests that the median percentage 
expression of CD69 and HLA-DR is higher in CBT patients compared to healthy 
controls and remains higher compared to healthy controls for up to 100 days 
post-transplant.  
 
Taken together, our data shows that CBT patients have activated NK cells post-
transplant and this is shown via the expression of NK cell markers such as 
CD69 and HLA-DR. As NK cells in CBT patients were activated, the expression 
patterns of activating and inhibitory (NKG2A, NKG2C and CD57) receptors 
were also measured post-transplant.  
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Figure 4.4 Percentage expression of CD69 and HLA-DR in the CD56dim CD16negative NK cell 
population. The bar chart represents the percentage expression of CD69 and HLA-DR within 
CD56dim CD16negative NK cells in CBT patients. At the respective time points the number of 
patient samples collected were the following: D28: 14, D60: 10 and D100: 10. Furthermore, n=5 
healthy control samples were tested. Result are presented as a tukey analysis and a non-
parametric, Mann Whitney analysis was performed between the time points and the healthy 
controls (p= 0.01, p= 0.001).  
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4.4 Activating and inhibitory receptors of NK cells in cord blood transplant 
patients  
 
The pattern of activating and inhibitory marker expression of NKG2A, NKG2C 
and CD57 were identified in CBT patients for up to 100 days post-transplant as 
shown in Figure 4.5, 4.6 and 4.7. To determine the expression patterns of 
activating and inhibitory receptors in NK cells, thawed isolated PBMCs from 
healthy adults and patients were used.  
 
The percentage expression of NKG2A and NKG2C was measured in NK cells 
of CBT patients to understand the patterns of the respective activation and 
inhibitory receptors. As previously described, CMV is a common viral infection 
post-transplant and patients have increased expression of NKG2C on NK cells 
post-infection. Increased expression of NKG2C on NK cells can lead to direct 
lysis and cytotoxicity of the target cell. Alternatively, NKG2A is an inhibitory 
receptor that suppresses the cytolytic activity of NK cells. CD57 coupled with 
NKG2A or NKG2C demonstrates NK cell maturation.  
 
The median percentage of CD56brightCD16dim NK cells expressing 
NKG2A+CD57+ was significantly higher at day +28 (5%), +60 (9%) post-CBT 
compared to healthy controls (0%) (p=0.03 and p=0.02, respectively). 
Furthermore, the median percentage of CD56bright CD16dim NK cells expressing 
NKG2A+CD57+ was higher at day +100 (3%) post-CBT compared to healthy 
controls (0%). There was no pattern of expression of NKG2C+CD57+ in 
CD56bright CD16dim NK cells and expression levels remained below 1% up to 100 
days post-CBT. This is lower compared to healthy controls, where a median 
expression was recorded at 20%. This demonstrates that the percentage 
expression of NKG2A+CD57+ within CD56bright CD16dim NK cells population is 
higher compared to healthy controls and the level of expression of 
NKG2C+CD57+ within CD56bright CD16dim NK cells is lower compared to healthy 
controls. Therefore, this indicates that CD56bright CD16dim NK cells have a higher 
expression of inhibitory receptors compared to healthy controls. This could 
indicate that CD56bright CD16dim NK cells are mature with an inhibitory 
phenotype. 
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Figure 4.5 Percentage expression of NKG2A+CD57+ and NKG2C+CD57+ expression 
within the CD56bright CD16dim  NK cell population. The bar chart represents the percentage 
expression of NKG2A+CD57+ and NKG2C+ and CD57+ expression within the CD56bright 
CD16dim NK cell population in CBT patients. At the respective time points the number of patient 
samples collected were the following: D28: 14, D60: 10 and D100: 10. Furthermore, n=5 healthy 
control samples were tested. Result are presented as a tukey analysis and a non-parametric, 
Mann Whitney analysis was performed between the time points and the healthy controls (p= 
0.05).  
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The median percentage of CD56dimCD16positive NK cells expressing 
NKG2A+CD57+ was significantly higher at day +28 (7%), +60 (14%) +100 
(15%) post-CBT compared to healthy controls (3%) (p=0.02, p=0.007 and 
p=0.02, respectively). Throughout the three time points, the expression of 
NKG2C+CD57+ was not detected on CD56dim CD16positive NK cells. Overall, this 
data suggests that the CD56dim CD16positive NK cell population also have an 
inhibitory phenotype due to the increased expression of NKG2A+CD57+. 
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Figure 4.6 Percentage expression of NKG2A+CD57+ and NKG2C+CD57+ within the 
CD56dim CD16positive NK cell population. The bar chart represents the percentage expression 
of NKG2A+CD57+ and NKG2C+CD57+ within the CD56dim CD16positive NK cell population in 
CBT.. At the respective time points the number of patient samples collected were the following: 
D28: 14, D60: 10 and D100: 10.  Furthermore, n=5 healthy control samples were tested.  Result 
are presented as a tukey analysis and a non-parametric, Mann Whitney analysis was performed 
between the time points and the healthy controls, (p= 0.05 and p=0.01). 
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The median percentage of CD56dim CD16negative NK cells expressing 
NKG2A+CD57+ was significantly higher at day +28 (4%) and +60 (7%) post 
CBT compared to healthy controls (p=0.04 and p=0.01, respectively). 
Furthermore, the median percentage of CD56dim CD16negative NK cells 
expressing NKG2A+CD57+ was higher at day +100 (15%) post-CBT compared 
to healthy controls (3%). The expression of NKG2C+CD57+ was undetected 
within the CD56dim CD16negative NK cell population of CBT patients. Overall, this 
data shows that CD56dim CD16negative NK cells could have an inhibitory 
phenotype as expression levels of NKG2A+CD57+ are higher compared to 
healthy controls. Furthermore, there is no expression of NKG2C+CD57+ on 
CD56dim CD16negative NK cells within CBT patients suggesting that there is no 
activation of this cell subset post-transplant. 
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Figure 4.7 Percentage expression of NKG2A+CD57+ and NKG2C+CD57+ within the 
CD56dim CD16negative NK cell population. The bar chart represents the percentage expression 
of NKG2A+CD57+ and NKG2C+CD57+ expression within the CD56dim CD16negative NK cell 
population in CBT patients. At the respective time points the number of patient samples 
collected were the following: D28: 14, D60: 10 and D100: 10. Furthermore, n=5 healthy control 
samples were tested. Result are presented as a tukey analysis and a non-parametric, Mann 
Whitney analysis was performed between the time points and the healthy controls (p= 0.05). 
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4.5 Percentage expression of intracellular IFN-γ within the CD56bright 
CD16negative, CD56dim CD16positive and CD56dim CD16negative NK cells in 
cord blood transplant patients.  
 
IFN-γ is a pro-inflammatory cytokine released by NK cells. The release of IFN-γ 
from NK cells mediates clearance of microbes and tumours through a number 
of pathways, as previously described. Understanding the pattern of IFN-γ 
expression in CBT patients could demonstrate that NK cells can produce IFN-γ 
but also that these NK cells could be involved in GvL responses and clearing 
infection post-transplant. Additionally, identifying the intracellular expression of 
IFN-γ in NK cells within CBT patients could imply that CBT patients have NK 
cells with a cytotoxic capacity. The patterns of IFN-γ intracellular expression are 
shown in Figure 4.8a, 4.8b and 4.8c. The expression of IFN-γ has been 
measured in non-stimulated conditions. Thawed isolated PBMCs from healthy 
adults and patients were used to determine the intracellular expression patterns 
IFN-γ in NK cells. 
 
The median percentage of CD56bright CD16negative NK cells expressing IFN-γ 
(Figure 4.8a) was higher at day +28 (70%) and +60 (80%) and +100 (64%) 
post-CBT compared to healthy controls (0%). Additionally, the median 
percentage of CD56dim CD16positive NK cells expressing IFN-γ (Figure 4.8b) was 
significantly higher at day +28 (66%) and +60 (67%) and +100 (62%) post-CBT 
compared to healthy controls (0%) (p=0.0001, p=0.0007 and p=0.0007). The 
median percentage of CD56dim CD16negative NK cells expressing IFN-γ (Figure 
4.8c) was significantly lower at day +28 (64%) and +60 (68%) and +100 (62%) 
post-CBT compared to healthy controls (77%) (p=0.03 and p=0.02). Overall, 
this data demonstrates that all three NK cell populations in CBT patients 
express IFN-γ intracellularly and the expression is highest within the CD56bright 
CD16negative and CD56dim CD16positive NK cell populations. However, within the 
CD56dim CD16negative NK cell population intracellular expression of IFN-γ is 
similar to healthy adults. 
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Figure 4.8 Intracellular expression of IFN-Ɣ in CD56bright CD16negative, CD56dimCD16positive and 
CD56dimCD16negative NK cells. The bar charts represent the percentage expression of IFN-Ɣ 
within (A) CD56brightCD16negative, (B) CD56dimCD16positive and (C) CD56dimCD16negative NK cells in 
CBT patients. At the respective time points the number of patient samples collected were the 
following: D28: 14, D60: 10 and D100: 10. Furthermore, n=5 healthy control samples were tested. 
Result are presented as a tukey analysis and a non-parametric, Mann Whitney analysis was 
performed between the time points and the healthy controls. (p= 0.05 and p= 0.001). 
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4.6 Killing capacity of cord blood transplant NK cells  
 
In this current study, the cytotoxic capacity of isolated NK cells from CBT 
patients was analysed. To determine the cytotoxic capacity, NK cells were 
isolated from thawed PBMCs and were then tested in an in vitro killing assay. 
Our previous data shows that NK cells are activated via the expression of CD69 
and HLA-DR. Respectively, NK cells have a higher expression of the inhibitory 
marker NKG2A. Furthermore, all of the NK cell subsets express IFN-Ɣ 
intracellularly, which could promote the cytotoxic activity of NK cells. Based on 
these findings it was hypothesised that NK cells in CBT patients are cytotoxic. 
This hypothesis was tested by measuring the cytotoxicity capacity of NK cells 
directed towards leukaemic cells (K562) at a 1:1 ratio as described in Chapter 
2, Section 2.8.8. Thawed isolated NK cells from PBMCs of patients and healthy 
adult control samples were incubated with K562 cells for four hours and the 
percentage reduction of the K562 population was measured via flow cytometry.  
 
The data in Figure 4.9 shows that NK cells had a cytotoxic capacity to K562 
leukaemic cell blasts at all time points post-CBT. The median percentage of 
specific cell lysis of K562 cells is shown at the following time points post-
transplant: day 28, 60, 100 and 180.  
 
The median percentage of specific K562 cell lysis at day +28 (36%, range: 
19.48-95.15%), +60 (44%, range: 31.72–71.85%), +100 (18%, range: 5.43–
73.84%) and +180 (39%, range: 5.87-79.96%) post-CBT, shows that CBT 
patient NK cells are capable of lysing K562 leukaemic cell blasts to the same 
degree as healthy controls (32%, range: 6.27 – 78.2%). Furthermore, patient 
NK cells are able to direct killing towards K562 cells at a 1:1 ratio.  
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Figure 4.9 Killing of K562 cells in vitro by patient NK cells and healthy control NK cells. 
The bar chart represents the percentage of K562 cells lysed by patient NK cells. Isolated 
CD56+ NK cells from patient samples were incubated with K562 cells for four hours and the 
percentage of K562 cells were measured via flow cytometry. At the respective time points the 
number of patient samples collected were the following: D28: 14, D60: 10, D100: 10 and D180: 
10.  Furthermore, n=5 healthy control samples (PBMCs) were tested for this assay. Result are 
presented as a tukey analysis and a non-parametric, Mann Whitney analysis was performed 
between the time points and the healthy controls. 
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4.7 Discussion 
 
As far as we are aware, this is the first study within the UK to investigate the 
post-transplant functionality of NK cells in CBT patients. Various studies have 
assessed the phenotype of CB NK cells and PB NK cells. However, there is 
limited data on the functionality of NK cells in a post-CBT setting.  
 
NK cells are the first lymphocyte population that reconstitute in CBT patients 
and this occurs within one month post-transplant (Jacobson et al., 2012, 
Ruggeri et al., 2011).  T cell reconstitution is delayed compared to NK cells. 
However, as NK cells reconstitute before T cells they are believed to have a 
GvL role post-transplant (Ruggeri et al., 2002). This has not been thoroughly 
investigated in CBT patients and the phenotype and cytotoxic activity of NK 
cells was assessed in this study to better understand the function of these cells 
post-transplant.  
 
In this study, it is shown that there are three NK cell subpopulations within CBT 
patients: CD56bright CD16negative, CD56dim CD16negative and CD56dim CD16positive NK 
cells. There were a higher percentage of CD56dim CD16negative NK cells in CBT 
patients compared to healthy controls and a lower percentage of CD56dim 
CD16positive NK cells compared to healthy controls. However, little is known 
about CD56dim CD16negative NK cells and future NK cell studies should be 
undertaken to identify the functionality of these cells in HSCT, particularly within 
CBT patients. As previously described, Poli et al. considered CD56dim 
CD16negative NK cells to be one of the sub-populations of NK cells and this group 
has also stated that little is known about the function of this subset (Poli et al., 
2009)  In addition, a study conducted by Romee et al. highlights that NK cells 
down regulate CD16 expression and CD56dim CD16positive NK cells shed and 
down regulate CD16 upon exposure to tumour targets (Romee et al., 2013). 
Furthermore, CD56dim CD16positive NK cells lose CD16 expression through the 
action of matrix metalloproteinase enzymes upon NK cell interaction with 
tumour antigens (Grzywacz et al., 2007).  
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CD56dim NK cells have cytolytic effector functions and can lyse target cells. 
Additionally, CD56dim NK cells are a major source of pro-inflammatory cytokines 
and chemokines, which are rapidly produced after target cell recognition. 
Furthermore, CD56dim NK cells can exert a higher cytotoxic function compared 
to CD56bright NK cells (Cooper et al., 2001).  
 
Complete phenotypic and functional maturation of NK cells can take up to 
several months post-transplant. Early post-transplant, patients have a high 
proportion of immature CD56bright NK cells. This shifts to a high proportion of 
CD56dim NK cells within several months (Nguyen et al., 2008). The analysis in 
this current study was performed on patient samples within the first 100 days 
post-CBT. The data shows there were a high proportion of CD56dim NK cells, 
early post-transplant. This corroborates data by Nyugen et al (Nguyen et al., 
2008). Therefore, the phenotypic shift from CD56bright to a CD56dim NK cell 
population could demonstrate that there is reconstitution of CD56dim CD16negative 
and CD56dim CD16positive NK cell subsets. However, to further understand the 
phenotype and function of these NK cell subsets, further studies are required to 
elucidate their role.  
 
Data within this current study shows that the expression of CD69 is higher in 
CBT patients early post-transplant compared to healthy controls. Furthermore, 
the expression levels of CD69 are significantly higher in all three NK cell 
populations compared to healthy controls. This corroborates data presented by 
Beziat et al. who has shown that NK cell subsets have increased expression of 
CD69, early post-transplant and this indicates early activation of NK cells in 
CBT patients (Beziat et al., 2009). In addition, this current study also shows that 
the NK cell subpopulations in CBT patients had a higher expression of HLA-DR 
compared to healthy controls. This also highlights that NK cells are activated 
post-CBT. When combined, high expression of CD69 and HLA-DR in CBT 
patients compared to healthy controls shows that NK cells are activated post-
transplant.  
 
CBT-patients can be challenged by a number of infections post-transplant and 
the various pathogenic antigens could lead to NK cell activation. Higher 
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expression of HLA-DR by NK cells is associated with the release of pro-
inflammatory cytokines, suggesting that a functional immune response takes 
place to lyse the target cell (Zingoni et al., 2004). Overall, this suggests that NK 
cells within CBT patients are activated post-transplant.  
 
Herein, it has been shown that NK cells in CBT patients are activated. The 
expression patterns of NKG2A+CD57+ and NKG2C+CD57+ were further 
investigated to understand the expression patterns of activating and inhibitory 
receptors in CBT patients. Through this analysis, it has been shown that there is 
a very low level of NKG2C+CD57+ expression within CBT patients compared to 
healthy controls. However, CBT patients have a higher expression of 
NKG2A+CD57+ compared to healthy controls in all three NK cell 
subpopulations. This could suggest that NK cells, early post-transplant, have an 
inhibitory phenotype in CBT patients. A study conducted by Kordelas et al. 
demonstrates that patients with severe GvHD have significantly reduced levels 
of NKG2C after allogeneic HSCT (Kordelas et al., 2016). However, this could 
not be correlated in this current study, as GvHD data was not complete. The 
expression patterns of NKG2A+CD57+ or NKG2C+CD57+ could therefore be 
used to distinguish whether there are mature-activating or mature-inhibitory NK 
cells post-CBT, respectively. In a study conducted by Romee et al. it has been 
observed that NK cells have a mature-inhibitory phenotype, early post-
transplant, with increased expression of NKG2A. Furthermore, the expression 
of NKG2A is induced by IL-12 and IL-18 (Romee et al., 2012). This could 
suggest that NK cells, early post-CBT, have a memory like phenotype and their 
phenotype is induced via cytokine stimulation. However, further studies would 
be required to assess the presence and level of cytokines in CBT patients and 
whether patient NK cells can be stimulated via cytokines.  
 
Additionally, the intracellular expression of IFN-γ was higher in the CD56bright 
CD16negative and CD56dimCD16positive NK cell populations compared to healthy 
controls. However, the intracellular expression of IFN-γ was equal in the 
CD56dimCD16negative NK cell subpopulation of CBT patients compared to healthy 
controls. The intracellular expression of IFN-γ in all three NK cell populations 
could be due to the activation of NK cells within the patient. Post-transplant, it is 
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known that the immune profile of a patient is highly inflammatory and this is due 
to the presence of inflammatory cytokines such as IL-1, IL-6 and TNF-α. 
Additionally, the immune system will be challenged by a number of foreign 
antigens. In turn, this could induce the activation of NK cells, which could 
subsequently cause the intracellular production of IFN-γ within NK cells of CBT 
patients. IFN-γ is released by NK cells and mediates clearance of microbes and 
tumours through a number of pathways, as previously described. Data within 
this current study corroborates published data by showing that IFN-γ expression 
is higher in CBT patients compared to healthy controls (Beziat et al., 2009). 
CBT patients are immunocompromised post-transplant and are administered a 
number of immunosuppressive agents as part of their GvHD prophylaxis. Early 
post-transplant, the use of immunosuppressive agents can suppress cytokine 
release and the levels of IFN-γ can be impaired, however the expression IFN-γ 
normalises after several months (Melenhorst et al., 2012). Furthermore, CMV 
infection has been shown to influence IFN-γ expression on NK cells and CMV 
infection induces rapid maturation of NK cells with the increased expansion of 
CD56dim NK cells. (Della Chiesa et al., 2014). Overall, there was a higher 
proportion of CD56dim NK cells in CBT patients within this current study and 
these cells were capable of expressing IFN-γ. However, in this current study, 
infection data was not complete and therefore correlations of infection with 
CD56dim NK cell percentages could not be made. Therefore, further studies must 
be undertaken to understand whether CMV infection impacts NK cell maturation 
post-CBT.  
 
The cytotoxic functions of NK cells are highly important and there is limited of 
data that defines the cytotoxic capacity of NK cells in CBT patients. Herein, NK 
cells from CBT patients can mount a cytotoxic response to K562 cells, which 
verifies data demonstrated by Beziat el al. who performed this analysis on 
freshly isolated NK cells (Beziat et al., 2009). However, in this current study, to 
understand the cytotoxic capacity of NK cells, thawed and isolated NK cells 
were used. These NK cells can also mount a cytotoxic response against K562 
cells. Unfortunately, cytolytic degranulation of NK cells could not be identified as 
the cell viability of NK cells reduced upon staining of CD107a. To understand 
the cytotoxic capacity of NK cells in CBT patients, further work can be done by 
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conducting in vitro killing assays on alternative cell lines such as 721.221 and 
Jurkat cells. Furthermore, the use of patient AML cells could also provide a 
better understanding of NK cell cytotoxic capacity. This could enhance our 
understanding of the cytotoxic capacity of NK cells and whether they can lyse 
primary malignant cells.   
 
To summarise, the predominant NK cell subpopulation in CBT patients was 
CD56dim CD16negative. All three NK cell sub-populations were activated with high 
expression of CD69 and HLA-DR. NK cell subpopulations in CBT patients had 
an inhibitory phenotype and all sub-populations expressed IFN-γ intracellularly. 
The cytotoxic capacity of NK cells was measured and NK cells from CBT 
recipients can directly lyse K562 leukaemic blast cells. Herein, NK cells in CBT 
patients showed a functional capacity.  
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Chapter 5 : Kinetics and diversity of 
reconstituting B cell subsets in cord blood 
transplant patients. 
 
5.1 Background and Aims 
 
In Chapter 3, it was shown that CD19+ B cell reconstitution occurs by 100 days 
post-transplant. In contrast, patterns of B cell reconstitution have been 
investigated in several mPB and BMT studies, which have shown that absolute 
B cell reconstitution takes place between 180 and 365 days post-transplant 
(Storek et al., 1993, Storek et al., 2001b, Avanzini et al., 2005, Lev et al., 2012). 
Comparatively, CBT recipients have a faster B cell reconstitution, which takes 
place between 100 and 180 days post-CBT (Nakatani et al., 2014).  
 
B cells play a crucial role in humoral immune responses and a diverse B cell 
repertoire is key for an effective immune response. Healthy adult individuals 
have a broad B cell repertoire enabling them to recognise a variety of self and 
non-self antigens. In HSCT, it has been demonstrated that reconstituting B cells 
could have a diverse BCR repertoire, as early as 90 days post-transplant 
(Beaudette-Zlatanova et al., 2013). This highlights that early B cell 
reconstitution and increased BCR diversity is required as part of reconstitution 
of adaptive immunity. This is essential as CBT patients are prone to a number 
of opportunistic infections within the first few months post-transplant. In addition, 
if complete B cell reconstitution takes place early post-transplant, then immune 
defence mechanisms can be primed to clear opportunistic infections. 
Furthermore, in CBT patients, early B cell reconstitution is associated with lower 
incidence of GvHD. This could be due to a higher absolute number of B cells 
that reconstitute earlier post-transplant compared to BMT and mPB transplant 
recipients (Jacobson et al., 2012).  
 
With these important functions of B cells in mind, the diversity and kinetics of B 
cell reconstitution was measured in CBT patients. Overall, this was measured to 
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determine the time in which B cell recovery takes place and to understand 
whether the sequential maturation stages take place during B cell 
reconstitution.  
 
CB grafts predominantly contain naïve B cells, which could mean that there are 
a high proportion of B cells with low BCR diversity and these cells have not 
been challenged by antigens. Initial B cell development takes place in fetal 
tissue and in the BM. Once HSCs differentiate into CD19+ pro-B cells, gene 
rearrangement of the immunoglobulin heavy chain and the Ig light chain locus 
takes place. This allows maturation of a pro-B cell into a pre-B cell. 
Subsequently, further gene arrangement takes place within a pre-B cell and the 
light chain of the Ig locus rearranges to give rise to a functional immature B cell 
(Cooper, 1987, Uckun, 1990). During Ig locus gene recombination in B cells 
there is production of excision circles known as kappa deleting recombination 
circles (KRECs). KRECs are formed during B cell maturation within the BM and 
are bi-products of recombination events that cause exclusion of the Ig kappa 
locus (Siminovitch et al., 1985, van Zelm et al., 2007). This takes place within B 
cells that have failed to reproductively rearrange the Ig kappa gene on both 
alleles (Beishuizen et al., 1997). The Ig kappa gene becomes non-functional 
and this leads to deletion of the gene segment. Furthermore, this leads to the 
formation of a coding joint and excision loop (KRECs), which is excluded from 
further gene rearrangements (Beishuizen et al., 1997).  
 
Naïve/immature and transitional B cells released into the periphery from the BM 
contain high levels of KRECs and as these B cells proliferate and mature the 
copy number of KRECs dilute. The measurement of KRECs provides an 
indication of B cell output from the BM. KREC copy numbers increase in 
allogeneic HSCT patients for up to 180 days post-transplant and this correlates 
with increased absolute numbers of naïve, transitional/immature B cells 
(Mensen et al., 2013). In CBT recipients, there is rapid neogenesis of B cells 
compared to BMT recipients, which has been confirmed through KRECs 
quantification (Nakatani et al., 2014). Therefore, this highlights that KREC 
quantification can be used as an important genetic marker to monitor BM output 
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of B cells. With this in mind, KREC quantification was performed in this current 
study to better understand the output of B cells from the BM in CBT patients.  
B cell maturation within the BM is a highly important stage in B cell 
development. However, there are a number of developmental stages involved 
in B cells maturation, which occur within the periphery. These are essential 
stages that are required for the production of antibody secreting B cells, which 
are one of the most mature B cell populations. In this project, the kinetics and 
recovery of B cell subsets at the various maturation stages in CBT patients 
have been identified and quantified.  
 
Once B cells mature within the BM they differentiate into transitional B cells and 
are released into the peripheral blood system. Transitional B cells express cell 
surface markers such as CD24 and CD38. Through the use of these cell 
surface markers, transitional B cells can be characterised as CD4-
CD19+CD24+CD38+. A study conducted by Marie-Cardine et al. shows that 
transitional B cells are the first B cell subpopulation to reconstitute after HSCT. 
Furthermore, they are defined as an important developmental stage, which is 
required before differentiation into mature B cells (Marie-Cardine et al., 2008). 
As far as we are aware, the kinetics of transitional B cell reconstitution has not 
been formally investigated in CBT patients. Therefore, defining the kinetics of 
transitional B cell reconstitution will demonstrate whether this key 
developmental stage takes place post-transplant.  
 
Once transitional B cells develop they migrate from the BM to the spleen and 
differentiate into naïve B cells. In the spleen, naïve B cells are presented with a 
number of antigens, which results in maturation and differentiation into antibody 
class-switched memory B cells (De Silva and Klein, 2015). Additionally, in BMT 
and mPB transplant studies, the development of naïve B cells is considered a 
key B cell subtype that can produce a range of antibodies, which recognise self 
and non-self antigens. In CBT studies, absolute counts of naïve B cells were 
highest within the PB of patients within the first year of transplant (Charrier et 
al., 2013, Servais et al., 2014). With these key roles in mind the kinetics of 
naïve B cell reconstitution was measured in CBT patients. Furthermore, in this 
current study naïve B cells have been defined as CD19+CD10+CD21+CD27-.  
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In the periphery and spleen, naive B cells differentiate into mature B cells upon 
antigenic and cytokine stimulation. The maturation of naive B cells causes loss 
of CD38 expression and there is continued CD24 expression on the cell 
surface. A CBT murine study has revealed that there is an increase in absolute 
numbers of mature B cells post-transplant (Wang et al., 2012b). Comparatively, 
this is also seen in adult human BMT studies and reconstitution of mature B 
cells occurred by six months post-transplant (Storek et al., 1993). Similarly, in 
CBT studies it has been demonstrated mature B cell reconstitution also occurs 
within this time frame (Renard et al., 2011, Kanda et al., 2012). With this in 
mind, it is important to understand the time to reconstitution of mature B cells in 
CBT patients. Mature B cells play a major role in infection clearance and the 
increased absolute counts of mature B cell post-transplant are associated with 
reduced incidence of aGvHD in HSCT recipients (Corre et al., 2010, Storek et 
al., 2001b). Furthermore, a study conducted by Weber et al. has shown that IL-
10 produced by donor and host B cells in HSCT recipients mediate a regulatory 
function to suppress aGvHD after HSCT (Weber et al., 2014). Taking this into 
consideration, the kinetics of mature B cell reconstitution was measured in CBT 
patients. Furthermore, the expression of mature B cells as was defined as CD4-
CD19+CD24+CD38-. 
 
Naïve B cells can further differentiate into other B cell subsets such as activated 
B cells and memory B cells. These subsets can be characterised through the 
identification of cell surface markers such as CD21 and CD27. CD21 is a 
complement receptor that is expressed on B cells and is an essential marker 
used to identify memory B cells (Avery et al., 2005). CD27 expression aids in 
identifying B cell subpopulations such as activated and memory B cells as it is 
expressed on 40% of B cells. CD27 is highly expressed on memory B cells and 
has been used to specifically distinguish memory B cells from naïve B cell 
subtypes. Furthermore, the expression patterns of CD27 correlate with high 
expression levels of IgM and IgD antibodies, which shows that the cell has 
reached a mature state (Klein et al., 1998). Additionally, CD10 is another cell 
surface marker that can be used to identify B cell subsets. CD10 is commonly 
expressed by common lymphoid progenitors (CLP) that reside within the BM 
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and circulating B cells in the periphery have reduced expression of CD10. CLPs 
within the BM migrate either to the thymus to mature into T cells or remain 
within the BM to mature into B cells (Galy et al., 1995). CD10 is important in 
haematological diagnosis as early B cells, pro-B cells and pre-B cells express 
CD10. However, within this study CD10 has been used to negatively select for 
activated B cells, memory B cells and naïve B cells.  
 
Through the use of surface markers such as CD21 and CD27, B cell subsets 
such as activated B cells, which are defined as CD19+CD10-CD21+CD27+, have 
been identified in this study. Activated B cells can be induced by APCs, which 
leads to somatic hypermutation and the generation of antigen specific 
antibodies. These antibodies can aid in the clearance of various pathogens 
(Agematsu et al., 1997). Interestingly, Agemastu et al. demonstrates that 
CD27+ B cells are absent in CB and the absolute counts of these cells increase 
with age in healthy individuals. Furthermore, CD27+ B cells can produce large 
numbers of Igs via direct contact with CD70 on CD4+ T cells (Agematsu et al., 
1997). This is highly important in healthy individuals as well as HSCT recipients 
as it highlights that B cells can produce various antibodies that can distinguish 
self and non-self antigens. Therefore, it is important to map the kinetics of 
activated B cells reconstitution in CBT patients. This could demonstrate whether 
CBT recipients have the potential to develop antibody-producing cells that could 
aid in clearing infection.  
 
Activated B cells undergo somatic hypermutation upon antigenic stimulation. 
This leads to the differentiation and maturation of activated B cells into memory 
B cells that can identify antigens upon secondary infection. Therefore, memory 
B cells play a fundamental role in clearance of microbes upon secondary 
infection. A study conducted by Thorarinsdottir et al. shows that CD21-CD27+ B 
cells are Ig class switched in healthy individuals and are antigen experienced. 
Furthermore, they can mount an immediate response to secondary infection 
(Thorarinsdottir et al., 2016). In HIV, Hepatitis C and malaria-infected 
individuals, the absolute numbers of memory B cells are increased. The 
expansion of these cells is due to chronic activation by the infective agents and 
auto-antigens present within the respective diseases (Charles et al., 2011, Moir 
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et al., 2008, Weiss et al., 2009). In HSCT, it has been demonstrated that 
memory B cells increase in absolute numbers post-BMT. However, the number 
of memory B cells is lower compared to naïve B cells (Avanzini et al., 2005). 
The kinetics of memory B cell reconstitution is poorly defined in CBT patients. A 
better understanding of the restoration of humoral immunity can be achieved by 
monitoring the kinetics of memory B cell reconstitution in CBT recipients. 
Furthermore, this will also provide an insight into the reconstitution kinetics of 
antibody producing B cells in CBT patients. Therefore, in this current study, the  
kinetics of memory B cells has been measured in CBT patients and these cells 
have been defined as CD19+CD10-CD21-CD27+ B cells.  
 
Therefore in this study the kinetics and diversity of B cells in CBT patients was 
investigated. This was performed to further understand the time taken for B cell 
reconstitution post-transplant. Through this we can understand the key 
developmental stages involved in B cell reconstitution in CBT patients. This can 
provide an insight into the time in which BM output recovers and whether key 
developmental stages take place to reconstitute humoral immunity.  
 
The specific aims of this chapter are to investigate the following: 
1. Determine whether early reconstitution of CD19+ B cells impacts overall 
survival of CBT patients.  
2. Map the kinetics of KREC excision circles within CBT patients to 
determine BM output of B cells in CBT patients.  
3. Determine whether the copy number of KREC excision circles impacts 
the overall survival of CBT patients.  
4. Map the kinetics of transitional B cell reconstitution in CBT patients.  
5. Determine whether the absolute counts of transitional B cells impact the 
overall survival of CBT patients.  
6. Map the kinetics of naïve B cell reconstitution in CBT patients.  
7. Map the kinetics of mature B cell reconstitution within CBT patients.  
8. Determine whether the absolute counts of mature B cells impact the 
overall survival of CBT patients.  
9. Map the kinetics of activated B cell reconstitution in CBT patients.  
10. Map the kinetics of memory B cell reconstitution in CBT patients.  
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5.1.1 Overall survival of cord blood transplant patients according to the 
CD19+ B cell count at 28 days post-transplant  
 
In Chapter 3, it was shown that the reconstitution of CD19+ B cells takes place 
within 100 days post-transplant. With this in mind, it was hypothesised that the 
early reconstitution of CD19+ B cells may reduce infection and improve overall 
survival of CBT patients. Therefore, the patients were segregated into two 
groups, above and below the 28-day median CD19+ B cell count (n=21 patients 
were in each group). Landmark analysis was performed to assess whether 
there was a difference in the overall survival between the two groups as shown 
in Figure 5.1. This data demonstrates that patients with an absolute CD19+ B 
cell count above the median at 28 days had a two year overall survival of 87% 
(95% CI, 25-34%) compared to 50% (95% CI, 15-29%) for those patients with a 
day 28 CD19+ B cell count below the median (p= 0.04)  
 
 
Figure 5.1. Overall survival of CBT patients according to the CD19+ B cell count at 28 
days post-transplant. Kaplan-Meier curve to represent the landmark analysis for CBT patients 
above and below the 28-day median absolute counts of CD19+ B cells. 
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5.1.2 Absolute copy numbers of KRECs in cord blood transplant patients  
 
The quantification of KREC copy numbers is a highly sensitive measure of B 
cell output from the BM. In this current study, the reconstitution of B cells takes 
place by 100 days post-transplant. With this in mind, the output of B cells from 
the BM was assessed via KREC quantification (Figure 5.2).  
 
At 28 days post-CBT, the median KREC levels were significantly lower 
compared to healthy controls (p=0.0004). By 60 days post-CB, patients had a 
higher median of KREC (422517 copy number/107 cells) copy numbers 
compared to healthy controls (276393 copy number/107 cells). Furthermore, at 
60 days post-transplant, the interquartile range for KREC copy number/107 cells 
was broader in CBT patients (0-997636 copy number/107 cells) compared to 
healthy controls (148222-421035 copy number/107 cells). At 100 days post-
CBT, median copy number of KRECs increased and the interquartile range was 
broadest (602203-1189392 copy number/107 cells) compared to all other time 
points and healthy controls. By 180 days post-CBT, the median copy numbers 
increased in to 1091208 copy number/107 cells, which was significantly higher 
compared to all other time points and healthy controls (p=0.03). By 365 days 
post-CBT, the median copy number of KRECs was significantly higher 
compared to healthy controls (p=0.006). Additionally, the median copy number 
of KREC were also significantly higher compared to healthy controls at 720 
days post-CBT (p=0.02). Overall, KREC copy numbers recover to the normal 
range by 60 days in CBT patients. This could suggest that the output of B cells 
from the bone marrow could recover by 60 days post-CBT.  
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Figure 5.2 Absolute copy numbers of KRECs in CBT patients. Box and whisker plots showing 
the copy number of KREC genes, copy number per 107 Cells. A real-time PCR assay was 
performed to quantify KREC genes. At each time point the following number of samples were 
acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26, D720 = 14. Furthermore, n = 
10 healthy control samples were tested. Results are presented as a tukey analysis and a non-
parametric; Mann Whitney analysis was performed between the time points and the healthy 
controls. 
!! 197 
5.1.3 Overall survival of cord blood transplant patients according to the 
KREC copy number at 60 days post-transplant 
 
KREC analysis specifically demonstrates that BM output of B cells recovers in 
CBT patients by 60 days post-transplant. It was therefore hypothesised that 
early reconstitution of B cells may clear infection and improve overall survival. 
Therefore, survival was plotted according to above and below the median 60 
day KREC copy number value (n=21 patients were in each group). The 60-day 
value was used, as there were insufficient KREC copy numbers at 28 days to 
allow the analysis. To test this hypothesis landmark analysis was performed on 
patients who were above and below the median copy number of KRECs at 60 
days post-CBT (422517 copy number/107 Cells), as shown in Figure 5.3.  
 
After a follow-up time of 24 months, the probability of overall survival was 68% 
(95% CI, 18-31%) for patients above the median copy number of KRECs at 60 
days post-CBT. Furthermore, the probability of overall survival was 75% (95% 
CI, 16-24%) for patients below the absolute copy number of KRECs at 60 days 
post-CBT. There were no major differences between the two groups in terms of 
overall survival.  
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Figure 5.3 Overall survival of CBT patients according to the KREC copy number at 60 
days post-transplant. The graph above is a Kaplan-Meier curve for the overall survival of CBT 
patients above and below the 60-day median copy number of KRECs.  
!! 199 
5.1.4 Transitional B cell count recovery following allogeneic cord blood 
transplantation  
 
As our results indicate that there is rapid reconstitution of CD19+ B cells in CBT 
patients, the diversity of B cell subsets and their patterns of reconstitution in 
CBT patients were further investigated. The reconstitution patterns of CD19+ 
transitional B cells were identified in CBT patients. These cells are defined as 
CD4-CD19+CD24+CD38high, as shown in Figure 5.4.  
 
At 28 days, the absolute median count of transitional B cells (0 cells/µl, range: 
0-45 cells/µl) in CBT patients was significantly lower compared to healthy 
control PB (12 cells/µl) (p=0.0001). The median absolute counts at 60 days 
were similar to the 28 day median count post-transplant. However, by 100 days 
post-transplant, the absolute median counts of transitional B cells increased to 
35 cells/µl, which was higher compared to healthy control PB. Furthermore, the 
interquartile range was broader in CBT patients (0-130 cells/µl) at 100 days 
compared to healthy control PB (6-24 cells/µl). At 180 days post-CBT, the 
absolute median counts of transitional B cells remained at similar levels to 
healthy controls. However, the interquartile range was broader in CBT patients 
(0-259 cells/µl) compared to healthy control PB. Furthermore, the interquartile 
range was broadest at 180 days in CBT patients compared to all other time 
points. By 365 days post-transplant, the absolute median levels of transitional B 
cells increased to 89 cells/µl, which was significantly higher compared to 
healthy control PB (p=0.0005). Subsequently, the absolute median levels 
decreased to 40 cells/µl at 720 days. However, this was significantly higher 
compared to healthy control PB (p=0.03). Overall, this data suggests that 
reconstitution of transitional B cells takes place by 100 days post-transplant and 
the absolute median counts of transitional B cells remain higher compared to 
healthy controls between 100 and 720 days post-CBT. 
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Figure 5.4 Absolute counts of transitional B cells in CBT patients. Box and whisker plots 
showing the absolute counts, cells per microliter, of transitional B cells (CD4-
CD19+CD24+CD38high) in CBT patients. Flow cytometry was performed to quantify the absolute 
counts of transitional B cells (CD4-CD19+CD24+CD38high). At each time point the following 
number of samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26, 
D720 = 14. Furthermore, n=10 healthy control PB samples were also tested. Result are 
presented as a tukey analysis and a non-parametric, Mann Whitney analysis was performed 
between the time points and the healthy controls, p<0.05 (*), p<0.001 (***) and p<0.0001 (****).  
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5.1.5 Overall survival of cord blood transplant patients according to the 
absolute transitional B cell number at 60 days post-transplant  
 
As previously shown, reconstitution of transitional B cells occurs by 100 days 
post-CBT. Given the survival difference according to the absolute CD19+ B cell 
count at 28 days, it was hypothesised that the recovery of transitional B cells 
differentiate into mature B cells and may reduce infection and improve overall 
survival. To test this hypothesis, patients were segregated into two groups, 
above and below the 60-day transitional B cell median (n=21 patients were in 
each group). Survival was plotted according to the absolute transitional B cell 
median at 60 days post-CBT (4 cells/µl) (Figure 5.5). The day 60 transitional B 
cell value was used, as there were insufficient transitional B cells at 28 days 
post-transplant to allow this analysis.  
 
The probability of overall survival was 71% (95% CI, 20-31%) at 2 years post-
transplant for patients above the 60 day transitional B cell absolute median 
count. The probability of overall survival was 73% (95% CI, 26-42%) for patients 
below the 60-day transitional B cell absolute median count. Overall, this 
suggests that the early reconstitution of transitional B cells does not impact on 
the overall survival of CBT patients post-transplant.  
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Figure 5.5 Overall survival of CBT patients according to the transitional B cell number at 
60 days post-transplant. A Kaplan-Meier curve for the overall survival of CBT patients above 
and below the median for the 60-day transitional B absolute count.  
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5.1.6 Naïve B cell count recovery following allogeneic cord blood 
transplantation  
 
Naïve B cells are one of the early B cells released into the PB system and are 
antigen inexperienced. As previously described, upon antigenic stimulation 
these cells differentiate into mature B cells to produce antigen specific 
antibodies. With this in mind, the reconstitution of naïve B cells has been 
identified in CBT patients (Figure 5.6). These cells have been defined as 
CD19+CD10+CD21+CD27-. 
 
In CBT patients at 28 days, the absolute median level (0 cells/µl, range 0-38 
cells/µl) of naïve B cells was significantly lower compared to healthy control PB 
(113 cells/µl) (p=0.0001). The absolute median levels in CBT patients remained 
lower compared to healthy control PB up to 100 days post-transplant. At 100 
days post-CBT, the absolute median level of naïve B cells was 118 cells/µl. 
Furthermore, the interquartile range in CBT patients (10-531 cells/µl) at 100 
days was broader compared to healthy control PB (64-231cells/µl). The 
absolute median levels of naïve B cells increased to 193 cells/µl at 180 days 
post-CBT, which was higher compared to healthy control PB (113 cells/µl). The 
highest absolute median level of naïve B cells was recorded at 365 days post-
transplant (660 cells/µl) and was significantly higher compared to healthy 
control PB (p=0.04). By 720 days, the absolute median levels of naïve B cells 
decreased to 263 cells/µl. However, absolute median counts of transitional B 
cells were higher compared to healthy control PB (113 cells/µl). The broadest 
interquartile range (132-1537 cells/µl) was recorded at 720 days post-CBT and 
was broader compared to healthy control PB and all other time points. Overall, 
the absolute numbers of naïve B cells reach the healthy control range by 100 
days post-CBT and then continue to rise beyond that for up to 720 days post-
transplant. This suggests that the reconstitution of naïve B cells occurs by 100 
days.  
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Figure 5.6 Absolute counts of naive B cells in CBT patients. Box and whisker plots showing 
the absolute counts, cells per microliter of naïve B cells within CBT patients in the UK. Flow 
cytometry was performed to quantify naive B cells. At each time point the following number of 
samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26 and D720 = 14. 
Furthermore, n=10 healthy control PB patient samples were acquired. Result are presented as 
a tukey analysis and a non-parametric, Mann Whitney analysis was performed between the 
time points and the healthy controls, p<0.05 (*) and p<0.001 (***).  
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5.1.7 Mature B cell count recovery following allogeneic cord blood 
transplantation  
 
As our results indicate that there is reconstitution of CD19+ B cells and 
transitional B cells in CBT patients by 100 days post-CBT, the reconstitution 
pattern of mature B cells in CBT patients were further investigated. These cells 
are defined as CD4-CD19+CD24+CD38low as shown in Figure 5.7. 
 
At 28 days post-CBT, the median absolute counts of mature B cells within CBT 
patients (12 cells/µl) were significantly lower compared to healthy control PB 
(148 cells/µl) (p=0.0001). By 60 days post-CBT, the median absolute counts 
increased to 10 cells/µl, which was lower compared to healthy control PB. By 
100 days post-CBT there was an increase in the median absolute counts of 
mature B cells in CBT patients (145 cells/µl) and the interquartile range (0-667 
cells/µl) was broader compared to healthy control PB (86-269 cells/µl). At 180 
days the median absolute count increased to 366 cells/µl. This was higher 
compared to healthy control PB and the broadest interquartile range was also 
observed at this time point in CBT patients (0-1896 cells/µl) Successively, at 
365 days the median absolute count remained higher (870 cells/µl) compared to 
healthy control PB and the interquartile range (333-1802 cells/µl) was also 
broader compared to healthy control PB (p=0.0001). At 720 days post-CBT, the 
median absolute levels (443 cells/µl) remained higher compared to healthy 
control PB and the interquartile range was also broader (336-1483 cells/µl) 
compared to healthy control PB (p=0.0007). Overall, this data suggests that the 
reconstitution of mature B cells takes place by 100 days post-transplant. 
Absolute median levels of mature B cells are higher compared to healthy 
control PB from 180 days to 720 days post-CBT. The increase in mature B cell 
numbers could be due to the fact that there is maturation of naïve B cells by 
720 days post-transplant. Therefore, this could suggest that there is restoration 
of humoral immunity in CBT patients, which takes place by 720 days post-
transplant.  
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Figure 5.7 Absolute counts of mature B cells in CBT patients. Box and whisker plots 
showing the absolute counts, cells per microliter of mature B cells within CBT patients. Flow 
cytometry was performed to quantify mature B cells. At each time point the following number of 
samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26 and D720 = 14. 
Furthermore, n=10 healthy control samples were acquired. Result are presented as a tukey 
analysis and a non-parametric, Mann Whitney analysis was performed between the time points 
and the healthy controls, p<0.01 (**), p<0.001 (***) and p<0.0001 (****).  
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5.1.8 Overall survival of cord blood transplant patients according to the 
mature B cell count at 60 days post-transplant.  
 
In this current study, it has been demonstrated that the reconstitution of mature 
B cells within CBT patients takes place by 100 days post-transplant. Given the 
survival difference according to the absolute CD19+ B cell count at 28 days, it 
was hypothesised that the recovery of mature B cells may reduce infection and 
improve overall survival in CBT patients. Survival was plotted according to 
above and below the 60-day median absolute count of mature B cells. The 60-
day value was used, as there were insufficient mature B cells at 28 days to 
allow this analysis. To test this hypothesis, landmark analysis was performed on 
patients who were above (n=21) and below (n=21) the 60-day absolute median 
count of mature B cells (10 cells/µl), as shown in Figure 5.8.  
 
After a follow-up time of 24 months, the probability of overall survival was 79% 
(95% CI, 22-32%) for patients above the 60-day mature B cell absolute median 
count. Furthermore, the probability of overall survival was 67% (95% CI, 22-
39%) for patients below the 60-day mature B cell absolute median count. 
Overall, this suggests that the early reconstitution of mature B cells does not 
impact the overall survival of CBT patients post-transplant.  
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Figure 5.8 Overall survival of CBT patients according to the mature B cell count at 60 
days post-transplant. Kaplan-Meier curve for overall survival in CBT-patients above and below 
the 60-day absolute count median of mature B cells.  
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5.1.9 Activated B cell count recovery following allogeneic cord blood 
transplantation  
 
Activated B cells are an essential component of humoral immune responses. 
They are stimulated by the presentation of pathogenic antigens, which leads to 
their maturation and the generation of antigen specific antibodies. With this in 
mind, we have mapped the kinetics of reconstitution of activated B cells in CBT 
patients, which have been defined as CD19+CD10-CD21+CD27+ (Figure 5.9).  
 
At 28 days post-CBT, the absolute median counts (0 cells/µl range: 0-44 
cells/µl) of activated B cells were significantly lower in CBT recipients compared 
to healthy control PB (26 cells/µl) (p=0.0002). Sequentially, at 60 days post-
transplant the absolute median counts were also significantly lower compared 
to healthy control PB absolute median levels (p=0.001). At 100 days post-CBT, 
absolute median levels increased to 12 cells/µl. However, median levels were 
still below the healthy control PB levels. At 180 days post-CBT, the absolute 
median levels of activated B cells (33 cells/µl) were higher compared to healthy 
control PB (26 cells/µl). The absolute median levels remained constant at 365 
days post-CBT and the highest median levels were measured at 720 days post-
CBT (104 cells/µl) compared to healthy control PB (26 cells/µl). The broadest 
interquartile range was measured at 720 days post-transplant in CBT patients 
(17-244 cells/µl) compared to healthy control PB (18-73 cells/µl). Overall, this 
data suggests that there is an increase in the absolute count of activated B cells 
in CBT patients. Furthermore, the absolute numbers of activated B cells reach 
the healthy control range by 180 days and then continue to rise beyond that for 
up to 720 days post-transplant. This could be due to maturation of transitional 
and naïve B cells between 100 and 180 days post-CBT. Antigens could 
stimulate these B cell subtypes by 100 days and this could induce their 
development into activated B cells.  
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Figure 5.9 Absolute counts of activated B cells in CBT patients. Box and whisker plots 
showing the absolute counts, cells per microliter of activated B cells within CBT patients. Flow 
cytometry was performed to quantify activated B cells. At each time point the following number 
of samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26 and D720 = 
14. Furthermore, n=10 healthy control PB samples were acquired. Result are presented as a 
tukey analysis and a non-parametric, Mann Whitney analysis was performed between the time 
points and the healthy controls, p<0.01 (**) and p<0.001 (***).  
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5.1.10 Memory B cell count recovery following allogeneic cord blood 
transplantation  
 
Memory B cells are an essential cell type in humoral immune reactions. Upon 
antigenic stimulation, activated B cells develop into memory B cells. The 
development of memory B cells demonstrates that long term B cell immunity 
takes place, which leads to specific antibody production against foreign 
pathogens. Furthermore, it also demonstrates that B cells could develop a 
broad BCR repertoire to distinguish a variety of antigens. Restoration of long-
term humoral immunity is vital for the clearance of infection and long-term 
management of secondary infections that may arise in CBT patients. In this 
study, memory B cells are characterised as CD19+CD10-CD21-CD27+ and the 
kinetics of reconstitution was investigated in CBT patients (Figure 5.10).  
 
At 28 days post-transplant, the absolute median count of memory B cells was 
significantly lower in CBT patients (0 cells/µl) compared to healthy control PB 
(30 cells/µl) (p=0.0001). Sequentially, at 60 days post-CBT the absolute median 
count of memory B cells was also significantly lower in CBT patients compared 
to healthy control PB (p=0.0001). The absolute median count of memory B cells 
remained below healthy control PB for up to 100 days. At 180 days post-CBT 
the absolute median levels of memory B cells in CBT patients (33 cells/µl) 
increased and were equivalent to healthy control PB (30 cells/µl). Respectively, 
the interquartile range (15 – 288 cells/µl) is broadest at 180 days post-CBT 
compared to healthy control PB (20 – 52 cells/µl) and all other time points. The 
absolute median counts increased and were highest at 365 days post-
transplant (95 cells/µl), which was significantly higher compared to healthy 
control PB (p=0.03). However, by 720 days post-transplant, the absolute 
median levels of memory B cells were reduced in CBT patients to 31 cells/µl, 
which was equivalent to the absolute median levels within healthy control PB. 
Overall, this data suggests that memory B cell reconstitution takes place by 100 
days post-transplant. Furthermore, it can be seen that there is an increase in 
the absolute number of memory B cells by 365 days post-CBT and a decrease 
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in activated B cells by the same time point. This could suggest that activated B 
cells are maturing into memory B cells by 365 days post-CBT.  
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Figure 5.10 Absolute counts of memory B cells in CBT patients. Box and whisker plots 
showing the absolute counts, cells per microliter of memory B cells within CBT patients. Flow 
cytometry was performed to quantify memory B cells. At each time point the following number of 
samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26 and D720 = 14. 
Furthermore, n=10 healthy control PB samples were acquired. Result are presented as a tukey 
analysis and a non-parametric, Mann Whitney analysis was performed between the time points 
and the healthy controls, p<0.01 (**) and p<0.0001(****).  
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5.2 Discussion 
 
As far as we are aware, the current study is one of the first studies to 
investigate the diversity and kinetics of B cell reconstitution in CBT patients 
within the UK. As previously described in Chapter 3, section 3.3, it has been 
shown that CD19+ B cell reconstitution takes place by 100 days post-transplant. 
Data from this current study corroborates with other CBT immune reconstitution 
studies that also show this pattern of B cell reconstitution (Jacobson et al., 
2012, Kanda et al., 2012, Beaudette-Zlatanova et al., 2013). However, to 
extend upon published data, this current study identifies the reconstitution of a 
broad subset of B cell populations (activated B cells, naïve B cells and memory 
B cells) in CBT patients. By measuring the reconstitution patterns of B cells 
subsets, the kinetics and diversity of B cells were defined in CBT patients.  
 
In this study, CBT patients with an absolute count above the 28-day median of 
CD19+ B cells have a better overall survival compared to patients below 
median CD19+ absolute count. As far as we are aware, there are no other CBT 
studies that have demonstrated this even though other studies have shown 
early reconstitution of B cells in CBT patients. However, it has been reported in 
severe combined immunodeficiency patients that long-term survival is improved 
in patients with higher CD19+ B cell absolute counts after BMT (Lev et al., 
2012). Additionally, in paediatric studies, immune reconstitution kinetics has 
been used as an early predictor for mortality. However, B cells have not been 
used in survival analysis even though there is rapid reconstitution of B cells 
within this patient cohort (Bartelink et al., 2013). With this in mind, it is important 
to investigate the overall survival of HSCT patients and future immune 
reconstitution studies should aim to correlate overall survival with B cell 
reconstitution as they could reduce infection and improve overall survival. 
 
Through the use of immunophenotyping methods it has been demonstrated that 
there was early reconstitution of CD19+ B cells in CBT patients. This led to the 
development and testing of specific gene segments found in naïve/transitional B 
cells, known as KRECs. Identification of these gene excision circles was 
performed, as it is a sensitive measure to quantify the output of B cells from the 
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BM in CBT recipients. This method was used to measure the kinetics of naïve 
and transitional B cell reconstitution in CBT patients. KRECs are bi-product 
excision circles that are excised through the gene re-arrangements in the Ig 
locus of B cells during B cell maturation within the BM (Siminovitch et al., 1985, 
van Zelm et al., 2007). In this current study, absolute copy numbers of KRECs 
increase in CBT patients between 28 and 720-days post-transplant. In the 
median number of patients (n=21) at 60 days, KREC copy numbers reached the 
healthy normal range.  Therefore data from this current study corroborates data 
from a study conducted by Nakatani et al. who demonstrated that B cell 
reconstitution occurs by 100 days post-transplant. Furthermore, Nakatani et al. 
also showed that high KREC levels are associated with a decrease frequency 
of infectious episodes in CBT patients (Nakatani et al., 2014). Unfortunately, 
infection data was not collected for this current study, as it was incomplete and 
correlations between infection and KREC copy numbers could not be made. 
KREC copy numbers have also been measured in a BMT study of RAG-
deficient SCID patients. These patients had an increase in absolute copy 
numbers of KRECs after BMT. In these patients, B cell reconstitution occurs 
within the first six months post-transplant (Lev et al., 2012). There is an 
increasing amount of data that confirms that there is a rise in absolute KRECs 
post-HSCT and this is associated with enhanced B cell neogenesis. Data from 
this current study also corroborates that there is a rise in KREC levels in CBT 
patients post-transplant. (Sottini et al., 2014, Serana et al., 2010, Sottini et al., 
2012, Mensen et al., 2013, Mensen et al., 2014). 
 
Herein, we have shown that there is an increased number of KRECs in CBT 
patients for up to 720 days post-transplant. Furthermore, the number of KRECs 
is higher compared to healthy controls. With this in mind, it was hypothesised 
that the absolute number of KRECs could impact overall survival of CBT 
patients. To test this hypothesis, patients were separated into two groups, 
above and below the 60-day KREC median copy number and a landmark 
analysis was performed. The 60-day median copy number was used, as there 
were insufficient KREC copy numbers at 28-days post-CBT to perform this 
analysis. The analysis showed that there is no difference in survival between 
the two groups. As far as we are aware, similar survival analysis has not been 
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performed in HSCT studies, comparing KREC levels with overall survival. 
However, as B cells are one of the first lymphocytes to reconstitute in CBT 
patients after NK cells, it could be believed that they could play a major role in 
reducing post-transplant complications such as infection and GvHD. Through 
this analysis, we believe that future studies in immune reconstitution should 
assess the impact of increased KREC levels and should be correlated with 
clinical outcomes post-transplant. This could provide a better understanding as 
to whether early B cell reconstitution impacts clinical outcomes such as GvHD 
and incidence of infection. Again, this could not be correlated in this current 
study, as the GvHD and infection data was not complete.  
 
Transitional B cells and immature B cells are the first B cell subtype to be 
released from the BM upon B cell maturation. This current study shows that 
transitional B cells (CD4-CD19+CD24+CD38+) reconstitute by 60 days post-
transplant. In human development, transitional B cells are the first to arise 
before the mature B cell subtype and are considered an important intermediate 
for the generation of mature B cells. In a study conducted by Marie-Cardine et 
al. it has been demonstrated that transitional B cells are the first subtype of B 
cells that reconstitute within BMT recipients.  This is followed by an increase in 
absolute numbers of mature B cells. However, as absolute numbers of mature 
B cells increase, absolute numbers of transitional B cells decrease (Marie-
Cardine et al., 2008). This suggests that B cells are maturing within CBT 
patients and the data that we have presented within this project corroborates 
with this. 
 
The expansion of transitional B cells has also been reported in a number of 
other diseases such as: HIV patients with advanced disease; patients with 
idiopathic CD4 T cell lymphocytopenia; X linked lymphoproliferative syndrome 
and patients with SLE (Malaspina et al., 2006, Cuss et al., 2006, Sims et al., 
2005, Malaspina et al., 2007). This shows transitional cells increase in 
immunodeficient and autoimmune patients and they could be an essential cell 
type to develop into mature B cells. The increase in absolute B cell numbers 
could be a compensatory mechanism to overcome lymphopenia in HIV and 
CD4 T cell lymphopenia patients. Therefore, absolute B cell numbers could 
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increase, as they are required to fill a cell niche. Similarly, this theory could be 
applied to CBT patients, as there is delayed reconstitution of T cells post-
transplant and B cells could expand and proliferate to compensate for the 
reduced numbers of T cells. Furthermore, the expansion of transitional B cells 
within CBT patients could occur due to factors addressed in Chapter 3, Section 
3.3.  
 
It is likely that the development of transitional B cells is a critical checkpoint in B 
cell maturation. However, if the development of B cells breaks down and the 
expansion of transitional B cells does not take place, autoimmune diseases 
such as rheumatoid arthritis and SLE could develop (Samuels et al., 2005, 
Yurasov et al., 2005). It could also be likely that the development of GvHD in 
HSCT patients is due to the breakdown in tolerance of B cell development. 
Early post-transplant, transitional B cells have a low BCR diversity, which could 
lead to the production of antibodies that induce the development of GvHD (Kier 
et al., 1990, Patriarca et al., 2006). With this in mind, the development of 
transitional B cells and the regulation of B cell tolerance are essential post-
transplant to prevent the development of GvHD in CBT patients.  
 
In this project, the kinetics of naïve B cell reconstitution was investigated to 
understand whether there is restoration of a key developmental stage in B cell 
maturation. Naïve B cells are a key developmental point in healthy adults as 
they arise from transitional B cells, which develop within the spleen upon 
antigen stimulation (De Silva and Klein, 2015). In this project, data shows that 
naïve B cell numbers increase in CBT patients and absolute counts are higher 
compared to healthy controls. Respectively, the highest absolute levels of naïve 
B cells are seen in CBT patients at 365 days post-transplant. This corroborates 
data seen within HSCT studies, where there were higher absolute numbers of 
naïve B cells within the first year of transplant (Charrier et al., 2013, Servais et 
al., 2014). Therefore, this highlights that naïve B cell reconstitution takes place 
by 365 days post-CBT and this fundamental maturation stage leads to mature B 
cell formation.  
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Mature B cells arise from the maturation of naïve and transitional B cells, which 
occurs through antigenic challenge. This takes place in secondary lymphoid 
organs. In the secondary lymphoid organs, mature B cells express IgM and IgD 
antibodies. Mature B cells can recirculate between the blood and lymphoid 
organs and can enter B cell follicles within lymph nodes and the spleen. In 
these microenvironments, B cells encounter T cells, which induces B cell 
maturation and antibody production (Klein et al., 1998). With these important 
roles in mind, the kinetics of mature B cell reconstitution was measured in CBT 
patients. The highest absolute count of mature B cells was measured at 365 
days post-CBT. This supports the data demonstrated by Marie-Cardine et al. 
who displays that there an increase in the number of mature B cells in HSCT 
patients, which occurs within the first year post-transplant (Marie-Cardine et al., 
2008). In this current study, there is reconstitution of mature B cells in CBT 
patients by 100 days post-transplant. Furthermore, over the 720-day follow up 
period, it has been shown that there is an increase in the absolute number of 
mature B cells whilst there is a decrease in the absolute numbers of transitional 
B cells. As previously described, the development of mature B cells arises 
through maturation and proliferation of transitional B cells. Therefore, our data 
could be demonstrating that transitional B cells are maturing and undertaking a 
mature B cell phenotype over the 720-day follow up. As it has been shown that 
that there is a rapid reconstitution of mature B cells in CBT patients, it was 
hypothesised that early reconstitution of mature B cells could impact overall 
survival of CBT patients. However, through this analysis it was seen that the 
overall survival is not impacted by higher or lower absolute levels of mature B 
cells at 28 days post-CBT.  
 
In the spleen and germinal centre of lymph nodes, B cells can become 
activated through antigen presentation via APCs. This leads to increased 
expression of CD27 and antibody expression such as IgM and IgD. The 
activation of B cells is an important stage in humoral responses as B cells 
undergo somatic hypermutation and produce antigen specific antibodies 
(Agematsu et al., 1997). Herein, it has been shown that activated B cells 
reconstitute by 100 days post-CBT.  
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Furthermore, activated B cells can mature into memory B cells and it has been 
demonstrated in this study that memory B cells reconstitute by 100 days post-
CBT. However, the levels of memory B cells remain low up to 180 days post-
CBT and reconstitution of memory B cells takes place by 365 days post-
transplant. This also corroborates HSCT studies where it has been observed 
that memory B cell reconstitution occurs by one year post-transplant (Avanzini 
et al., 2005). A reason as to why memory B cells develop by 365 days post-
transplant could be related to the fact that many CBT patients are vaccinated 
post-transplant. Generally in the UK, patients are vaccinated between six 
months and two years post-transplant (Ljungman et al., 2009). Therefore, 
vaccination could cause an increase in memory B cells post-transplant, 
particularly at one year post-transplant. This increase in memory B cells could 
be due to vaccines causing antigenic stimulation of B cells and maturation of 
naïve B cells. This subsequently leads to an increased memory B cell subset 
post-transplant.  
 
Additionally, the development and expansion of memory B cells has also been 
associated with infectious episodes such as EBV, which is a common 
opportunistic infection in HSCT patients and will infect resting B cells. This can 
lead to the activation of resting B cells, causing them to proliferate. It has also 
been shown that memory B cells are enriched with regulatory B cells and these 
are present in healthy individuals. However, HSCT patients who develop 
cGvHD have been shown to lack memory B cells that produce IgM and a have 
a reduction in regulatory B cells numbers (Khoder et al., 2014). Respectively, 
these memory B cells have been shown to produce IL-10 and can suppress 
immune reactions. Therefore, this highlights a key role for memory B cells as 
they could express and secrete IgM antibodies. Additionally, they could play an 
immunomodulatory role with regulatory B cells that leads to less severe cGvHD 
(Sarvaria et al., 2016). This suggests that maturation of B cells is important in 
HSCT patients, however further functional maturation of B cells is also crucial in 
HSCT to prevent development of severe GvHD.  
 
Overall, this current study shows that there is early reconstitution of B cells in 
CBT patients and that there is reconstitution of the different B cell 
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subpopulations post-transplant. B cells undergo a various maturation stages 
and these subsets reconstitute in CBT patients, which could lead to restoration 
of humoral immunity. However, further analysis is required to understand the 
functionality of B cells in CBT recipients. Additionally, studies of BCR specificity 
and diversity are required to understand how broad the BCR repertoire is post-
CBT. BCR spectratyping was not performed in this current study and could 
have provided an insight into the restoration of B cell specificity for antigens. 
Additionally, measuring antibody titre levels for IgM and IgD could have also 
provided an indication of B cell maturation in CBT recipients. Functional studies 
are required to understand whether B cells also play a functional role in CBT 
patients and whether they aid in the clearance of infection and reduce the 
incidence of cGvHD. 
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Chapter 6 : T cell reconstitution and diversity in 
cord blood transplant patients 
 
6.1 Background and Aims 
 
T cells are an essential component of the adaptive immune system and play a 
pivotal role in inducing cell-mediated responses against foreign pathogens. 
These cells also have a crucial role in inducing GvHD and the rapid 
reconstitution of T cells are known to play a role in aGvHD development 
(Sakoda et al., 2007). However, T cells are also required for an optimised GvL 
response and could reduce the incidence of relapse (Barrett, 2008).  
 
HSCT recipients are severely immunocompromised post-transplant and 
experience delayed immune reconstitution, which increases the risk of 
infectious complications and this compromises tumour immunosurveillance 
(Maury et al., 2001). Delayed T cell reconstitution can occur due to T cell 
depletion from the graft and thymic damage caused by conditioning prior to 
HSCT (Douek et al., 2000). The development of GvHD can further exacerbate a 
delay in T cell reconstitution, which can increase the risk of life threatening viral, 
bacterial and fungal infections (Storek et al., 2002). Notably, in Chapter 3, it was 
shown that the reconstitution of CD3+, CD4+ and CD8+ T cells are delayed in 
CBT patients. CD3+ and CD4+ T cell reconstitution could take longer than 720 
days and CD8+ T cell reconstitution occurs by 365 days post-transplant. 
However, the reconstitution patterns of T cell subsets in CBT patients required 
further assessment and have been addressed in this chapter. 
 
T cell reconstitution can occur through two pathways known as the thymic 
dependent and thymic independent pathway. The thymic dependent pathway 
occurs when naïve T cells are being produced within the thymus from CLPs. 
However, thymic independent reconstitution occurs where mature T cells from 
the graft expand and proliferate within the recipient (Williams et al., 2007).  
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Thymopoiesis is the production of naïve T cells from the thymus and it begins in 
childhood and continues into adulthood. However, the level of thymopoiesis 
varies in adulthood. The recovery of thymopoiesis after HSCT is an important 
determinant of naïve T cell output from the thymus and the level of T cell 
receptor diversity (Komanduri et al., 2007). Thymic output can be determined in 
HSCT patients via measurement of the expression patterns of cell surface 
markers such as CD31 (Douek et al., 2000). CD31 is a cell surface marker that 
aids in identifying naïve T cells that have recently egressed from the thymus 
(Kohler and Thiel, 2009). These T cells are known as recent thymic emigrants 
(RTEs). CD31+ (CD4+ or CD8+) T cells contain a high number of T cell 
receptor excision circles (TRECs), which are excision circles of DNA of the delta 
locus and become excised during rearrangement of the T cell receptor gene 
(Ribeiro and Perelson, 2007). Approximately 70% of newly produced T cells 
within the thymus contain TRECs and in adults there is a decline in the number 
of TRECs due to thymic involution (Lynch et al., 2009). On the other hand, 
TRECs can still be detected within T cells of elderly patients and this 
demonstrates that the thymus still has a functional component irrespective of 
age (Douek et al., 1998, Douek et al., 2000). In this current study, the median 
age of patients was 48 years old and as patients were older they could have 
reduced thymic output due to thymic involution. Factors that contribute to a 
delay in T cell reconstitution include: patient age, conditioning and 
chemotherapy and post transplant immunosuppression. (Lynch et al., 2009). 
With this in mind, it was hypothesised that thymic output of naïve T cells will be 
delayed in this cohort of CBT patients. To test this hypothesis, TREC gene copy 
numbers were quantified to measure the output of naïve T cells from the 
thymus in CBT patients. Furthermore, the absolute quantification of RTEs 
(CD31+CD45RA+) via immunophenotyping was performed as an alternative 
measure of thymic output in CBT patients. 
 
Complete T cell reconstitution is also dependent on peripheral expansion of T 
cells. This takes place within the peripheral blood system where naïve T cells 
differentiate into mature T cells upon antigenic stimulation. To better understand 
the reconstitution of specific T cell subsets, surface markers such as CD45RA 
and CCR7 have been used (Sallusto et al., 2014). The combination of CD45RA 
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and CCR7 can define T cell subsets such as: naïve (CD45RA+CCR7+), central 
memory T cells (CD45RA-CCR7-), effector T cells (CD45RA-CCR7+) and 
effector memory T cells (CD45RA+CCR7-).  
 
Within the periphery, naïve T cells migrate to secondary lymph nodes where a 
number of antigens will be presented by APCs (Butcher and Picker, 1996). The 
migration of naïve T cells to secondary lymph nodes is mediated through the 
expression of chemokine receptors such as CCR7. T cells expressing CCR7 
are able to enter secondary lymphoid tissues via the high endothelial venules. 
Ligands for CCR7 are expressed by high endothelial venules of secondary 
lymphoid organs, parenchymal cells within T zones of lymph nodes and by 
endothelial cells at the openings of the lymphatic vessels within peripheral 
tissues (Gunn et al., 1998). At these sites, APCs will promote the maturation of 
naïve T cells into effector, effector memory T cells and, subsequently, central 
memory T cells. CCR7+ T cells can be defined as effector T cells as they 
express lymph node homing receptors and lack an immediate effector function. 
However, these cells can be stimulated by DCs and differentiate into CCR7- 
effector T cells upon secondary antigenic stimulation. Effector T cells migrate 
mainly through peripheral tissues and their migration is mediated by integrins 
and chemokine receptors (Baggiolini, 1998, Sallusto and Baggiolini, 2008).  
 
Upon antigenic stimulation, effector T cells differentiate into effector memory 
and central memory T cells. Both effector memory and central memory T cells 
differentiate from naïve T cells. Respectively, the two memory subtypes have 
different effectors functions; effector memory T cells have been shown to 
produce IL-4, IL-5 and IFN-γ, whereas central memory T cells produce IL-2 only 
(Sallusto et al., 1999). This highlights the fact that both memory cell subsets are 
required for different responses in immunity. Investigating the kinetics and 
diversity of all four T cell subtypes within CD4+ and CD8+ T cells populations 
will aid in identifying whether CBT patients form immunological memory post-
transplant. Identification of these four subtypes will also aid in understanding 
the thymic independent reconstitution of T cells in CBT patients. 
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Tregs are a subpopulation of T cells that play a crucial role in regulating or 
suppressing other cells within the immune system, particularly through the 
secretion of cytokines such as IL-10, IL-35 and TGF-β (Annacker et al., 2003, 
Collison et al., 2007, Read et al., 2000). Tregs control the immune response to 
self and foreign antigens and have been proven to prevent autoimmune 
diseases. Tregs express surface markers such as CD4, CD25 and FoxP3 
(Curiel, 2007). In HSCT recipients, the function and reconstitution of Tregs is 
affected and poor reconstitution of Tregs has been shown to be associated with 
increased incidence of cGvHD (Trenado et al., 2003, Taylor et al., 2002). In this 
current study, Tregs have been defined as CD3+CD4+CD25+CD127lo. 
Furthermore, intranuclear staining has allowed identification of Foxp3 and so 
Tregs have also been defined as CD3+CD4+CD25+CD127loFoxp3+. Due to 
their important roles, the kinetics of Treg recovery has been measured in CBT 
patients. 
  
In healthy individuals, 95% of T cells in PB express the αβ TCR and the 
remaining 5% of T cells express the γδ TCR receptor. γδ T cells can be 
activated by non-MHC complex antigen presentation, predominantly via NK cell 
receptors and TLRs. This causes γδ T cells to have a unique role in innate and 
adaptive immune responses (Vantourout and Hayday, 2013). In allogeneic 
HSCT studies, γδ T cells increase in absolute numbers and are protective 
against CMV reactivation and disease (Knight et al., 2010). Herein, the 
percentage expression of αβ and γδ T cells was measured to understand 
whether there is an increase or decrease in the expression of the respective 
TCRs in CBT patients. 
 
T cell activation is an important stage in T cell functionality. CD69 is known as 
an early marker of T cell activation and can be expressed as early as four hours 
after T cell activation. In turn, this promotes and initiates protein tyrosine 
kinases and calcium influx, which leads to the increased production of cytokines 
such as IL-2 and TNF-α (Santis et al., 1992). Post-antigenic challenge, T cells 
express CD25, which is expressed later compared to CD69. CD25 is known as 
a mid-level expression marker as it is expressed later compared to CD69 
(Theze et al., 1996). The expression of CD25 on T cells is induced by cytokines 
!! 224 
such as IL-2, IL-12, IL-4 and TNF-α. CD25 is the IL-2-alpha receptor chain and 
upon its expression on T cells it will initiate the proliferation and differentiation of 
T cells (Gately et al., 1991, Mitchell et al., 1989, Vassalli, 1992). HLA-DR is a 
class II MHC receptor and is widely expressed on APCs such as macrophages, 
monocytes, B cells and DCs. Subsequently, they present processed exogenous 
antigens to CD4+ T cells. However, T cells also express HLA-DR upon 
activation. HLA-DR is expressed later on T cells compared to CD69 and CD25 
and is known as a late activation marker (Moriya et al., 1987). Taken together, 
the measurement of the respective markers have been analysed within this 
study to understand whether T cells are activated in CBT patients. This provides 
an insight into the functional activity of T cells in CBT patients. 
 
In this chapter, the thymopoiesis of T cell recovery was assessed in CBT 
patients by measuring absolute counts of naïve T cells, recent thymic emigrants 
and genetic analysis was performed to measure TREC copy numbers within T 
cells. This was performed to understand and identify the kinetics of thymic 
dependent recovery in CBT patients. Immunophenotyping was also used to 
measure the absolute counts of T cell subsets in the PB of CBT patients. This 
was performed to measure the kinetics of thymic-independent recovery and to 
define the time taken for T cell reconstitution to occur in CBT patients. 
Furthermore, the percentage expression of αβ and γδ T cells was measured to 
assess the kinetics of TCR recovery in CBT patients and the expression pattern 
of T cell activation markers was measured to identify whether T cells are 
activated post-CBT.  
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The specific aims of this chapter are the following:  
 
1. Map the kinetics of recovery of CD45RA+CCR7+ (CD4+ and CD8+) 
naïve T cells in CBT patients.  
2. Map the kinetics of recovery of CD31+ recent thymic emigrants (CD4+ 
and CD8+) in CBT patients.  
3. Map kinetics of recovery of TRECs in CBT patients. 
4. Identify the ratio of CD4:CD8 T cells in CBT patients. 
5. Map the kinetics and diversity of CD4+ and CD8+ effector T cells in CBT 
patients. 
6. Map the kinetics of recovery of CD4+ and CD8+ effector memory T cells 
in CBT patients.  
7. Map the kinetics of recovery of CD4+ and CD8+ central memory T cells 
in CBT patients. 
8. Map the kinetics of recovery of regulatory T cells in CBT patients. 
9. Determine expression patterns of αβ and γδ T cells within CBT patients.  
10. Determine the expression patterns of CD25, CD69 and HLA-DR, 
activation markers within CD4+ and CD8+ T cells in CBT patients.  
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6.2 CD4+ and CD8+ T cell ratios in cord blood transplant patients  
 
Monitoring the reconstitution patterns of CD4+ and CD8+ T cells provides an 
indication of thymic recovery. The absolute count measurements for CD4+ and 
CD8+ T cells have been shown in Chapter 3, Figure 3.4 and Figure 3.5, 
respectively. These results have displayed that CD8+ T cells reconstitute within 
CBT patients by 365 days post-transplant. However, CD4+ T cell reconstitution 
could take longer than 720 days to reconstitute within CBT patients.  
 
In this current study, the ratio of CD4:CD8 T cells has been calculated to 
understand what ratio is seen in CBT patients, as shown in Figure 6.1. The 
ratios of CD4:CD8 T cells post-transplant are as follows: day +28 (80: 20), +60 
(71:29), +100 (69:31), +180 (70:30), +365 (56:44) and +720 (55:45). 
Respectively, the CD4:CD8 T cell ratio in healthy control PB was 63:37. Overall, 
this data suggests that by 720 days post-transplant, CBT patients have a 1:1 
ratio of CD4:CD8 T cells. Furthermore, this indicates that CBT patients have a 
similar ratio of CD4:CD8 T cells compared to healthy controls.  
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Figure 6.1 Ratio of CD4 to CD8 T cells in CBT patients. Pie charts are used to represent the 
ratio of CD4+ and CD8+ T cells in CBT patients. At each time point, the following number of 
samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26 and D720 = 14. 
Furthermore, n=10 healthy control samples were also tested. The data presented in the graph 
above are the mean averages of CD4+ and CD8+ T cells in CBT patients at the respective 
patient sample time points.  
 
!! 228 
6.3 Naïve T cell count recovery following allogeneic cord blood 
transplantation  
 
In Chapter 3, it was shown that the reconstitution of CD3+, CD4+ and CD8+ T 
cells is delayed. With this in mind, it was hypothesised that naïve T cell 
reconstitution is delayed in CBT patients. To test this hypothesis, the absolute 
counts of T cell subsets were identified and measured in CBT patients using 
flow cytometry. In this chapter, the kinetics of naïve T cell reconstitution was 
assessed via detection of cell surface markers such as: CD4, CD8 CD45RA 
and CCR7 shown in Figure 6.2 and Figure 6.3.  
6.3.1 Naïve CD4+ T cell count recovery following allogeneic cord blood 
transplantation  
 
At 28 days post-transplant, the median number (26 cells/µl) of naïve CD4+ T 
cells was significantly lower compared to healthy control PB (345 cells/µl) and 
the interquartile range was also narrower in CBT patients (5-69 cells/µl) 
compared to healthy control PB (166-658 cells/µl) (p=0.004). At 60 days post-
CBT, median counts of naïve CD4+ T cells (16 cells/µl) were significantly lower 
compared to healthy control PB and the interquartile range was narrower (2.5-
35 cells/µl) compared to healthy control PB (p=0.002). At day 100 post-CBT, 
median absolute counts of CD4+ naïve T cells (7 cells/µl) were at the lowest 
level compared to all of the respective time points and was significantly lower 
compared to the median healthy control PB value (p=0.002). Respectively at 
the same time point, the interquartile range (3.5-70.5 cells/µl) was narrower 
compared to healthy control PB. At 180 days post-CBT, the interquartile range 
(3-70 cells/µl) was narrower compared to the interquartile range observed in 
healthy control PB. Furthermore, the median levels in CBT patients (26 cells/µl) 
at 180 days were also significantly lower compared to healthy control PB 
(p=0.003). At 365 and 720 days post-CBT, median absolute counts in patients 
remained lower compared to healthy control PB. Additionally, the interquartile 
range was narrower at 365 (8-86 cells/µl) and 720 days post-CBT (10-138 
cells/µl) compared to healthy control PB. Overall, this data suggests that the 
absolute value of CD4+ naïve T cells is significantly lower compared to healthy 
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controls. Furthermore, this data shows that the reconstitution of naïve CD4+ T 
cells is delayed in CBT patients and could take longer than 720 days to 
reconstitute in CBT patients.  
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Figure 6.2 Absolute counts of CD4+ naive T cells in CBT patients. Box and whisker plots 
showing the absolute counts, cells per microliter, of CD4+ naïve T cells within CBT patients. 
Flow cytometry was performed to quantify CD4+ naïve T cells. At each time point the following 
number of samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26, 
D720 = 14 and healthy control PB = 10. Analysis was performed between the time points and 
the healthy controls as a non-parametric, Mann-Whitney test. Results are presented as tukey 
analysis. p<0.05 (*) and p<0.01 (**).  
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6.3.2 Naïve CD8+ T cell count recovery following allogeneic cord blood 
transplantation  
 
At 28 days post-CBT, the median absolute number of CD8+ naïve T cells (8 
cells/µl) was significantly lower compared to healthy control PB (158 cells/µl) 
(p= 0.005). At successive time points between 60 days and 180 days post-CBT, 
the median absolute level of CD8+ naïve T cell numbers remained lower 
compared to healthy control PB. Respectively, the interquartile ranges between 
28 days and 180 days post CBT were narrower compared to the healthy control 
PB (37-219 cells/µl). By 365 days post-CBT, the median absolute counts of 
CD8+ naïve T cells increased but remained lower compared to healthy control 
PB. However, the interquartile range was broadest at 365 days (3-179 cells/µl) 
post-CBT compared to healthy control PB. At 720 days post-CBT, the median 
absolute counts increased (63 cells/µl). However, this was lower compared to 
healthy control PB. Overall, the absolute numbers of CD8+ naïve T cells were 
lower in CBT recipients compared to healthy controls. This suggests that the 
reconstitution of CD8+ naïve T cells is delayed in CBT patients for up to 720 
days post-CBT. 
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Figure 6.3 Absolute counts of CD8+ Naive T cells in CBT patients. Box and whisker plots 
showing the absolute counts, cells per microliter, of CD8+ naïve T cells within CBT patients. 
Flow cytometry was performed to quantify CD8+ naïve T cells. At each time point the following 
number of samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26, 
D720 = 14 and healthy control PB = 10. Analysis was performed between the time points and 
the healthy controls as a non-parametric, Mann-Whitney test. Results are presented as tukey 
analysis. p<0.01 (**) and p<0.001 (***).  
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6.4 CD31+ recent thymic emigrant cell count recovery following allogeneic 
cord blood transplantation 
 
Thymopoeisis can be measured by quantifying the absolute counts of RTEs in 
CBT patients. The expression of CD31 on T cells is associated with naive T 
cells that egress from the thymus. In this study, both CD4+ and CD8+ RTEs 
have been quantified to assess the kinetics of naïve T cells from the thymus of 
CBT patients, as shown in Figure 6.4 and Figure 6.5.  
 
6.4.1 CD4+CD31+ recent thymic emigrant cell count recovery following 
allogeneic cord blood transplantation 
 
At 28 days post-CBT, median absolute counts of CD4+ RTEs (16 cells/µl) were 
significantly lower compared to healthy control PB (279 cells/µl). Additionally, 
the interquartile range of CD4+ RTEs at 28 days post-CBT was narrower in 
patients compared to healthy control PB (175-358 cells/µl) (p=0.0001). At 
successive time points up to 720 days, the median levels of CD4+ RTEs 
remained low compared to healthy control PB. Respectively, the interquartile 
ranges of CD4+ RTEs in CBT patients were narrower compared to healthy 
control PB. At all time points between 60 days and 720 days, CBT recipients 
showed to have significantly lower absolute counts of RTEs compared to 
healthy control PB. Furthermore, the broadest interquartile range was seen at 
365 days post-CBT. This data suggests that the number of RTEs post-CBT 
were considerably lower in CBT patients compared to healthy control PB and 
the reconstitution of RTEs could take longer than 720 days.  
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Figure 6.4 Absolute counts of CD4+ recent thymic emigrants in CBT patients. Box and 
whisker plots showing the absolute counts, cells per microliter, of CD4+ RTEs within CBT 
patients. Flow cytometry was performed to quantify CD4+ RTEs. At each time point the 
following number of samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 
= 26, D720 = 14 and healthy control PB = 10. Analysis was performed between the time points 
and the healthy controls as a non-parametric, Mann-Whitney test. Results are presented as 
tukey analysis. p<0.01 (**) and p<0.001 (***). 
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6.4.2 CD8+ CD31+ recent thymic emigrant cell count recovery following 
allogeneic cord blood transplantation 
 
CBT recipients at 28 days post transplant had a significantly lower median 
absolute count of CD8+ RTEs (2 cells/µl) compared to healthy control PB (251 
cells/µl) (p=0.0001). Additionally, the interquartile range of CD8+ RTEs in CBT 
patients at 28 days was lower (0-3 cells/µl) compared to healthy control PB 
(204-310 cells/µl). The interquartile ranges also remained narrow between 60 
and 100 days post-CBT and were narrower compared to healthy control PB. 
Median absolute counts of CD8+ RTEs were also significantly lower in CBT 
patients up to 180 days compared to healthy control PB. Respectively, at 180 
days post-CBT the interquartile range was broader compared to all other time 
points (3-212 cells/µl). At successive time points between 180 and 720 days, 
the median absolute counts of CD8+ naïve T cells were significantly lower 
compared to healthy control PB. Overall, this data suggests that there were 
very low absolute counts of CD8+ RTEs in CBT recipients post-transplant. 
Furthermore, absolute counts were significantly lower compared to healthy 
controls. In combination with CD4+ recent thymic emigrant data, this data also 
suggests that reconstitution of CD8+ RTEs could take longer than 720 days 
post-CBT.  
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Figure 6.5 Absolute counts of CD8+ recent thymic emigrants in CBT patients. Box and 
whisker plots showing the absolute counts, cells per microliter, of CD8+ RTEs within CBT 
patients. Flow cytometry was performed to quantify CD8+ RTEs. At each time point the 
following number of samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 
= 26, D720 = 14 and healthy control PB = 10. Analysis was performed between the time points 
and the healthy controls as a non-parametric, Mann-Whitney test. Results are presented as a 
tukey analysis. p<0.01 (**) and p<0.001 (***) and p<0.0001 (****).  
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6.5 TREC quantification in cord blood transplant patients  
  
TRECs are excision loops of DNA that are formed as a gene bi-product during T 
cell maturation within the thymus. Naïve T cells express high quantities of 
TRECs and once these T cells are released from the thymus into the periphery, 
the excision loops are diluted through clonal expansion of T cells. TRECs were 
quantified in CBT patients to assess the thymic output of naïve T cells, as 
shown in Figure 6.6. Absolute copy numbers of TRECs were quantified as 
described in Chapter 2, Section 2.7.20. Throughout the six time points in this 
current study, TREC copy numbers were not detected in the majority of 
patients. However, in ten patients TRECs were quantified at different time 
points throughout the study and these patients had higher levels of TRECs 
compared to healthy controls. Furthermore, the ten TREC positive samples 
were CD31+CD45RA+. However, the TREC negative samples were 
CD31+CD45RA+.  Overall, this suggests that thymic output is delayed in CBT 
patients and could take longer than 720 days to improve. 
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Figure 6.6 Copy number of TRECs in CBT patients. Box and whisker plots showing the copy 
number of TREC genes, copy number per 107 Cells. A real-time PCR assay was performed to 
quantify TREC genes. At each time point the following number of samples were acquired: D28 
= 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26, D720 = 14 and healthy controls = 10. 
Analysis was performed between the time points and the healthy controls as a non-parametric, 
Mann-Whitney test. Results are presented as a tukey analysis. 
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6.6 Effector T cell count recovery following allogeneic cord blood 
transplantation  
 
Upon antigenic stimulation, naïve T cells differentiate into effector T cells. In this 
current study, CD4+ and CD8+ effector T cells are defined as 
CD3+CD4+CD45RA+CCR7- and CD3+CD8+CD45RA+CCR7- T cells, respectively 
(Figure 6.7 and Figure 6.8). The quantification of effector T cells has been 
performed to understand the kinetics of reconstitution of these cells in CBT 
patients. This T cell subset is a crucial development stage that could lead to 
further maturation and differentiation into central memory and effector memory 
T cells.  
6.6.1 CD4+ effector T cell count recovery following allogeneic cord blood 
transplantation 
 
At 28 days post-CBT, the median absolute counts (3 cells/µl) of CD4+ effector T 
cells were significantly lower compared to healthy control PB (26.5 cells/µl) 
(p=0.02). Furthermore, the interquartile range was narrower (0-19 cells/µl) in 
CBT patients compared to healthy control PB (8-64 cells/µl). Between 60 and 
100 days post-CBT, the median absolute counts increased and the interquartile 
range (1-53 cells/µl) at 100 days was equivalent to the interquartile range of 
healthy control PB (8-64 cells/µl). By 180 days post-CBT, median levels of 
CD4+ effector T cells (25 cells/µl) were similar to that seen in healthy control PB 
(26 cells/µl). Furthermore, the interquartile range within CBT patients (3-102 
cells/µl) at day 180 was broader compared to healthy control PB. By 365 days 
post-CBT, median absolute counts of CD4+ effector T cells increased to 32 
cells/µl. The interquartile range also broadened (4-145 cells/µl) within CBT 
patients and was broader compared to healthy control PB. However, at 720 
days, median levels of CD4+ effector T cells decreased (14 cells/µl) and the 
interquartile range (0-54 cells/µl) was narrower compared to healthy control PB. 
Overall, this data suggests that the reconstitution of CD4+ effector T cells 
occurs by 60 days as the median absolute counts are equivalent to healthy 
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adults. Furthermore, the median absolute number of CD4+ effector T cells 
reaches the healthy control range over the two-year follow up.  
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Figure 6.7 Absolute counts of CD4+ effector T cells in CBT patients. Box and whisker plots 
showing the absolute counts, cells per microliter, of CD4+ effector T cells within CBT patients 
Flow cytometry was performed to quantify CD4+ effector T cells. At each time point the 
following number of samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 
= 26, D720 = 14 and healthy control PB = 10. Analysis was performed between the time points 
and the healthy controls as a non-parametric, Mann-Whitney test. Results are presented as a 
tukey analysis. p<0.05 (*). 
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6.6.2 CD8+ effector T cell count recovery following allogeneic cord blood 
transplantation  
 
At 28 days post-CBT, patients had a significantly lower median absolute count 
of CD8+ effector T cells (2 cells/µl) compared to healthy control PB (146 
cells/µl) (p=0.006). Respectively, at 28 days post-CBT, the interquartile range of 
CD8+ effector T cells (0-18 cells/µl) was narrower compared to healthy control 
PB (19-223 cells/µl). The median absolute count of CD8+ effector T cells 
remained low at subsequent time points up to 720 days post-CBT compared to 
healthy control PB. The broadest interquartile range was recorded at 180 days 
post-CBT (0-365 cells/µl) and was broader compared to healthy control PB (19-
223 cells/µl). Overall, this suggests that CBT patients had low absolute 
numbers of CD8+ effector T cells post-transplant and the absolute counts of 
CD8+ effector T cells remained low for up to 720 days post-CBT.
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Figure 6.8 Absolute count of CD8+ effector T cells in CBT patients. Box and whisker plots 
showing the absolute counts, cells per microliter, of CD8+ effector T cells within CBT patients. 
Flow cytometry was performed to quantify CD8+ effector T cells. At each time point the 
following number of samples were acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 
= 26, D720 = 14 and healthy control PB = 10. Analysis was performed between the time points 
and the healthy controls as a non-parametric, Mann-Whitney test. Results are presented as a 
tukey analysis, p<0.05 (*) and p<0.01 (**). 
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6.7 Effector memory T cell count recovery following allogeneic cord blood 
transplantation  
 
Effector memory T cells, also known as CCR7- T cells, migrate to sites of 
inflammation and display immediate effector functions. In CBT patients, this 
could include various inflammatory responses involved in GvHD or clearance of 
infection. Therefore, in this study the kinetics of reconstitution of CD4+ and 
CD8+ effector memory T cells has been measured in CBT patients, as shown in 
Figure 6.9 and Figure 6.10.  
 
6.7.1 CD4+ effector memory T cell count recovery following allogeneic 
cord blood transplantation 
 
At 28 days post-CBT, the median absolute count of CD4+ effector memory T 
cells (24 cells/µl) was significantly lower compared to healthy control PB (315 
cells/µl) (p=0.0001). Furthermore, the interquartile range at 28 days post-CBT 
was narrower (12-46 cells/µl) compared to healthy control PB (267-392 cells/µl). 
At 60 days post-CBT, the median absolute count of CD4+ effector memory T 
cells increased in CBT patients (93 cells/µl). However, the value was 
significantly lower compared to healthy control PB (p=0.001). The interquartile 
range (50-222 cells/µl) was broader at 60 days post-CBT compared to healthy 
control PB. A further increase in median absolute count of CD4+ effector 
memory T cells was seen at 100 days post-CBT. However, the median absolute 
count remained below the healthy control PB median count (p=0.0136). 
Similarly, the interquartile range in CBT patients (43-354 cells/µl) at day 100 
was broader compared to healthy control PB. The median absolute count of 
CD4+ effector memory T cells increased at 180 days post-CBT in patients (232 
cells/µl). However, at this time point, the median absolute count of CD4+ 
effector memory T cells was lower compared to healthy control PB. The 
interquartile range at 180 days post-CBT was higher compared to healthy 
control PB. The median CD4+ effector memory T cell value (395 cells/µl) was 
the highest at 365 days post-CBT and was higher compared to healthy control 
PB. Respectively, at 365 days the interquartile range was broader (102-508 
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cells/µl) compared to healthy control PB. By 720 days post-CBT, the median 
absolute count of CD4+ effector memory T cells decreased (219 cells/µl). 
However, at this time point, the interquartile range (14-639 cells/µl) was 
broadest compared to all other time points and compared to healthy control PB. 
Overall, this data demonstrates that there is an increase in CD4+ effector 
memory T cells between 28 and 365 days post-CBT. Furthermore, 
reconstitution takes place by 365 days post-transplant.  
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Figure 6.9 Absolute counts of CD4+ of effector memory T cells in CBT patients. Box and 
whisker plots showing the absolute counts, cells per microliter, of CD4+ effector memory T cells 
within CBT patients. Flow cytometry was performed to quantify CD4+ effector memory T cells. 
At each time point the following number of samples were acquired: D28 = 44, D60 = 42, D100 = 
25, D180 = 26, D365 = 26, D720 = 14 and healthy control PB = 10. Analysis was performed 
between the time points and the healthy controls as a non-parametric, Mann-Whitney test. 
Results are presented as a tukey analysis, p<0.05 (*) and p<0.0001 (****). 
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6.7.2 CD8+ effector memory T cell count recovery following allogeneic 
cord blood transplantation 
 
The median absolute count of CD8+ effector memory T cells (29 cells/µl) was 
significantly lower compared to healthy control PB (261 cells/µl) at 28 days 
post-CBT (p=0.0001). Respectively at 28 days post-CBT, the interquartile range 
(7-69 cells/µl) was narrower compared to successive time points and healthy 
control PB (93-284 cells/µl). At successive time points, there was an increase in 
the median absolute counts of CD8+ effector memory T cells, where the highest 
median count was recorded at 365 days post-CBT (384 cells/µl). This was 
higher compared to healthy control PB. The interquartile range also broadened 
between 100 days and 720 days post-CBT and respectively at these four time 
points the interquartile ranges recorded in patients were broader compared to 
healthy control PB. The broadest interquartile range was recorded at 720 days 
post-CBT (38-1094 cells/µl). Overall, this data shows that there is an increase in 
the number of CD8+ effector memory T cells between 28 and 365 days post-
CBT. Furthermore, reconstitution of CD8+ effector memory T cells takes place 
by 100 days post-CBT.  
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Figure 6.10 Absolute counts of CD8+ effector memory T cells in CBT patients. Box and 
whisker plots showing the absolute counts, cells per microliter, of CD8+ effector memory T cells 
within CBT patients. Flow cytometry was performed to quantify CD8+ effector memory T cells. 
At each time point the following number of samples were acquired: D28 = 44, D60 = 42, D100 = 
25, D180 = 26, D365 = 26, D720 = 14 and healthy control PB = 10. Analysis was performed 
between the time points and the healthy controls as a non-parametric, Mann-Whitney test. 
Results are presented as a tukey analysis p<0.0001 (****). 
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6.8 Central memory T cell count recovery following allogeneic cord blood 
transplantation  
 
CCR7+ central memory T cells are known to express lymph node homing 
receptors. However, they lack immediate effector functions. Once central 
memory T cells migrate to the lymph nodes or are stimulated by antigens, they 
differentiate into CCR7- effector memory T cells. Furthermore, they could play a 
role in GvHD mediated responses, clearance of infection and could be involved 
in GvL responses. With this in mind, the kinetics of central memory T cell 
reconstitution has been measured in CBT patients, as shown in Figure 6.11 and 
Figure 6.12.   
 
6.8.1 CD4+ central memory T cell count recovery following allogeneic cord 
blood transplantation  
 
At 28 days post-CBT, the absolute median absolute counts of central memory T 
cells (6 cells/µl) were lower compared to healthy control PB (407 cells/µl) 
(p=0.0001). Furthermore, the median value was lowest at 28 days post CBT 
compared to all of the other time points. Respectively, the interquartile range (1-
27 cells/µl) at 28 days was narrower compared to all other time points and the 
healthy control PB interquartile range (318-682 cells/µl.) The median absolute 
counts of CD4+ central memory T cells were significantly lower compared to 
healthy control PB for the successive time points (+60 days = 6 cells/µl, +100 
days = 4 cells/µl, +180 days = 48 cells/µl, +365 days = 83 cells/µl and +720 
days = 245 cells/µl (p=0.0001, p=0.0001, p=0.0001, p=0.001 and p=0.009, 
respectively)). The interquartile ranges were broader at these respective time 
points compared to 28 days post-CBT. However, the interquartile ranges were 
narrower between 60 and 720 days compared to healthy control PB. The 
broadest interquartile range was recorded at 720 days in CBT patients (95-341 
cells/µl). Overall, this data shows that the absolute median count of CD4+ 
central memory T cells were significantly lower in CBT patients compared to 
healthy control PB. Therefore, this suggests that reconstitution of CD4+ central 
memory T cells could take longer than 720 days in CBT patients.  
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Figure 6.11 Absolute counts of CD4+ central memory T cells in CBT patients. Box and 
whisker plots showing the absolute counts, cells per microliter, of CD4+ central memory T cells 
within CBT patients. Flow cytometry was performed to quantify CD4+ central memory T cells. At 
each time point the following number of samples were acquired: D28 = 44, D60 = 42, D100 = 
25, D180 = 26, D365 = 26, D720 = 14 and healthy control PB = 10. Analysis was performed 
between the time points and the healthy controls as a non-parametric, Mann-Whitney test. 
Results are presented as a tukey analysis, p<0.01 (**) and p<0.0001 (****). 
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6.8.2 CD8+ central memory T cell count recovery following allogeneic cord 
blood transplantation  
 
Median absolute levels of CD8+ central memory T cells were significantly lower 
in CBT patients (3 cells/µl) at 28 days post-transplant compared to healthy 
control PB (21 cells/µl) (p=0.0003). Respectively, the interquartile range in CBT 
patients at 28 days (0-11 cells/µl) was narrower compared to healthy control PB 
(15-181 cells/µl). The median absolute counts of CD8+ central memory T cells 
increased at subsequent time points. The highest median absolute counts of 
CD8+ central memory T cells were measured in CBT patients at 365 (87 
cells/µl) and 720 days (221 cells/µl) post-transplant. At 720 days, the median 
absolute count of CD8+ central memory T cells was higher compared to healthy 
control PB. The broadest interquartile ranges were recorded at 365 days (9-423 
cells/µl) and 720 days (42-462 cells/µl) post-CBT, compared to healthy control 
PB. This data suggests that the number of CD8+ central memory T cells 
increased over the 720 day follow up period in CBT patients. The greatest 
range of cells was recorded in patients between 365 and 720 days post-
transplant. This therefore indicates that CD8+ central memory T cells 
reconstitute by 365 days post-transplant. 
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Figure 6.12 Absolute count of CD8+ central memory T cells in CBT patients. Box and 
whisker plots showing the absolute counts, cells per microliter, of CD8+ central memory T cells 
within CBT patients. Flow cytometry was performed to quantify CD8+ central memory T cells. At 
each time point the following number of samples were acquired: D28 = 44, D60 = 42, D100 = 
25, D180 = 26, D365 = 26, D720 = 14 and healthy control PB = 10. Analysis was performed 
between the time points and the healthy controls as a non-parametric, Mann-Whitney test. 
Results are presented as a tukey analysis, p<0.05 (*) and p<0.001 (***). 
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6.9 CD4+ and CD8+ T cell stages in cord blood transplant patients  
 
In this study, the composition of the CD4+ T cell and CD8+ T cell compartment 
was assessed to better understand the kinetics and diversity of CD4+ and 
CD8+ T cells in CBT patients, as shown in Figure 6.13 and Figure 6.14. 
Understanding the diversity of recovering subsets within CD4+ and CD8+ T cell 
populations will provide an insight into the reconstitution patterns of different T 
cell subsets within the respective T cell compartments in CBT patients.  
6.9.1 T stages within the CD4+ T cell population of cord blood transplant 
patients  
 
At 28 days post-CBT, patients had a high proportion of naïve T cells at 43% in 
the CD4+ T cell population. However, at successive time-points the percentage 
of naïve T cells decreased to 4% by day 720, which was lower compared to 
healthy control PB (34%). There were an increase in the proportion of CD4+ 
effector T cells between 28 days and 100 days post-CBT, from 40% to 82%. 
Throughout the first three time points, the percentage of CD4+ effector T cells 
were higher compared to healthy control PB (3%). However, the percentages of 
CD4+ effector T cells between 100 and 720 days post-CBT were similar to 
healthy control PB. 
  
At 28 days post-CBT, 40% of CD4 T cells were CD4+ effector memory T cells. 
Through subsequent time-points, the percentage of CD4+ effector memory T 
cells increased to 71% by day 180. However, between day 180 and 720 there 
was a decrease from 71% to 44%. When compared to healthy control PB 
(27%), CBT patients had a higher percentage of CD4+ effector memory T cells. 
At 28 days post-CBT, 11% of the CD4+ T cell compartment consisted of CD4+ 
central memory T cells. There was no change in this percentage for up to 365 
days. However, at 720 days post-CBT, 49% of CD4+ T cells were CD4+ central 
memory T cells, which were higher compared to healthy control PB (36%). 
Overall, our data suggests that the naïve T cell population decreased over two 
years and there was an increase in the effector memory and central memory 
population within the CD4+ T cell population. By 720 days post-transplant it can 
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be seen that there was a higher percentage of central memory and effector 
memory T cells within the CD4+ T cell population compared to healthy controls.  
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Figure 6.13 Percentage of T cell subsets within the CD4+ T cell population. Pie charts are 
used to represent the percentage of T cell stages in the CD4+ T cell population of CBT patients 
in the UK. At each time point the following number of samples were acquired: D28 = 44, D60 = 
42, D100 = 25, D180 = 26, D365 = 26, D720 = 14 and healthy control PB = 10. The data 
presented in the graph above are the mean averages of the respective subpopulations of CD4+ 
T cells within CBT patients at the respective time points.  
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6.9.2 T stages within the CD8+ T cell population of cord blood transplant 
patients  
 
Similar to the CD4+ T cell compartment, the percentages of T cells within the 
CD8+ T cell compartment were determined. At 28 days post-CBT, 7% of CD8+ 
T cells were naïve. Between 60 and 180 days post-transplant, the percentage 
of CD8+ naïve T cells decreased down to 3%. However, at 365 days and 720 
days, there was an increase in the naïve subset of CD8+ T cells (17% and 48%, 
respectively). By 720 days post-CBT, the percentage of naive T cells within the 
CD8+ T cell population was higher compared to healthy control PB. 
 
The central memory population at 28 days was 20% of the CD8+ T cell 
population. At successive time points, there was a decrease in the central 
memory T cell population, down to 2% by 100 days post-CBT. Subsequently, 
the central memory population increased to 14% by 720 days post-CBT within 
the CD8+ T cell compartment. This was lower compared to healthy control PB 
(27%).  
 
The effector memory population within the CD8+ T cell compartment was the 
predominating subpopulation throughout the six time points. At 28 days, 68% of 
CD8+ T cells were effector memory T cells. This subpopulation increased to 
93% by 180 days post-CBT. This was the highest-level recorded at all six time 
points. The effector memory population decreased from 93% at day 180 to 36% 
at 720 days post-CBT. By 720 days, the percentage of effector memory T cells 
within patients was equivalent to the percentage within healthy control PB 
(37%).  
 
The effector T cell population was a small subpopulation within the CD8+ T cell 
compartment. At 28 days post-CBT, 5% of CD8+ T cells were effector T cells. 
At subsequent time points, there was very little change in the percentage of the 
effector T cell population. By 720 days post-CBT, 2% of the CD8 T cells were 
effector T cells, which was lower compared to the same population identified 
within healthy control PB (23%). 
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Figure 6.14 Percentage of T cell subsets within the CD8+ T cell population in CBT 
patients. Pie charts are used to represent the percentage of T cell stages in the CD8+ T cell 
population of CBT patients in the UK. At each time point the following number of samples were 
acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26, D720 = 14 and healthy 
control PB = 10.  The data presented in the graph above are the mean averages of the 
respective subpopulations of CD8+ T cells within CBT patients at the respective time points.  
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6.10 Regulatory T cell count recovery following allogeneic cord blood 
transplant  
 
Tregs play a crucial role in regulating immune responses and are suppressors 
of autoreactive and alloreactive immune responses. Due to these fundamental 
roles, the kinetics of Treg recovery has been measured in CBT patients, as 
shown in Figure 6.15.  
 
At 28 days post-CBT median absolute counts (7 cells/µl) of Tregs were lower 
compared healthy control PB (54 cells/µl). Respectively, the interquartile range 
at 28 days (2-28 cells/µl) was narrower compared to healthy control PB (47-92 
cells/µl). Subsequently, at 60 days post-CBT, there was an increase in the 
interquartile range (6-89 cells/µl) in CBT patients. However, median absolute 
counts remained significantly lower in CBT patients (12 cells/µl) compared to 
healthy control PB (p=0.03). At successive time points, there was an increase in 
the absolute median counts of Tregs within patients between 100 and 720 days 
post-CBT. The interquartile range was broadest at 365 days post-CBT (20-516 
cells/µl) and was broader compared to healthy control PB. However, by 720 
days post-CBT, the median absolute count of Tregs in CBT patients (26 cells/µl) 
was significantly lower compared to healthy control PB (54 cells/µl) (p=0.04). 
Overall, this data shows that Tregs reconstitute in CBT patients by 365 days 
post-transplant.  
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Figure 6.15 Absolute counts of Tregs in CBT patients. Box and whisker plots showing the 
absolute counts, cells per microliter, of Tregs within CBT patients, in the UK. Flow cytometry 
was performed to quantify Tregs. At each time point the following number of samples were 
acquired: D28 = 44, D60 = 42, D100 = 25, D180 = 26, D365 = 26, D720 = 14 and healthy adult 
PB = 10. Analysis was performed between the time points and the healthy controls as a non-
parametric, Mann-Whitney test. Results are presented as a tukey analysis, p<0.05 (*) and 
p<0.001 (***). 
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6.11 αβ and γδ T cells within cord blood transplant patients   
 
In healthy individuals, 95% of the T cells within PB express the αβ TCR and the 
remaining express the γδ TCR (Vantourout and Hayday, 2013). However, the 
percentage or number of αβ and γδ T cells that are present within CBT patients 
is not well documented. The percentages of the respective TCRs were 
measured in CBT patients, as shown in Figure 6.16 A-D and Figure 6.17. This 
was performed on thawed PBMCs from CBT patients and healthy controls.  
 
There were a higher percentage of αβ T cells within the CD4+ and CD8+ T cell 
population (figure 6.16A and 6.16B) compared to γδ T cells (figure 6.16C and 
6.17D). At 28 days post CBT, the median percentage levels of αβ CD4+ T cells 
were equivalent to levels seen in healthy controls. However, median percentage 
levels decreased between 60 and 100 days were lower compared to healthy 
controls. The median levels of CD8+ αβ T cells (figure 6.16B) were equivalent 
to healthy controls. Between 28 and 100 days post-CBT, the median levels of 
CD8+ αβ T cells decreased and did not fall below 80%.  
 
The percentage of γδ T cells was low throughout the first three time points 
(figure 6.16C and D). Percentage levels of both CD4+ and CD8+ γδ T cells 
remained below 2% in CBT patients between 28 and 100 days post-transplant. 
The interquartile range was equivalent to levels seen in healthy controls.  
 
At 28, 60 and 100 days post CBT patients had significantly lower expression 
levels of TCR αβ in CD3+CD4-CD8- T cells (Figure 6.17) compared to healthy 
controls (D60 p=0.01 and D100 p=0.01). Respectively, at 28, 60 and 100 days 
post transplant CBT patients had significantly lower expression of TCR γδ 
expression in CD3+CD4-CD8- T cells compared to healthy controls (D28, D60 
and D100 p=0.001).  
 
Overall, this data suggests that the percentage of αβ and γδ T cells within CBT 
patients post-transplant is within the same range observed in healthy controls. 
However, the expression of TCR αβ and γδ were significantly lower in CBT 
patients compared to healthy controls within CD3+CD4-CD8- T cells.  
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Figure 6.16 Percentage of αβ and γδ T cells in the CD4+ and CD8+ T cell population within CBT patients. Box and whisker plots showing the 
percentage of CD4+ αβ T cells (A), CD8+ αβ T cells (B), CD4+ γδ T cells (C), CD8+ γδ T cells (D). At each time point the following number of samples 
were acquired: D28 = 14, D60 = 10, D100 = 10 and healthy controls = 5. Analysis was performed between the time points and the healthy controls as a 
non-parametric, Mann-Whitney test (no significance was observed). Results are presented as a tukey analysis.  
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Figure 6.17 Percentage expression of TCR αβ and TCR γδ in CD3+CD4-CD8- T cells 
within CBT patients. Box and whisker plots showing the percentage expression TCR αβ and 
TCR γδ in CD3+CD4-CD8- T cells. At each time point the following number of samples were 
acquired: D28 = 14, D60 = 10, D100 = 10 and healthy controls = 5. Analysis was performed 
between the time points and the healthy controls as a non-parametric, Mann-Whitney test. 
Results are presented as a tukey analysis, p<0.01 (**) and p<0.001 (***). 
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6.12 Percentage expression of activation markers in T cells of cord blood 
transplant patients  
 
Activation molecules are expressed on T cells when antigens, mitogens and 
cytokines stimulate them. Early post-transplant, recovering T cell subsets that 
are adoptively transferred from the graft will predominantly be naïve. Upon 
stimulation, T cells express early, mid and late activation markers and this 
primes the T cells to proliferate and differentiate into effector and memory T 
cells. In this current study, the measurement of CD69, CD25 and HLA-DR on 
CD4+ and CD8+ T cells was measured (as shown in Figure 6.18 and 6.19) to 
understand the activation of reconstituting T cells in CBT patients. This was 
performed on thawed PBMCs from CBT patients and healthy controls. 
6.12.1 Percentage expression of activation markers within CD4+ T cells 
 
The median percentage of CD4+ T cells expressing CD25 (Figure 6.18A) was 
significantly lower at day +28 (0%, range: 0-51%) (p=0.03) post-CBT compared 
to healthy controls (13%, range: 10-18%). The median percentage of CD4+ T 
cells expressing CD25 was higher at day +60 (18%, range: 7-68%) and +100 
(23%, range: 5-32%) post-CBT compared to healthy controls.  
 
Additionally, the median percentage of CD4+ T cells expressing CD69 (Figure 
6.18B) was significantly higher at day +28 (100%, range: 86-100%) and +60 
(92%, range: 31-97%) (p=0.0002 and p=0.04, respectively) post-CBT compared 
to healthy controls (48%, range: 45-51%). The median percentage of CD4+ T 
cells expressing CD69 was higher at day +100 (81%, range: 39-97%) post-CBT 
compared to healthy controls.  
 
Furthermore, the median percentage of CD4+ T cells expressing HLA-DR 
(Figure 6.18C) was significantly higher at day +28 (56%, range: 44-99%), +60 
(80%, range: 47-95 %) and +100 (77%, range: 56-94%) (p=0.0007, p=0.001 
and p=0.0007 respectively) post-CBT compared to healthy controls (43%, 
range: 38-47%).  
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Overall, this data suggests that there is an increase in the percentage of CD4+ 
T cells expressing CD25 and HLA-DR. However, there is a decrease in the 
percentage of CD4+ T cells expressing CD69. Furthermore, this demonstrated 
that CD4+ T cells in CBT patients are activated within the first three months 
post-CBT.  
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Figure 6.18 Percentage expression of activation markers (CD25, CD69 
and HLA-DR) within the CD4+ T cell population of CBT patients. Box and 
whisker plots showing the percentage of CD25 (A), CD69 (B) and HLA-DR 
(C) activation markers within CD4+ T cells of CBT patients. At each time 
point the following number of samples were acquired: D28 = 14, D60 = 10, 
D100 = 10 and healthy controls = 5. Analysis was performed between the 
time points and the healthy controls as a non-parametric, Mann-Whitney test. 
Results are presented as a tukey analysis. p<0.05 (*) and p<0.001 (***). 
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6.12.2 Percentage expression of activation markers within CD8+ T cells  
 
Additionally, the percentages of CD8+ T cells expressing activation markers 
(CD25, CD69 and HLA-DR) were measured in CBT patients.  
 
The median percentage of CD8+ T cells expressing CD25 (Figure 6.19A) was 
similar at day +28 (0%, range: 0-6%), +60 (2%, range: 0-14 %) and +100 (2%, 
range:0-9%) post-CBT compared to healthy controls (1%, range: 0-13%).  
 
Furthermore, the median percentage of CD8+ T cells expressing CD69 (Figure 
6.19B) was significantly higher at day +28 (90%, range: 43-100%), +60 (74%, 
range: 41-93 %) and +100 (66%, range: 32-86%) (p=0.0003, p=0.002 and 
p=0.008, respectively) post-CBT compared to healthy controls (32%, range: 30-
45%).  
 
Additionally, the median percentage of CD8+ T cells expressing HLA-DR 
(Figure 6.19C) was similar at day +28 (67%, range: 54-100%) post-CBT 
compared to healthy controls (64%, range: 41-68%). The median percentage of 
CD8+ T cells expressing HLA-DR was significantly higher at day +60 (96%, 
range: 86-99 %) and +100 (91%, range: 71-99%) post-CBT compared to 
healthy controls  (p=0.001 and p=0.0007, respectively) 
 
Overall, this data suggests that the expression of CD25 is equivalent to healthy 
controls in CD8+ T cells and there is a higher expression of CD69 and HLA-DR 
within CBT patients compared to healthy controls. Furthermore, this suggests 
that CD8+ T cells have mid and late activation within the first three months post-
CBT. 
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Figure 6.19 Percentage expression of activation markers (CD25, CD69 
and HLA-DR) within the CD8+ T cell population of CBT patients. Box and 
whisker plots showing the percentage of CD25 (A), CD69 (B) and HLA-DR (C) 
activation markers within CD8+ T cells of CBT patients. At each time point the 
following number of samples were acquired: D28 = 14, D60 = 10, D100 = 10 
and healthy controls = 5. Analysis was performed between the time points and 
the healthy controls. Analysis was performed between the time points and the 
healthy controls as a non-parametric, Mann-Whitney test. Results are 
presented as a tukey analysis. p<0.01 (**) and p<0.001 (***). 
A B 
C 
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6.13 Discussion 
 
In Chapter 3, it was shown that the there is delayed reconstitution of CD3+, and 
CD4+ T cells for up to 720 days post transplant. However, CD8+ T cell 
reconstitution takes place by 365 days. This corroborates data of other HSCT 
studies shown in Chapter 3, Table 3.2. In this study, TREC analysis was 
performed to assess thymic output. Furthermore, the kinetics of T cell 
reconstitution was measured to assess thymic and thymic independent 
reconstitution in CBT patients.  
 
In this study, patients have a 1: 4 ratio of CD4:CD8 T cells at 28 days and 
between 60 and 365 days this shifts to a 2:1 ratio for CD4: CD8 T cells.  
However, by 720 days post-transplant there is a 1:1 ratio of CD4:CD8 T cells, 
which suggests that there is an increase in numbers of CD4+ T cells within the 
CD3+ T cell population. As previously shown, CD8+ T cells reconstitute by 365 
days post-CBT, this could be the reason as to why there is a shift to a 1:1 ratio 
of CD4:CD8 T cells by 720 days. The increase in numbers of CD8+ T cells is 
also seen in other HSCT studies. In a study conducted by Alho et al. there is a 
1:1 ratio of CD4:CD8 T cells in transplanted patients by 365 and 547 days post-
transplant (Alho et al., 2016). Data within this project corroborates this, as there 
is a 1:1 ratio of CD4 to CD8 T cells in CBT patients within the same time frame. 
Furthermore, Komanduri et al. also demonstrates that there is an increase in 
the number of CD8+ T cells within the first year of transplant and in their cohort 
of patients there is an inverted ratio of CD4:CD8 T cells. This shows that there 
is an increase in absolute numbers of CD8+ T cells, post-transplant, compared 
to CD4+ T cells (Komanduri et al., 2007). Again, data within this current study 
verifies this data as we have showed that CD8+ T cells reconstitute sooner 
compared to CD4+ T cells.  
 
To assess thymic output and thymic dependent reconstitution, the kinetics and 
diversity of naïve T cells reconstitution was measured. RTEs were identified via 
the detection of cell surface markers such as CD31. Furthermore, naïve T cells 
were identified through cell surface markers such as CD45RA and CCR7. In 
this project, the kinetics of reconstitution of naïve T cells (CD45RA+CCR7+) 
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was delayed in CBT patients for both CD4+ and CD8+ T cells. This 
corroborates a CBT study conducted by Komanduri et al. who demonstrated 
that were low absolute levels of CD45RA+CCR7+ naïve T cells in CBT patients 
for up to one year post-transplant (Komanduri et al., 2007). Respectively, the 
number of naïve T cells was also observed to be lower in dUCBT patients within 
a study conducted by Jacobson et al. for up to 18 months post-transplant 
(Jacobson et al., 2012). Data within this current study verifies this as CBT 
patients had low absolute levels of CD45RA+CCR7+ naïve T cells in PB post-
transplant.  
 
To further measure thymic output, the kinetics of reconstitution was measured 
by identifying the absolute numbers of RTEs in CBT patients. In healthy adults, 
CD31+ T cells are a distinct population of naïve T cells that are released from 
the thymus upon T cell maturation (Junge et al., 2007). CD31+ is a glycoprotein 
expressed on naive T cells that allows egression of T cells from the thymus 
(Kohler and Thiel, 2009). In this thesis, the absolute counts of CD31+ RTEs 
(CD4+ and CD8+) are lower compared to healthy controls and remain lower for 
up to 720 days post-transplant. This indicates that thymic output is reduced in 
CBT patients compared to healthy controls.  
 
Moreover, CD31+ RTEs are known to contain high levels of TRECs (Gaballa et 
al., 2016, Kohler and Thiel, 2009, Ribeiro and Perelson, 2007, Sottini et al., 
2014). In this thesis, TREC levels in CBT patients post-transplant are lower 
compared to healthy controls. Furthermore, TREC levels were undetected in the 
majority of patients for up to 720 days. In comparison, it has been shown that 
TREC levels are lower in CBT patients compared to BM and mPB recipients. 
Additionally, this has been highlighted in a study conducted by Komanduri et al. 
where absolute copy numbers of TRECs were lower compared to autologous 
and allogeneic grafts (Komanduri et al., 2007). Together, the data in this current 
study shows that there are low absolute counts of RTEs and low TRECs copy 
numbers. This could suggest that thymic output is reduced and delayed in CBT 
patients. Furthermore, this correlates with the fact there are low absolute levels 
of naïve T cells in CBT patients. Overall, this suggests that thymic output and 
thymic dependent reconstitution is delayed for up to 720 days in CBT patients. 
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Thymic output could be delayed in HSCT patients due to factors including the 
recipient’s age, intensity of conditioning and whether GvHD develops. The 
recipient age is particularly important as thymic involution takes place in older 
individuals and this leads to a decrease in naïve T cell output (Lynch et al., 
2009). Thymic activity is dependent on age and the ability for the thymus to 
recover is influenced by the recipient’s age. The thymus is highly active during 
the initial six months of life and remains active throughout childhood. Over time, 
the thymus involutes and during this period the cellular cortical and medullary 
tissues reduce in terms of cellular content. Subsequently, this leads to a 
reduced proliferative expansion within the thymus and reduction in the release 
of early thymocytes (Douek et al., 1998, Haynes et al., 2000). Therefore, in CBT 
patients, thymic reconstitution may be prolonged, as lymphoid-myeloid 
progenitor cells will need to migrate to the thymus and undergo selection before 
maturing into a naïve T cell. However, there could be thymic involution in CBT 
patients, which impacts naïve T cell reconstitution post-transplant.  
 
As previously described, the intensity of conditioning can also impact thymic 
recovery of T cells. An increase in intensity of conditioning can lead to a degree 
of thymic damage. Subsequently, this can impair negative selection of T cells 
within the thymus. This leads to the release of auto-reactive and allo-reactive T 
cells and ultimately leads to the development of GvHD. Delays in thymic output 
have been correlated with thymic damage in HSCT studies demonstrating that 
intense conditioning regimens impact and delay thymic recovery (Wu et al., 
2013, Bacigalupo et al., 2009, Ballen et al., 2004, Corradini et al., 2005). 
Overall, it can be believed that intense conditioning regimens can induce thymic 
damage and this prolongs thymic recovery of T cells in CBT patients. 
 
The development of GvHD can also impact thymic reconstitution in CBT 
patients. The development of aGvHD can delay thymic output and is correlated 
with a reduced number of naïve T cells in HSCT patients (MacMillan et al., 
2009). This is due to the fact that the host lympho-haematopoietic system 
begins to serve as a target of allo-immunity and donor T cells. These T cells are 
alloreactive against recipient tissue antigens. GvHD is also known to interfere 
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with all stages of T cell development including: pre-thymic, thymic and post-
thymic development (Aguila, 2010, Beschorner et al., 1978, Dulude et al., 
1999). Furthermore, the administration of GvHD prophylaxis and 
immunosuppression can also delay naïve T cell output in CBT patients (Sabry 
et al., 2009). The morphology of the thymus can also change due to GvHD 
development, which causes reduction in the number of lymphoid cells and the 
composition of the stromal compartment of the thymus. This leads to a 
reduction in thymic output and it has been seen that aGvHD affects T cell 
maturation within the thymus. This occurs before rearrangement of the TCR β-
chain gene and subsequently this leads to development of auto and alloreactive 
T cells in the thymus (Clave et al., 2009). Therefore, a balance is required post-
transplant whereby the correct dose of GvHD prophylaxis is administered to 
patients to favour thymic development and suppress GvHD development. 
Unfortunately, in this current study it was not possible to make correlations 
between GvHD development and thymic reconstitution, as the GvHD data was 
not complete.  
 
Aside from thymic reconstitution, thymic independent reconstitution of T cells 
was also measured in CBT patients. Thymic independent reconstitution is the 
transfer of mature/naïve T cells from the donor to the recipient. This leads to 
proliferation and expansion of T cells in the peripheral blood of the recipient. 
Additionally, naïve T cells can also differentiate into effector T cells (Mackall et 
al., 1993). The measurement and quantification of thymic independent T cell 
reconstitution was performed via the absolute counts of effector T cells, effector 
memory T cells and central memory T cells in the PB of CBT recipients. The 
presence of these T cells in healthy adults indicates the fundamental stages of 
T cell development that are required for adaptive immune responses. Herein, 
CD4+ effector T cells reconstitute in CBT patients by 60 days post-transplant. 
Furthermore, absolute levels of CD4+ effector T cells remain within the healthy 
control range for up to 720 days post-transplant. In contrast, the absolute 
counts of CD8+ effector T cells in CBT patients are lower compared to healthy 
controls and remain low up to 720 days post-transplant. This corroborates data 
by Komanduri et al. who also demonstrates that CD4+ effector T cells 
reconstitute within CBT patients between 30-60 days post-transplant 
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(Komanduri et al., 2007). A further allogeneic HSCT study by Alho et al. also 
demonstrates that there is an increase in the number of effector T cells in 
patients post-transplant and these patients experience homeostatic expansion 
of effector T cells post-transplant (Alho et al., 2016).  
 
Effector T cells can differentiate and mature into two further subtypes of T cells 
known as effector memory and central memory T cells. These are two subsets 
of memory T cells with distinct homing potentials and effector functions of cell 
mediated immunity. Both effector memory and central memory T cells can 
respond to secondary stimulation of antigens and are crucial for the clearance 
of pathogens (Sallusto et al., 1999). Within this current project, CD4+ effector 
memory T cells reconstitute by 365 days and CD8+ effector memory T cells 
reconstitute by 100 days post-transplant. Komanduri et al. also shows this in 
CBT patients, where an increase in the number of CCR7- effector memory T 
cells is seen in CBT patients for up to one year post-transplant. Furthermore, 
the effector memory T cell population is the predominant population in the T cell 
compartment post-transplant (Komanduri et al., 2007).  
 
Central memory T cells are CCR7+ and can migrate to lymphoid tissues where 
they are activated by antigens (Sallusto et al., 1999, Sallusto et al., 2004). Data 
from this current project demonstrates that the kinetics of CD4+ central memory 
T cell reconstitution is delayed in CBT patients and could take longer than 720 
days to reconstitute. However, CD8+ central memory T cells reconstitute by 100 
days post-transplant. As previously discussed, central memory T cells migrate 
to the lymphoid tissues and this could explain why there are fewer circulating 
central memory T cells present in the PB of CBT patients.  
 
Thymic independent reconstitution could take place due to a number of reasons 
in CBT recipients. Early post-transplant, adoptively transferred donor T cells or 
recipient T cells that survive conditioning could proliferate, giving rise to 
increased numbers of effector memory and central memory T cells. The 
proliferation of the respective cells can also occur due to interactions with 
antigens (Mackall et al., 1996). Expansion of effector T cells in HSCT patients 
occurs from HPE, as the transfer of mature T cells replenishes the T cell 
!! 269 
compartment. Furthermore, HPE takes place as adoptively transferred T cells 
undergo low affinity interactions with self-antigens (Goldrath and Bevan, 1999). 
This is further driven by cytokines such as IL-7, which is a non-redundant 
cytokine that stimulates naïve T cell expansion. IL-7 is known to regulate the 
naïve T cell pool and drives proliferation of naïve T cells in HPE (Mackall et al., 
2001, Park et al., 2004). In CBT, it has been shown that IL-7 levels are elevated 
for prolonged periods of time and have been correlated to increase effector T 
cell and effector memory T cell numbers (Politikos et al., 2015). Future studies 
should measure plasma concentrations of IL-7 in CBT patients. The levels of IL-
7 could then be correlated with the reconstitution of effector T cells in CBT 
patients. This could demonstrate whether there is an increase in effector T cell 
numbers due to increased IL-7 levels (Mackall et al., 1993, Politikos et al., 
2015). Additionally, it has been determined that HPE occurs through the antigen 
dependent pathway where T cells circulating within the periphery undergo 
oilgoclonal expansion. This gives rise to increased numbers of effector memory 
and central memory T cells (Hakim et al., 1997).  
 
T cell subsets were identified in this study to observe the composition of the 
CD4+ and CD8+ T cell compartments. By 720 days post-transplant, the CD4+ T 
cell population contained fewer naïve T cells and there was an increase in 
effector memory T cells compared to 28 days post-CBT. However, in the CD8+ 
T cell population there is a greater proportion of naïve T cells, effector memory 
T cells and central memory T cells. This corroborates data presented by 
Komanduri et al. who also showed similar proportions of the respective cells in 
the CD4+ and CD8+ T cell populations (Komanduri et al., 2007).  
 
Furthermore, in HSCT, Tregs play a key role in mediating and suppressing 
immune reactions. In this current study, Tregs reconstitute within CBT patients 
by 365 days post-transplant. This verifies data by Kanda et al. who showed that 
Tregs reconstitution occurs by 365 days post-transplant in CBT patients. Treg 
reconstitution in CBT recipients has been compared to match sibling donors 
(MSD) and matched unrelated donors (MUD). The absolute counts of Tregs 
were similar in all three patient groups at 365 days post-transplant (Kanda et 
al., 2012). Additionally, increased absolute numbers of Tregs post-transplant 
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have been associated with improved immune reconstitution in haploidentical 
transplant recipients (Di Ianni et al., 2011).  
 
In addition, all T cells express TCRs on the on the surface of the cell. It is 
known that 95% of T cells express αβ TCR and 5% of T cells express γδ TCRs. 
(Vantourout and Hayday, 2013). The expression of TCR αβ and γδ is poorly 
defined in CBT patients and therefore it was assessed within this study. Herein, 
95% of CD4+ and CD8+ T cells expressed the αβ TCR. Respectively, 2% of T 
cells expressed the γδ TCR, this was similar to healthy controls. Therefore, the 
expression pattern of both TCRs in CBT patients is similar to healthy controls 
and this occurs by 28 days post-transplant. This suggests that there are no 
abnormalities in the reconstitution of the respective TCRs, in CBT patients.  
 
To further understand the activation of T cells in CBT patients, the expression 
patterns of early, mid and late activation markers such as CD69, CD25 and 
HLA-DR, respectively, were measured. It was shown that CD4+ T cells highly 
express CD69 by 28 days post-CBT. Subsequently, the expression of CD69 
decreased and there was an increase in the expression of CD25 and HLA-DR. 
This suggests that CD4+ T cells were activated early post-transplant. Similarly, 
the kinetics of activation markers, CD69 and HLA-DR, was the same in CD8+ T 
cells.  However, a lower expression of CD25 was observed in CD8+ T cells. 
Overall, this demonstrates that the reconstituting CD8+ T cells were activated 
early post-transplant. The activation of CD4+ and CD8+ T cells could be due to 
the pro-inflammatory environment within CBT patients, within the first three 
months post-transplant. This could induce the activation of T cells and therefore 
increase the expression of the respective activation markers.  
 
In CBT recipients, it is known that T cell reconstitution is delayed due to various 
factors. Host-related factors such as age can influence immune reconstitution 
as thymic involution limits the output of naïve T cells. Also, graft related factors 
could also affect the reconstitution of T cells post-transplant. It has been 
demonstrated that low doses of TNCs and T cells in the graft can impact thymic 
independent recovery in CBT patients (Niehues et al., 2001, Douek et al., 1998, 
Mackall et al., 1995). HLA disparity can also be considered as a graft related 
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factor that impacts T cell recovery. In CBT, there are fewer matching 
requirements between the donor and the recipient compared to other HSCT. 
This could mean that patients could have a higher degree of mismatches 
between the donor and the recipient, which could impact thymic selection and 
output and lead to a skewed TCR repertoire (Roux et al., 2000). 
 
Additionally, treatment related factors such as pre-transplant conditioning or the 
transplant procedure could also impact T cell reconstitution. T cell depleting 
agents such as ATG are commonly used post-transplant and can impact thymic 
independent reconstitution of T cells (Admiraal et al., 2015, Lindemans et al., 
2014). However, in this current study no patients were given ATG. Moreover, 
the use of myeloablative conditioning regimens and radiation-based regimens 
could also cause damage to the thymus. This could mean that the thymus 
would need to repair before it can resume T cell output to healthy control levels 
(Chung et al., 2001). In this current study, 17 patients had a MAC transplant.  
 
Another factor that can impact T cell reconstitution is the development of GvHD. 
This can impact thymic reconstitution due to increased numbers of alloreactive 
T cells within the HSCT recipient. Alloreactive T cells can damage stromal and 
lymphoid compartments of the thymus, where T cell development and selection 
takes place. Thymic damage induced by GvHD can delay the output of naïve T 
cells from the thymus (Krenger and Hollander, 2008, Clave et al., 2009, Uhlin et 
al., 2012). Additionally, GvHD prophylaxis is administered to patients to 
suppress inflammatory responses and prevent GvHD development. 
Corticosteroids as part of GvHD prophylaxis are potent lympho-depleting 
agents, which could reduce T cells within the CBT recipient.  This therefore 
causes a delay in T cell reconstitution.  
 
As far as we are aware, this is the only study in the UK that extensively 
measures the kinetics and diversity of T cell reconstitution in CBT patients. 
Overall, data in this study shows that T cell reconstitution is delayed in CBT 
patients and specifically thymic-dependent reconstitution is severely delayed. 
Furthermore, there is an increased absolute count of effector memory and 
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central memory T cells in CBT patients, which occurs by 365 days post-
transplant.  
 
Future studies and improvements should be undertaken to improve thymic 
output and to decrease the delay in naïve T cell reconstitution in CBT patients. 
The expansion of central memory and effector memory T cells post-transplant 
could also suggest an increase in T cells that can target towards infection or a 
balanced GvL effect. However, infection data was not complete and correlations 
could not be made between infection and the delay in immune reconstitution of 
T cells. To further understand the diversity of T cell receptors, TCR 
spectratyping could have provided a further insight into the restoration of TCR 
clones in CBT patients. This could have demonstrated the TCR diversity and 
whether reconstituting T cells can identify a variety of antigens.  
 
To better understand thymic independent expansion of T cells, future immune 
reconstitution studies in CBT require culturing patient T cells with IL-7 and 
measuring the proliferation via the use of CFSE and KI67. This would aid in 
determining whether T cells can proliferate in response to cytokine stimulation 
and their proliferative capacity can be measured through CSFE staining. 
Further functional studies are also required to understand whether 
reconstituting T cells in CBT patients aid in the clearance of infection and 
whether they partake in GvL responses in CBT patients.  
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Chapter 7 : Discussion and future work 
 
7.1  Background of the current study 
 
Reconstitution of immune cell subsets and balanced immune function is 
essential in CBT recipients, as it will reduce the development of post-transplant 
complications such as relapse, GvHD and infection. Immune reconstitution in 
HSCT has been studied internationally. However, a comprehensive study of 
immune reconstitution in CBT patients has not been performed in the UK. 
Studying immune reconstitution in CBT patients will provide an insight into the 
kinetics of recovery of the immune cell subsets in CBT patients. Hence, the aim 
of this study was to investigate the kinetics and diversity of reconstituting 
immune cell subsets in CBT patients within the UK. This chapter summarises 
and discusses data from this project and its relevance to clinical practice and 
proposes potential future work to extend the project.  
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7.2 Physiological relevance of this study 
 
7.2.1 Haematopoietic recovery and engraftment 
 
Immune reconstitution is an important facet of CBT. Delayed or defective 
immune reconstitution can lead to post-transplant complications such as GvHD, 
relapse and infection in CBT patients. One of the major problems of using CB 
as a source of HSC is the delay in immune reconstitution in comparison to PB 
and BM graft sources (Komanduri et al., 2007, Ruggeri et al., 2011). 
Haematopoietic recovery is an important measure of immune recovery in CBT 
and is clinically measured through the use of TNC counts, neutrophil 
engraftment and platelet engraftment (Kim et al., 2014). Neutrophil engraftment 
is clinically recorded as the first three consecutive days of neutrophil counts 
greater than 0.5 x109/L. Neutrophil engraftment occurs in the majority of CBT 
patients and can take place between 5-21 days (Laughlin et al., 2004, Rocha et 
al., 2004, Seggewiss and Einsele, 2010). Respectively, platelet engraftment is 
clinically recorded as three consecutive days of platelet counts at greater than 
20x109/L. The median time to platelet engraftment varies in CBT studies and 
occurs between 50 and 100 days post-CBT (Petropoulou and Rocha, 2011). 
Comparatively, this current study shows that the recovery of neutrophils and 
platelets occur within a median time of 20 days and 40 days, respectively. The 
time to engraftment can differ between patients and this is due to a number of 
factors including: the severity of the underlying disease; preparative 
conditioning used to clear the residual disease and pre-transplant 
radiotherapies and chemotherapies. Furthermore, TNC and CD34+ counts are 
an important factor for efficient engraftment in CBT patients. It has been shown 
that increased CD34+ cells and higher TNCs are associated with an increased 
probability and rate of neutrophil and platelet engraftment (Purtill et al., 2014, 
Danby and Rocha, 2014, Gluckman et al., 2004). It has also been reported that 
patients who receive G-CSF in the post-transplant period have a better rate of 
engraftment (Konuma et al., 2015). This highlights that there are number of 
clinical practices affecting the time in which engraftment takes place between 
patients.  
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A broad understanding of leucocyte reconstitution can be achieved through the 
measurement of CD45 expression. CD45 is a known as the common leucocyte 
antigen and has been used in this study to measure the kinetics of leucocyte 
reconstitution. As previously described, leucocyte reconstitution is clinically 
measured through neutrophil and platelet engraftment, which is validated on 
many automated analysers. However, in this study an automated analyser was 
not available. Therefore, CD45 was used to identify the expression patterns of 
leucocytes post-transplant and it has been shown that CD45+ leucocyte 
recovery takes place by 60 days post-transplant.  
7.2.2 Monocytes in cord blood transplant 
 
The reconstitution of CD14+ monocytes is poorly defined in CBT patients. 
However, in a recent study by Li et al. the reconstitution of CD14+ monocytes in 
CBT patients occurs by seven days post-transplant. Furthermore, the absolute 
counts of CD14+ monocytes were higher than the healthy control range in CBT 
patients for up to five years post-transplant (Li et al., 2017). Herein, it has been 
shown that there is early reconstitution of CD14+ monocytes, which occurs by 
28 days post-transplant. The exact function of monocytes in CBT patients is 
currently unexplored and the early reconstitution of monocytes highlights that 
their function should be investigated.  
 
In healthy adults, monocytes are able to prime naïve T cells and induce T cell 
proliferation (Bhardwaj et al., 1994). Additionally, monocytes play an active role 
in inflammation and upon antigenic stimulation, they can release pro-
inflammatory cytokines such as TNF-α and IL-1β (Ziegler-Heitbrock, 2007). This 
shows that monocytes have an immunomodulatory and pro-inflammatory role in 
healthy adults.  
 
In contrast, HSCT patients can be treated with corticosteroids post-transplant 
and there is an increase in the number of monocytes in patients treated with 
prednisolone. Furthermore, monocyte absolute numbers increase in patients 
with aGvHD. This causes further recruitment of Th17 cells and exacerbation of 
inflammatory responses. Therefore in HSCT, monocytes could recruit 
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inflammatory cells to induce GvHD responses (Reinhardt-Heller et al., 2017). 
Additionally, it is known that monocytes release BAFF upon activation. BAFF is 
a cytokine that promotes survival of B cells (Batten et al., 2000, Rolink et al., 
2002). This could explain why there are increased absolute numbers of B cells 
in CBT patients. However, future work is required to measure BAFF release 
from monocytes in CBT patients. This is highlighted later in this chapter.  
 
With the various functions of monocytes in mind, future work could be 
undertaken to further identify subpopulations of monocytes in thawed patient 
samples. This could be performed by identifying subpopulations of monocytes 
in CBT patients via the expression patterns of CD14 and CD16 using flow 
cytometry. These are both typical markers used to define monocytic populations 
(Rogacev et al., 2015). However, little is known about the number of monocytic 
cells in CBT recipients and their function post-transplant. Further efforts are 
required to elucidate their reconstitution patterns and role post-transplant.  
7.2.3  NK cell function in cord blood transplant 
 
NK cell reconstitution occurs within the first month post-CBT (Brahmi et al., 
2001, Jacobson et al., 2012, Ruggeri et al., 2011, Small et al., 1999, Somers et 
al., 2013, Thomson et al., 2000). Early, post-CBT, there are higher percentages 
of immature CD56bright NK cells. These NK cells then acquire the CD56dim 
phenotype within the first three months post-transplant (Cooley et al., 2005, 
Nguyen et al., 2008). CD56dim NK cells have a significantly higher cytotoxicity 
compared to CD56bright NK cells (Cooper et al., 2001, Nagler et al., 1989). In this 
thesis, a higher proportion of CD56dimCD16negative NK cells were present in CBT 
patients post-transplant compared to CD56bright CD16negative and CD56dim 
CD16postive NK cells. It is possible that these NK cells had a functional response 
to clear infection or could have been apart GvL related responses. However, 
further work is required to elucidate their functions post-transplant and this is 
described later in this chapter. Additionally, there is limited data on the function 
of CD56dimCD16negative NK cells in healthy adults and HSCT recipients. Poli et al. 
also highlights this that this subpopulation is present within healthy individuals. 
However, little is known about the function of this subpopulation of NK cells 
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(Poli et al., 2009). This highlights that further studies are required to elucidate 
the functions of the CD56dimCD16negative NK cell subpopulation post-CBT.  
 
Post-transplant, the immune system in CBT patients is highly inflammatory. NK 
cells become activated through the interaction with various antigens leading to 
the upregulation of stimulatory markers such as CD69 and HLA-DR (Pittari et 
al., 2010). Subsequently, this leads to the induction of cytotoxicity of the target 
cell via NK cells (Moretta et al., 1991). Early expression of both CD69 and HLA-
DR in CBT patients shows that early-reconstituted NK cells are prone to 
activation (Bjorkstrom et al., 2010). In this thesis, NK cells are activated which 
has been demonstrated by high expression of CD69 and HLA-DR.  
 
Activation and inhibitory markers such as NKG2A and NKG2C can also define 
the functionality of NK cells in CBT patients. Beziat et al. has shown that NK 
cells express NKG2A, an inhibitory receptor, which is expressed for up to three 
months post-transplant. Subsequently, the expression of NKG2A decreases 
and there is an increase in the expression of NKG2C, an activating NK cell 
receptor. This demonstrates that NK cells are activated post-transplant and 
there is a shift from inhibitory NK cells to activated NK cells after three months 
post-transplant (Beziat et al., 2012, Beziat et al., 2011, Beziat et al., 2009). 
CD57 further defines the maturation of NK cells in CBT patients. NK cells can 
be defined as CD57+NKG2A+ or CD57+NKG2C+, which are inhibitory-mature 
or activating-mature, respectively. In HSCT, the kinetics of reconstitution of 
inhibitory-mature NK cells occurs in the first three months post-transplant. This 
then shifts to an activating-mature NK phenotype after several months 
(Bjorkstrom et al., 2010, Lopez-Verges et al., 2010). Herein, there was a higher 
proportion of inhibitory-mature NK cells (NKG2A+CD57+) in CBT patients. 
However, this was investigated in the first 100 days post-CBT and further 
observations of the respective phenotypes could not be made due to limited 
patient samples at later time points. Additionally, Beziat et al. also demonstrates 
that there is rapid maturation of NK cells post-transplant that express activating 
receptors, NKp30 and NKp46, which are believed to indirectly override the 
NKG2A-inhibitory signal to allow elimination of leukaemic cells (Beziat et al., 
2009). Future work to further elucidate the function of NK cells post-transplant 
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would include determination of activating receptors such as NKp30, NKp46, and 
NKp80 via flow cytometry. The patterns of expression of activation markers 
could then be correlated with the expression patterns of NKG2A/NKG2C. This 
would aid in identifying the actions of NK cell cytotoxicity.  
 
NK cell function can also be defined by the expression of cytokines such as 
IFN-γ. IFN-γ is an important inflammatory cytokine that can be produced by NK 
cells. Cytokines such as IL-12 and IL-18 secreted by macrophages and DCs 
can induce the production of IFN-γ in NK cells (Matikainen et al., 2001). 
Commonly post-transplant, patients are prone to infections and IFN-α is 
produced during viral infections. This synergises with IL-12 and IL-18 to induce 
the production of IFN-γ. Respectively, TNF-α is also produced and induces the 
production of IFN-γ (Marshall et al., 2006). It has been shown that NK cells in 
CBT and allogeneic HSCT recipients produce IFN-γ, which could be released to 
clear infections, induce GvL responses and clear residual disease (Beziat et al., 
2009, Smyth et al., 2002). In this current study, the intracellular expression of 
IFN-γ in unstimulated isolated NK cells in CBT patients is high. This suggests 
that NK cells are stimulated post-transplant and possess the capacity to 
express IFN-γ. Given that the immune environment is highly pro-inflammatory 
post-transplant, the production of IFN-γ could be required to induce cytotoxic 
responses of NK cells. With this in mind, one could hypothesise that the 
expression and release of IFN-γ from NK cells in CBT patients could aid in 
immune responses to clear pathogens or drive NK cell cytotoxicity directed to 
residual disease. To test this hypothesis, in vitro killing assays could be 
performed. Isolated NK cells from CBT patients, stimulated with IFN- γ, would 
be used to test this. These NK cells would then be tested in an in vitro killing 
assay to assess their cytotoxic capacity against leukaemic cell lines such as 
K562, Daudi and Raji as well as primary AML blasts from patients. 
Respectively, the results would be compared to healthy controls and 
unstimulated NK cells from CBT patients.  
 
The cytotoxic capacity of NK cells is a key functional role that allows NK cells to 
directly lyse target cells. In HSCT, this is important as NK cells could be 
involved in clearing residual disease or clearing infection. NK cells in CBT 
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patients have been shown to directly lyse K562 target cells and AML blasts. 
Furthermore, the cytotoxic capacity of CBT recipient NK cells is equal to healthy 
adults. However, the cytotoxic capacity of CBT recipient NK cells is higher 
compared haploidentical HSCT recipient NK cells (Nguyen et al., 2005, Beziat 
et al., 2009, Nguyen et al., 2009). As T cell reconstitution is delayed in CBT 
patients, NK cells could play a crucial role in GvL responses. Additionally, NK 
cells switch from an immature to mature phenotype within the first-year post-
transplant and are stimulated and activated with a functional capacity to lyse 
target cells.  
 
With the entire functions of NK cells in mind, further work can be undertaken to 
better define their role in CBT recipients. In this thesis, three main NK cell 
subsets have been identified within CBT patients. Future work includes the 
isolation of CD56bright CD16negative, CD56bright CD16positive and CD56dimCD16positive 
and CD56dimCD16negative NK cells from patient samples. The respective 
subpopulations could then be co-cultured with leukaemic blast cells and their 
degranulation could be tested through the identification of CD107a. This would 
be measured via flow cytometry. Additionally, isolated NK cells could be 
cultured with leukaemic cell lines such as Daudi, Raji, RPMI8226, U266 and 
U937. This would demonstrate whether NK cells possess a cytolytic capacity 
against a broad range of leukaemic cells. Furthermore, the use of primary cell 
blasts from AML patients could also be used to better understand whether 
isolated NK cells from CBT patients can directly lyse leukaemic cells within 
patients. ADCC cytotoxicity can also be measured in future work where NK cells 
isolated from CBT patients could be directed against Raji cells and the 
degranulation of CD107a can be measured to assess the level of cytolytic 
activity (Shabrish et al., 2016).  
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7.2.4 B cells in cord blood transplant 
 
B cells are the second lymphocyte cell type to reconstitute in CBT patients after 
NK cells. KREC analysis and absolute counts of B cells have shown that B cell 
reconstitution takes place between three and six months post-CBT (Nakatani et 
al., 2014). In this current study, B cell reconstitution takes place in CBT patients 
within 100 days post-transplant, which has been shown via KREC analysis and 
absolute count measurement of CD19+ B cells.  
 
In allogeneic transplant, transitional B cells are the first subtype of B cell to 
enter the periphery from the bone marrow. In HSCT, absolute numbers of 
transitional B cells are higher in CBT patients compared to BMT recipients 
(Nakatani et al., 2014). At later time points, such as one year post-transplant, 
the absolute counts of transitional B cells decrease and there is an increase in 
the absolute number of mature B cells (Seggewiss and Einsele, 2010, Marie-
Cardine et al., 2008). Data within this thesis shows that the majority of B cells in 
CBT patients are transitional B cells and by 365 days post-CBT there is an 
increase in the absolute number of mature B cells. In CBT studies, the majority 
of B cells in patients are of a transitional phenotype and these studies have 
shown that the functionality of B cells is also restored in patients within the first-
year post-transplant (Charrier et al., 2013, Servais et al., 2014).  
 
In this current study, there are higher absolute numbers of B cells in CBT 
patients compared to healthy controls after 100 days post-transplant. In HSCT 
studies comparing mPB and CBT, an increase in the absolute number of B cells 
was associated with an increase in the cytokine BAFF. This cytokine is known 
to promote the survival of B cells (Jacobson et al., 2012). It could be released 
by B cells and could enhance the survival of B cells in CBT patients. 
Furthermore, the secretion of BAFF could lead to the increased proliferation of 
B cells post-transplant. Additionally, monocyte reconstitution is rapid and 
exceeds the number of monocytes seen within healthy adults. Activated 
monocytes can produce BAFF, which could stimulate the survival of B cells 
(Batten et al., 2000, Rolink et al., 2002). Therefore, increased numbers of B 
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cells post-transplant could be maintained through the presence of activated 
monocytes. In this thesis, the absolute number of CD14+ monocytes could be 
associated with the increased absolute numbers of B cells post-transplant. 
However, to elucidate this, measurement of BAFF in the serum of patient 
samples can be measured. This could be performed using an ELISA assay. 
The measurements could then be correlated to B cell reconstitution. 
Furthermore, monocytic cells could be isolated and their expression patterns of 
BAFF could be measured to further understand whether they possess the 
capacity to express and release BAFF.  
 
Aside from B cell reconstitution, B cell function has been demonstrated to also 
occur within the first year post-transplant. Within the first year post-transplant, 
there were higher numbers of naïve and transitional B cells in CBT recipients.  
However, the increase in mature B cells demonstrates that maturation was 
taking place within CBT patients. CBT studies have shown that there are higher 
levels of IgG in CBT patients compared to mPB and BM recipients (Jacobson et 
al., 2012). To better understand the reconstitution of B cell functionality, 
immunoglobulin measurements should be measured in CBT patients.  
Moreover, future work would include the measurement of IgG and IgM in CBT 
patient serum samples, via ELISA assays. Additionally, serum electrophoresis 
can be performed to test for monoclonal, oilgoclonal and polyclonal 
immunoglobulins. This would provide a greater understanding of B cell 
functionality and the maturation of B cells in CBT patients. Additionally, this 
would also identify the antibodies produced by B cells post-transplant. This 
could be correlated to B cell reconstitution in CBT patients and depending on 
the serum Igs present, correlations to functional maturity could be made. BCR 
spectratyping can also be undertaken as future work, which could be used to 
determine the broadness of the BCR repertoire in different groups of B cells 
(Wu et al., 2015).  
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7.2.5 T cells in cord blood transplant 
 
Delayed T cell reconstitution still remains a challenge in CBT. In a study 
conducted by Komanduri et al. it has been shown that T cells are the last 
lymphocytes to reconstitute within CBT patients and they recover between one 
and two years post-transplant (Komanduri et al., 2007). The kinetics of T cell 
reconstitution in this current study shows that complete T cell recovery could 
take longer than two years to recover.  
 
In CBT, thymic recovery is specifically delayed (Kanda et al., 2012, Komanduri 
et al., 2007, Ruggeri et al., 2011, Servais et al., 2014). CBUs contain 10-100 
fold fewer HSC and progenitors cells compared to BM and mPB grafts and this 
can result in delayed thymopoeisis. Therefore, in dUCBT patients, the complete 
absence of TRECs demonstrates that there is a delay in progenitor cells 
homing to the thymus and reconstituting the naïve T cell population. 
Furthermore, the absence of TRECs could also be due to a lack in thymic 
function (Komanduri et al., 2007). Data within this thesis shows that there are 
low absolute levels of RTEs post-transplant, which validates that there is 
delayed thymic recovery in CBT patients. Thymic reconstitution is affected by a 
patient’s age and younger individuals show to have better thymic recovery 
compared to older ones. This is due to thymic involution in older patients, which 
causes a decrease in thymic output (Lynch et al., 2009). The median age of 
CBT recipients in this current study is 48 years old and thymic involution in 
these patients could contribute to the delay in thymic output post-transplant.  
 
In CBT recipients, T cell reconstitution takes place through HPE and the 
majority of engrafting T cells are naïve and antigen inexperienced. A faster 
increase in peripheral T cell numbers are seen in recipients of dCBUs 
compared to sCBUs. Furthermore, increased HLA-disparity between the CBUs 
and the recipient could induce expansion of T cells through graft-versus-graft 
interactions (Lamers et al., 2016). It has been shown that fetal T cells convert 
rapidly compared to adult T cells into memory T cells upon proliferation (Early 
and Reen, 1999). This therefore increases the skewing towards an effector and 
central memory phenotype of T cells in CBT patients (Komanduri et al., 2007). 
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Data from this current study shows that there is a high proportion effector 
memory T cells in CBT recipients by 720 days post-transplant. This could 
suggests that there is either HPE of T cells in CBT patients or naïve T cells from 
the graft that have differentiated into effector memory T cells.  
 
Tregs are a subpopulation of T cells that can suppress immune responses and 
have immunoregulatory roles. In CBT recipients, Tregs reconstitute within the 
first year post-transplant. However, absolute counts of Tregs remain low within 
the first six months post-CBT (Jacobson et al., 2012). In this current project, 
Treg reconstitution occurs by 365 days post-transplant. The delay in 
reconstitution of Tregs could increase the chances of aGvHD and cGvHD 
development in CBT patients. Future efforts must be undertaken to improve the 
kinetics and reconstitution of Tregs in CBT patients and current on-going 
studies explore the use of Treg therapy, discussed later in this chapter. The aim 
of using Treg therapy in CBT patients is to suppress GvHD related reactions 
post-transplant.  
 
Overall, T cell reconstitution is delayed in CBT recipients post-transplant. 
Additionally, CBT patients could have reduced TCR diversity post-transplant. 
Both T cell diversity and TCR repertoire diversity are key elements in the 
recovery of immune competence. Defects in the reconstitution of a broad T cell 
diversity may limit the T cell-based GvL effect and predispose the patient to 
relapse (Talvensaari et al., 2002). It has been demonstrated that CB T cells lose 
their naïve phenotype in an antigen independent manner and at the same time 
antigen-driven proliferation of CB T cells causes oligoclonal expansion and 
reduction in the TCR diversity (Li and Xu, 2015). With this in mind, TCR 
spectratyping can be performed through future work to distinguish the TCR 
repertoire diversity in CBT patients. This could provide a global analysis of the 
distribution and clonal expansion of TCR subfamilies in CBT patients  
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7.3 Caveats and weakness of the study 
 
This study presents the results of kinetics and diversity of reconstituting cell 
subsets in CBT recipients. However, there was an immunophenotyping 
limitation where a four-colour immunofluorescent flow cytometry panel was set 
up in 2009 during the initial study design. This only allowed four surface 
markers to be identified on cell subsets at any given time. An increased number 
of surface markers could have been identified if more immunofluorescent 
colours could have been detected. 
 
Moreover, the reduction in the number of patient samples at later time-points 
was an additional limitation of this study. Samples could not be collected at 
certain time points due to poor health of the patients. The reduction in patient 
samples meant that there was limited data collected at later time points and this 
impacted the analysis undertaken to compare across and between time-points 
and healthy controls.  
 
Additionally, the retrieval of clinical data respective to the patient was also a 
limitation in this current study. In particular, infection, GvHD and relapse data 
were not complete and data was not available from transplant centres. This 
prevented correlations being made with reconstituting subsets. If future CBT or 
HSCT studies are performed then clinical data should be recorded to the 
highest level.  
 
The NK cell functional assays were performed on thawed PBMCs and thawed 
isolated NK cells. Limitations of this included a decrease in the viable number of 
PBMCs, which subsequently decreased the number of viable NK cells collected 
after isolation. Due to this, the number of patient samples analysed decreased 
as a viable NK cell population above 90% was required to perform cytolytic 
functional studies, as described in Chapter 2, Section 2.8.6.  
 
Additionally, due to the low absolute numbers of T cells within the patient 
samples, T cell functional studies could not be performed. This limited further 
understanding of T cell functionality in CBT patients.  
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An additional caveat of this study was that CD107a phenotyping could not be 
performed to identify NK cell degranulation. The isolated NK cells were not able 
to withstand the cell staining procedures and a high level of cell death was seen 
in the tested samples. Moreover, due to limited patient sample numbers, further 
tests of NK cell cytotoxicity directed against other leukaemic cell lines and 
patient leukaemia cells could not be performed. This could have demonstrated 
that NK cells in CBT patients have a broad range of cytotoxicity directed to 
various leukaemic cell lines. In addition, further NK cell functional studies 
against patient leukaemic cells could demonstrate whether reconstituting NK 
cells possess the capacity to lyse patient malignancies. This could have 
demonstrated whether CBT recipient NK cells play a vital role in GvL 
responses. With this in mind, future NK cell functional studies should be 
performed on freshly isolated NK cells to avoid the described issues.  
 
Moreover, in this study the reconstitution of B cells was shown. However, 
functional studies were not performed, as the viability of B cells recovered post-
thawing was very low. Future analysis of B cells and the impact on clinical 
outcomes in CBT is required, as B cells are one of the first major lymphocytic 
populations to reconstitute post-transplant. Additionally, a cytokine release 
analysis could have been performed to better understand the secretion patterns 
of pro-inflammatory and anti-inflammatory cytokines. The detection of IgM and 
IgD could have been analysed through ELISA assays. The incorporation of 
these tests could have given a better insight into the functionality of B cells. 
Future studies should include these tests when understanding B cell function in 
CBT patients as it will enhance the understanding of the function of B cells post-
transplant.  
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7.4 Translation to the clinic 
 
This study is the first within the UK to measure the kinetics and diversity of 
reconstituting immune cell subsets in CBT patients. It also serves as a clinical 
timeline: (1) for clinicians and scientist to have a better understanding of the 
kinetics and diversity of reconstituting immune cells in CBT patients and (2) to 
provide information for clinicians and research staff to investigate how to 
improve reconstitution of immune cell subsets in CBT patients. It is hoped if we 
have a better understanding of immune reconstitution we may be able to 
improve outcomes post-transplant.  
 
In this sample of UK performed CBT, the median time to neutrophil and platelet 
engraftment in CBT patients within the UK is 20 and 40 days, respectively. 
Various methods described in Chapter 1, Section 1.10.6, Table 1.2 are being 
undertaken to improve the time to engraftment in CBT patients. 
 
Through this study, it was shown that monocytes, NK cells and B cells are the 
first three lymphocytic populations to reconstitute in CBT patients. This occurs 
within the first three months post-transplant. NK cells are known to reconstitute 
rapidly, irrespective of the graft source and they play a key role in mediating 
GvL. Currently, there are various clinical trials that are on-going to understand 
the functions of NK cells in CBT patients (clinicaltrials.gov, Trial Numbers: 
NCT01619761, NCT02727803). The specific aims of these studies are to 
identify whether the infusion of NK cells post-transplant can reduce the 
incidence of relapse and decrease the risk of GvHD. Furthermore, the aim of 
these trials is to potentiate donor NK cell killing of cancer cells by ex vivo 
expansion. This will deliver various functions of NK cells where the 
reconstitution of NK cells have the potency to become alloreactive as 
demonstrated by the KIR-KIR ligand incompatibility hypothesis (Ruggeri et al., 
2005). Additionally, the infusion of NK cells post-transplant could be used to 
reduce the incidence of GvHD by inhibiting donor alloreactive T cells (Olson et 
al., 2010).  
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As previously described, B cell reconstitution is rapid in CBT patients and 
occurs within three months post-transplant. The increased absolute counts of B 
cells early post-transplant have been demonstrated to reduce the incidence of 
cGVHD (Jacobson et al., 2012). The main future directions of understanding B 
cell function in CBT patients is being investigated to elucidate their role in 
GvHD. Early reconstitution of B cells could indicate that they play a role in 
GvHD reactions. Various studies are investigating the effects of B cell depletion 
and the incidence of GvHD post-transplant, particularly demonstrated through 
the use of Rituximab (Bhatt et al., 2016).  
 
T cell reconstitution is severely delayed in CBT patients and it is fundamental 
for T cells to reconstitute to improve outcomes such as relapse or to 
prevent/treat infection. There has been much effort to use adoptively transferred 
T cells to improve immune reconstitution. This enhances the time in which 
infection can be treated or prevented in CBT patients. However, in the context 
of CBT, ex vivo strategies have been explored using Dynabeads, IL-2 and anti-
CD3/CD28 (Mazur et al., 2008, Okas et al., 2010). The expansion of T cells was 
possible although there was a high level of apoptosis of CD4+ T cells. 
Furthermore, IL-7 was used to reduce apoptosis and this promoted functional 
maturation of T cells. These expanded T cells lacked all reactivity against 
allogeneic cells but they could be primed against leukaemic cells (Davis et al., 
2010). Further clinical trials of expanded T cells are necessary, which would 
provide an understanding of T cell function post transplant and whether infused 
T cells can aid in the clearance of residual disease and clearance of infection. 
 
Moreover, further work has been undertaken to understand whether pathogen 
specific T cells can be expanded and primed against CMV antigens. This was 
undertaken through the isolation of CB T cells that were primed with IL-7 and IL-
12. These T cells were then stimulated with monocytes and DCs containing a 
CMV antigen (Hanley et al., 2012). This demonstrates a potential for ex vivo T 
cell priming for the clearance of specific pathogens. Additionally, cytotoxic T 
cells have been engineered via GMP methods that are directed to CMV, EBV 
and Adenovirus (ADV). These T cells have been stimulated via CB-DCs that 
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cytotoxic T cells are cultured in IL-7, IL-12 and IL-15. Thereafter, a second 
stimulation is undertaken using EBV transformed B cells. The results from this 
study are promising and only 25% of the CBU is used to produce in excess of 
200x108 viral specific cells (clinicaltrials.gov: trial number: NCT00880789). This 
highlights the potential for CB T cells to be primed and stimulated against 
pathogens and could be infused into patients with the hope of clearing 
opportunistic infections post-transplant.  
 
Tregs play a crucial role in transplantation tolerance within HSCT patients.  
Current therapeutic strategies are used to expand Tregs for infusion into HSCT 
patients to suppress immune system activation and promote immunologic 
tolerance. Tregs can modulate innate and adaptive immune responses and are 
used to improve outcomes post-transplant. Adoptive transfer of Tregs has been 
demonstrated as a potential immunotherapeutic strategy (June and Blazar, 
2006). Banked CBUs are used as a source of Tregs, which are isolated and 
expanded via stimulation with anti-CD3/CD28 microbeads and then stimulated 
with IL-2. The expanded Tregs have polyclonal reactivity due to non-specific 
TCR stimulation. Current on-going studies (clinicaltrials.gov trial number: 
NCT02991898, NCT02423915, NCT01937468) are now testing the infusion of 
these specifically expanded Tregs to better understand the dose of 
administration but also to review the outcomes of patients infused with these 
Tregs.  Furthermore, the aim of these studies is to address whether the infusion 
of Tregs suppresses or reduces the incidence of aGvHD.  
 
Taken together, data within this study provides a better understanding of 
immune reconstitution in CBT patients within the UK. All of the findings from this 
current project can facilitate decision making for future clinical applications of 
CBT and post-transplant therapeutics. Furthermore, findings from this study 
highlight key areas that can be improved to enhance immune reconstitution in 
CBT patients.  
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Chapter 8 : Appendix 
 
8.1 Poster Presentations  
 
- UCL Infection and Immunology Symposium, 2014 
 
- UCL Infection and Immunology Symposium, 2015 
 
- BSI Oxford Immunology meeting, 2016 
 
- EBMT - Marseille, 2017 
 
8.2 Publications 
 
Feliu J, Clay J, Raj K, Barber L, Devlia V, Shaw B et al.  
Transplant-acquired food allergy (TAFA) following cord blood stem cell 
transplantation in two adult patients with haematological malignancies. Br J 
Haematol. 2014 Nov;167 (3): 426-8 
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